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Abstract
Streptococcus pneumoniae, the pneumococcus, is an important pathogen globally, 
especially among children <5 years old. Pneumococcus colonises the human nasopharynx, 
and carriage is a prerequisite to disease. Understanding the concentration of 
pneumococcal colonisation may help us to better understand the pathogenesis of 
pneumococcal disease.
We hypothesized that If increased nasopharyngeal pneumococcal concentration is 
important in the pathogenesis of pneumonia then the concentration would be lowest 
among well children, intermediate among children with symptomatic upper respiratory 
tract infection (URTI) and highest among children admitted to hospital with WHO-defined 
pneumonia. We found that in fact, the nasopharyngeal pneumococcal concentration was 
of similar distribution among all three groups of children, and was highest among the
V; ' V; V
group with URTI.
We studied the nasopharyngeal concentration of pneumococcus among children <5 years 
old before, during and after episodes of symptomatic URTI with respiratory syncytial virus 
(RSV) or rhinovirus. Nasopharyngeal pneumococcal concentration increased 4-fold with 
onset of the viral infection, which may contribute to risk.
We examined the response of nasopharyngeal pneumococcal concentration to 
vaccination with the 10-valent pneumococcal conjugate vaccine (PCV-10) among children 
aged 12-23 months. Vaccine-type (VT) carriage concentration did not change, while non­
vaccine-type (NVT) concentration increased over six months post vaccination, which may 
have been a vaccine effect on VT relative to NVT concentration. There were large
differences in serotype-specific pneumococcal concentration within and between
individuals.
We investigated the performance of quantitative lytA PCR (qPCR) on blood samples in the 
diagnosis of invasive pneumococcal disease (IPD) among children <13 years old at Kilifi 
County Hospital, and among children 1-59 months old in a seven-country case-control 
study of pneumonia aetiology. lytA qPCR was not specific for the diagnosis of IPD, being 
positive among 5% of control participants. Pneumococcal DNA is more commonly found 
in the bloodstream of children in low and lower-middle income countries than has been 
appreciated.
Studying nasopharyngeal concentration of pneumococcus demonstrated why it is difficult 
to diagnose pneumococcal disease among young children in high-burden countries. Total 
nasopharyngeal concentration of pneumococcus is similar in well children as in disease. 
Serotype-specific concentration varies widely within and between children.
Pneumocodcal bloodstream invasion appears to be a freqdent occurrence, without 
always leading to IPD.
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Chapter One
1 Thesis Outline
1.1 Introduction
Pneumonia is the leading cause of death among children <5 years of age worldwide, and 
in Africa.1 Streptococcus pneumoniae, as well as being a leading cause of pneumonia,2 
causes invasive pneumococcal diseases (IPD) such as sepsis and meningitis, with a high 
case fatality. The reservoir of S. pneumoniae, the pneumococcus, is carriage in the human 
nasopharynx, particularly the nasopharynges of young children. Diagnosis of 
pneumococcal pneumonia and IPD is difficult, especially among young children in low and 
lower-middle income countries where carriage prevalence is highest and the burden of 
disease is greatest.
1.2 Research Question v v \
To better understand the relationship between healthy carriage of pneumococcus and 
pneumococcal pneumonia/invasive pneumococcal disease, and how this relationship 
affects our ability to diagnose pneumococcal disease in young children, using quantitative 
PCR to measure pneumococcal concentration.
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Specific Objectives
To quantify the nasopharyngeal concentration of pneumococcus in different 
disease states to understand the constraints on the diagnosis of pneumococcal 
pneumonia in young children.
a. Is nasopharyngeal pneumococcal concentration greater in children with 
pneumonia than in children with symptoms of upper respiratory tract 
infection (URTI) symptoms or in healthy children?
To describe the dynamics of pneumococcal concentration in the nasopharynx 
during symptomatic URTI with respiratory syncytial virus (RSV), or rhinovirus in 
children <5 years of age.
a. Do viral infections lead to an increase in nasopharyngeal pneumococcal 
concentration?
\ , v v . v .
b. If viral infections increase nasopharyngeal pneumococcal concentration, 
does this return to baseline after the viral URTI?
To describe the dynamics of pneumococcal concentration in the nasopharynx 
after immunisation with 10-valent pneumococcal conjugate vaccine (PCV-10).
a. Does nasopharyngeal total pneumococcal concentration change after 
PCV-10?
b. Does vaccine-type pneumococcal concentration decrease after PCV-10?
c. Does non-vaccine-type pneumococcal concentration increase after PCV-
4. To investigate the performance of lytA qPCR in the diagnosis of invasive 
pneumococcal disease using blood samples, in children in low and lower- 
middle income countries.
1.4 Overview and context of the thesis
The pneumococcal pathogenic process begins with transmission and acquisition of 
nasopharyngeal carriage of pneumococcus, followed by amplification, mucosal disease 
and finally invasive disease. Nasopharyngeal carriage of pneumococcus is thus a 
prerequisite for disease, but does not always lead to disease. Pneumococcal carriage is 
very common, with highest prevalence among young children. Diagnosis of pneumococcal 
disease is particularly difficult in young children in developing countries, precisely the 
group with the highest burden of disease where diagnosis is important.
V . v . \ ; .
The thesis begins with the-study of nasopharyngeal pneumococcal concentrations in 
health and disease, followed by an examination of the impact of symptomatic respiratory 
virus infection on nasopharyngeal pneumococcal concentration, in young children. Next, 
the effect of pneumococcal conjugate vaccination on nasopharyngeal pneumococcal 
concentration is studied. Finally the diagnosis of invasive pneumococcal disease is 
studied.
Nasopharyngeal pneumococcal density and pneumococcal concentration are both terms 
used in the published literature. Terms such as nasopharyngeal pneumococcal load or 
pneumococcal burden are also used. Density is a measure of mass per unit volume; in this 
case the mass of pneumococcus per unit volume in the nasopharyngeal secretions 
adherent to the posterior nasopharyngeal mucosae. In estimating the pneumococcal
density in the nasopharynx all that we can actually measure is the concentration of 
pneumococcus in a swab sample. For work performed in this thesis, the term 
nasopharyngeal pneumococcal concentration will be used. Methods exploring the 
estimation of nasopharyngeal pneumococcal concentration from a nasopharyngeal swab 
are detailed in the methodology section.
The research objectives in this thesis were nested within studies of respiratory and 
pneumococcal disease that took place at the Kenya Medical Research Institute (KEMRI)- 
Wellcome Trust Research Programme (KWTRP) in Kilifi, Kenya, and within a larger multi­
site pneumonia study. At Kilifi County Hospital (KCH), all paediatric medical admissions 
(ie. all admissions excluding accidents, surgical cases, poisoning and fresh burns) were 
invited to consent for collection of blood for invasive bacterial disease surveillance as part 
of the Pneumococcal Conjugate Vaccine Impact Studies (PCVIS),3 and Kilifi genome-wide 
association studies. The Pneumonia Etiology Research for Child Health (PERCH) project 
was a multi-site case-control study of the causes of pneumonia among children aged 1-59
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months that took place in Kilifi, Kenya, as well as in the Gambia, Mali, Zambia, South 
Africa, Thailand and Bangladesh over 2011-2014.4 Respiratory virus surveillance and 
studies of the aetiology of pneumonia have been carried out longitudinally at KCH 5-7 and 
data and sample collection for the PERCH study were introduced in a stepwise fashion in 
this context.
1.4.1 Objective One
The first objective asked whether nasopharyngeal pneumococcal concentration was 
greater in children with pneumonia than children with URTI symptoms or healthy 
children, in order to better understand the constraints on pneumococcal pneumonia 
diagnosis in young children. This objective used samples from the PERCH project.
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1.4.2 Objective Two
The second objective investigated whether pneumococcal concentration increased in 
response to a RSV or rhinovirus URTI in young children. This was a sub-study of a 
household RSV transmission study that took place in Kilifi County in 2009-2010.8'9 In the 
parent study, nasopharyngeal swabs were collected from all members of 47 households 
with at least one infant and a sibling, twice weekly for six months. A multiplex PCR was 
used to detect the presence of respiratory viruses.
1.4.3 Objective Three
The third objective examined the effect of PCV-10 on serotype-specific pneumococcal 
concentration in the nasopharynx. This was a sub-study of a randomized controlled trial 
of the immunogenicity, reactogenicity and impact on carriage of PCV-10 among children 
aged 12-59 months that took place in Malindi, Kenya (PRISM).10
1.4.4 Objective Four  ^  ^ ^
The fourth objective studied the performance of lytA qPCR from paediatric blood 
specimens in the diagnosis of IPD. This study was carried out on two sample sets, the first 
from ongoing paediatric invasive bacterial disease surveillance at KCH carried out at the 
KWTRP, which included participants in the Kilifi arm of the PERCH project. The second 
data set consisted of cases and controls from all sites participating in the PERCH project.
1.4.5 Declaration of the author's role
The author of this thesis conceived the idea for this work as a whole and for each of the 
objectives. She was the laboratory lead for the PERCH project in Kilifi and worked closely 
with the PERCH core laboratory lead, Professor David Murdoch, in setting up and
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validating laboratory assays for the PERCH project. Likewise, she led the KWTRP 
microbiology laboratory for the PRISM study and for the PCVIS project.
Method validation: The author designed and performed most of the work herself, or in 
some instances supervised a laboratory team in the performance of experiments 
designed by the author. In the comparison of DNA extraction instruments, experiments 
using the ABI PRISM 6100 were performed by the Kilifi genome-wide association studies 
laboratory team and were co-supervised by the author. Experiments designed by the 
author on DNA extraction methods for nasopharyngeal swabs in skim-milk tryptone 
glucose glycerol (STGG), and the effect of transport time of swabs in STGG on the 
measured pneumococcal concentration, were performed by an intern supervised by the 
author.
Objective one: The author designed the study, set up the laboratory work, performed 
some of the laboratory assays, supervised some of the laboratory assays, performed the 
data analysis Jand interpretation. ) v /
Objective two: The author designed the study, performed all of the laboratory work, 
performed the data analysis and interpretation. The STATA code used in the selection of 
viral episodes to investigate from the parent study was written together with Patrick 
Munywoki, the principal investigator of the parent study. Some of the illustrative figures 
are by Patrick Munywoki, these have each been clearly cited.
Objective three: The author designed the study, set up the laboratory work, performed 
some of the laboratory assays, supervised some of the laboratory assays, including DNA 
extraction for microarray, but not the microarray itself, which was done in Jason Hinds'
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laboratory at St George's University Hospital in London. The author performed the data 
analysis and interpretation.
Objective four: The author designed the study and set up the laboratory work in Kilifi. She 
drafted standard operating procedures for all the laboratories in the PERCH multi-site 
project. She supervised the laboratory work in Kilifi on Kilifi samples and performed the 
data analysis and interpretation for both the Kilifi sample set and the PERCH all-site 
sample set.
1.4.6 Publications during the PhD period
Morpeth SC, Huggett J, Murdoch DR, Scott JAG. Making standards for quantitative real­
time pneumococcal PCR. Biomolecular Detection and Quantification. 2014. Accepted.
Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, Borys D, Goldblatt D,
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Scott JA. Immunogenicity, impact on carriage and reactogenicity of 10-valent 
pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in 
Kenyan children aged 1-4 years: a randomized controlled trial. PLoS One. 2014 Jan 
21;9(l):e85459
Hammitt LL, Kazungu S, Morpeth SC, Gibson DG, Mvera B, Brent AJ, Mwarumba S, 
Onyango CO, Bett A, Akech DO, Murdoch DR, Nokes DJ, Scott JA. A preliminary study of 
pneumonia etiology among hospitalized children in Kenya. Clin Infect Dis. 2012 Apr;54 
Suppl 2:S190-9
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Chapter Two
2 Background
Pneumonia is the leading cause of death in children <5 years of age globally, and in 
Africa.1 Streptococcus pneumoniae is the leading cause of pneumonia,2 causes invasive 
pneumococcal diseases (IPD) such as sepsis and meningitis, and also causes mucosal 
diseases such as otitis media and sinusitis. Pneumococcal disease is the leading cause of 
childhood vaccine-preventable death in the world.11 Aetiological diagnosis of pneumonia 
for both epidemiological studies and clinical care is difficult; only ~13% of cases of 
radiologically-confirmed pneumonia are diagnosable by blood culture;12 sputum is not 
spontaneously produced by young children and differentiating carriage from disease 
using culture-positivity of sputum or nasopharyngeal samples is difficult; diagnostic 
serology is insensitive in children and requires paired acute and convalescent sera;13 and 
urinary antigen tests are not sufficiently specific for use in young children, presumably
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due to high rates of pneumococcal carriage.14,15 Comprehensive pneumonia aetiology 
studies find high prevalence of putative viral and bacterial pathogens among cases and 
controls that are difficult to interpret5 and interactions between respiratory viruses and 
pneumococci are likely to be important. Many of these diagnostic assays are easier to 
interpret for adults, but it is children under the age of five years, particularly in low and 
middle-income countries, who have the highest burden of disease and thus the greatest 
need for better diagnostic tests.
There are over 90 serotypes of pneumococcus that have been documented, with new 
types being discovered every year.16,17 Prevention of IPD in children has largely been 
achieved in the industrialised world by means of the 7-, 10- or 13-valent pneumococcal
conjugate vaccines (PCV), providing protection against the most common invasive 
serotypes, but serotype-replacement disease is occurring and is being monitored.18'21 In 
2011 Kenya introduced into the childhood vaccination programme PCV-10, a 10-valent 
pneumococcal conjugate vaccine which covers 71% of the serotypes responsible for cases 
of IPD in children in East Africa.22
2.1 Pathogenesis of pneumococcal pneumonia and invasive 
pneumococcal disease
2.1.1 Biology of the pneumococcus
Streptococcus pneumoniae (the pneumococcus) is a gram-positive, encapsulated 
diplococcus that is an almost exclusive human pathogen. The ecological reservoir for the 
pneumococcus is the human nasopharynx, particularly the nasopharynges of young 
children, although adults can also be carriers.23 IPD carries a high case-fatality, falling 
from 52-98% before antibiotics were available to 7-48% with the introduction of 
penicillin.24 The 93+ serotypes of pneumococcus are based on the polysaccharide capsule, 
the main virulence determinant. Invasion and colonisation potential are based largely on 
capsule type, but within serotypes there are also inter-strain differences in invasion 
potential.25 Indeed some common invasive serotypes, such as serotypes 1 and 5, are 
seldom found in carriage studies.26,27
A core genome has been proposed, comprising 73% of the pneumococcal genome, with 
some regions of diversity associated with invasion and others with colonisation.28'30 The 
alternative coding DNA at the capsular locus alone consists of over 1.8Mbp, nearly as 
large as the entire pneumococcal genome.16
30
The natural state of pneumococcal colonisation is in biofilms covering the mucosal 
surfaces of the nasopharynx. The pneumococcus is capable of taking up extracellular DNA 
from other pneumococci and related species by natural transformation, known as 
competence, with an estimated 5% of the pneumococcal genome consisting of insertion 
sequences.28 Entering the competent state is tightly regulated and involves quorum- 
sensing and fratricide.31 The quorum-sensing mechanism may also produce bacteriocins, 
which can also affect non-competent pneumococci to lyse and release DNA that is also 
taken up for transformation.32
The pneumococcus exists in two phases, an opaque phase and a transparent phase, and 
can spontaneously switch back and forward between phases. The opaque phase has more 
capsular polysaccharide and less teichoic acid in the cell wall and the transparent phase 
expresses less capsular polysaccharide and more teichoic acid. In addition there are 
differences in expression of various cell surface proteins between phases. The 
transparent phase is better at adherence to host epithelium in the nasopharynx and lung,
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whereas the opaque phase is more virulent and better suited to invasion.33,34 The 
polysaccharide capsule is crucial for evading opsonophagocytosis, protecting the cell- 
surface proteins from complement and antibodies, and as such is the most important 
pneumococcal virulence factor.
Pneumolysin is another key virulence factor. It is a pore-forming cytotoxin, lyses 
eukaryotic cells, and is also important for bacterial recognition by the innate immune 
system.35 Pneumolysin is released from pneumococcus when the bacterial cells autolyse, 
but may also be exported from the cell walls of intact pneumococci.36'37 Cell surface 
proteins associated with the pneumocccal cell wall such as pneumococcal surface adhesin 
A (PsaA), choline-binding proteins A and E (CbpA and CbpE), pilus protein, plasminogen
and fibronectin-binding proteins (PfbA and PfbB), pneumococcal adherence and virulence 
factors A and B (PavA and PavB) are important for adherence to nasopharyngeal 
epithelium.36
2.1.2 Biology of the interaction between pneumococcus and the host; from coloniser 
to invader
Certainly anti-capsular antibody provides protection against IPD in humans as is 
evidenced by the success of pneumococcal conjugate vaccination 18,20 but it is probably 
not the chief mechanism by which natural immunity abrogates the likelihood of IPD as 
unvaccinated children grow.38 The host inflammatory response to pneumococcal growth 
and invasion is complex and requires modulation in order to control pneumococcus and 
limit host damage.39
Infants, the elderly and the immunocompromised are at most risk of IPD. The specific 
forms of immunocompromise that predispose to IPD are; B-cell defects (including either
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an intrinsic B-cell problem or impaired T cell help), deficiencies of early components of 
the classical pathway of complement and C3 deficiency, asplenia, interleukin-1 receptor 
associated kinase-4 (IRAK-4) deficiency, myeloid differentiation factor (MyD88) 
deficiency,40 impaired nuclear factor-kappaB (NF-KB) activation and HIV infection.41'43 We 
can learn from these specific immunodeficiencies that antibody- and complement- 
mediated opsonization, splenic macrophages and the Toll-like receptor and interleukin-1 
receptor pathway to inflammatory cytokine production are vital for protective immunity
39 40 42to pneumococcus. ' '
Transforming growth factor (TGF)-pl and regulatory T-cells are key in tolerance of 
nasopharyngeal carriage of pneumococcus in mice and humans.44 Clearance of
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pneumococcal carriage by macrophages is an IL-17-secreting CD4+ T-cell (Thl7)- 
dependent process.35,45,46 Macrophages are important in controlling pneumococcal 
colonisation and also in preventing invasive and local pneumococcal disease.47 
Macrophage migration inhibitory factor (MIF)-deficient mice showed prolonged 
pneumococcal colonisation and had less macrophages in the upper respiratory tract than 
normal mice. Macrophages were dependent on pneumococcal pneumolysin to produce 
MIF. Mice deficient in the immune-modulating, small non-coding RNA, microRNA-155, 
were shown to have high-density colonisation and to be unable to clear pneumococcal 
carriage, with reduced macrophage recruitment to the nasopharynx, but remained able 
to prevent invasive disease.45 Murine host gene expression in nasal lymphoid tissue in 
response to asymptomatic pneumococcal carriage began with a type 1 interferon 
inflammatory response for the first two weeks, followed by a T-cell response and mucosal 
epithelial healing.48
In a neonatal and infant mouse model, clearance of pneumococcal nasopharyngeal
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colonisation was delayed, infant mouse macrophages showed reduced cytokine 
production and IL-17A production from adult CD4+ T-cells was delayed when infant 
macrophages were used as antigen-presenting cells 49 The reduction in risk for IPD after 
the first year of life in humans is thought to be at least partly due to maturation of the 
infant innate immune system.38
In a mouse model of immunosenescence, pneumococcal colonisation was prolonged in 
elderly compared to young adult mice, with delayed monocyte/macrophage influx and an 
altered innate immunity cytokine profile, but normal neutrophil responses. The authors 
postulated that impaired clearance of pneumococcal carriage could contribute to the 
increased risk of IPD in elderly humans.50 In an adult human experimental challenge
model, pneumococcal carriage was shown to stimulate a mucosal and systemic antibody 
response that was protective against further carriage on repeat challenge, and passive 
transfer of these sera gave cross-serotype protection against invasive disease in mice.51 
The authors suggested that low carriage prevalence amongst elderly human populations 
might result in a lack of immune boosting and thus an increased risk of IPD.
Prior nasopharyngeal colonisation with pneumococcus is known to be protective against 
subsequent fulminant pneumonia and septicaemia in mice. The ability to prevent 
subsequent invasive disease in previously colonised mice was shown to be 
opsonophagocytic antibody-mediated protection from bacteraemia, as CD4+ T-cells were 
not required, despite induction of Thl7 cytokines during re-challenge.52 This is unlike the 
protection from subsequent colonisation afforded by prior nasopharyngeal colonisation 
with pneumococcus in the mouse, which is CD4+ T-cell dependent.53 In humans, both 
antibody (anti-capsular polysaccharide and anti-protein) and Thl7 responses are likely to 
be involved in protection from subsequent colonisation.51
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Complement-deficiency is a well-known risk factor for IPD in humans.42 Depleting mice of 
complement prior to challenge with intra-nasal pneumococcus resulted in the majority 
developing IPD, with the protection from complement being neutrophil and antibody- 
independent.41 Both density of nasopharyngeal colonisation and density of infection of 
nasal lymphoid tissue were no different in complement-deficient or control mice prior to 
the development of septic symptoms, even though one-third of the complement- 
deficient mice were already bacteraemic. By contrast, density of nasopharyngeal 
colonisation among septic mice at the time of sacrifice was significantly higher than 
among non-septic mice. The authors concluded that complement does not prevent 
pneumococcal invasion of local lymphoid tissues but does prevent invasion into the
bloodstream. They suggested that colonisation might frequently result in pneumococcal 
bloodstream invasion, which is usually controlled by complement before IPD can become 
established. We do need to be careful in extrapolating directly from mouse models to 
human immunity. Studies have shown, for instance, that pneumococcal CbpA binds to 
factor H, an inhibitor of the complement alternative pathway, in humans, but does not 
bind to murine factor H.54 In studies of human bacteraemic pneumonia, the most 
common invasive serotypes have not always been those with the highest case-fatality; it 
has been suggested that host factors such as mannose-binding lectin deficiency (part of 
the lectin pathway of complement activation) might allow less-invasive serotypes to 
invade and cause fatal disease.55
Pneumococci that do invade the bloodstream are subject to phagocytosis by neutrophils. 
Pneumococci deficient in nitric oxide (NO) defence systems were able to colonise mice 
but NO defence genes were needed for bloodstream invasion, presumably to cope with 
intracellular killing once phagocytosed by macrophages and neutrophils.56 Pneumococci
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have been found to be capable of invading human erythrocytes in vitro and in the 
presence of erythrocytes were more able to evade neutrophil phagocytosis.57 
Opsonophagocytosis is enhanced by the immunising effect of prior colonisation. Mice 
previously colonised by pneumococcus were able to control and clear pneumococcal 
infection even when the bacteria were intravenously administered.52
In order to invade through the nasopharynx or, once in the bloodstream, into distal 
tissues such as the brain, pneumococci must be able to get through epithelial and 
endothelial cell barriers. CbpA, also known as pneumococcal surface protein C (PspC), 
interacts with the polymeric immunoglobulin receptor (plgR) to achieve pneumococcal 
adherence and invasion into epithelial cells. plgR exists to transport secretory IgA and IgM
across mucosal epithelium, and is then recycled back across the cell, during which 
pneumococci may take advantage of the system for ingestion and transcytosis across the 
epithelial cell barrier.58 The platelet-activating factor receptor (PAFR) is implicated in 
adhesion, invasion and translocation of pneumococcus through endothelial cells, 
although it appears not to be an absolute requirement for the development of IPD.59 
Human endothelial cells have been shown to uptake pneumococci by both a clathrin and 
caveolae-dependent endocytosis in vitro; 90% of pneumococci were destroyed in the 
lysosome but 10% achieved transcytosis to the basal cell surface.60
Dispersion of pneumococci from nasopharyngeal biofilms could help explain the switch 
from asymptomatic carriage of pneumococci to the potential for invasion. Pneumococci 
dispersed from biofilms were shown to express virulence factors and were more likely to 
be in the opaque phase than pneumococci grown in planktonic culture or pneumococci 
from intact biofilms. Dispersion of pneumococci from biofilms in vitro and in vivo was 
achieved by infection with influenza A virus, or by application of host signals normally
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found in response to viral infection, such as hyperthermia, norepinephrine and 
extracytoplasmic ATP.61 Transcriptome analysis demonstrated upregulation of 
carbohydrate metabolism and bacteriocins and downregulation of genes associated with 
colonisation (competence, fratricide and the transparent phenotype) among dispersed 
pneumococci.62
Pneumolysin is known to be an important virulence factor but we do not yet fully 
understand all of its effects beyond its cytotoxic capacity. Mice colonised with 
pneumolysin-deficient pneumococci had higher nasopharyngeal pneumococcal density 
than mice colonised with pneumolysin-expressing bacteria.35 Pneumolysin activated an 
inflammatory response that led to pneumococcal clearance, a finding that has not always
been consistent. This could be because the effect of pneumolysin may depend on the 
genetic background or context of the pneumococcal strain in question.63
Pneumococcal nasopharyngeal colonisation, particularly with a high density of organisms, 
is thought to be a prerequisite for pneumonia and/or IPD, which is more likely to occur in 
the presence of viral upper respiratory tract infection.64,65 It is believed that it is the 
recent nasopharyngeal acquisition of a virulent strain of an invasive serotype of S. 
pneumoniae that is the event that leads to disease if immune mechanisms fail. However, 
in the seminal study by Gray et al where this observation was made, 28 of the 31 
pneumococcal infections observed were otitis media.66,67
2.1.3 Are respiratory viruses a 'trigger' for pneumococcal invasion?
Certainly both respiratory viruses and bacteria such as Streptococcus pneumoniae, 
Haemophilus influenzae, Moraxella catarrhalis and non-pneumococcal streptococci are all 
very commonly found in the nasopharynges of healthy children.5,68 Respiratory viral
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infection in humans may result in upper respiratory tract symptoms such as coryza and 
nasal congestion. In young children, such symptoms may last at least 10 days.69,70
Temporal associations between circulating viral infections such as rhinovirus,71 RSV and 
influenza 72,73 and IPD in children and adults have been documented in ecological studies. 
Influenza infection was associated with elevated blood pneumococcal concentration in 
IPD in South Africa.74 Preceding influenza infection has been shown to be directly 
associated with severe pneumococcal pneumonia in children,75 bacterial co-infection has 
been common among severe pandemic influenza infections76 and considerable work has 
been done to investigate the relationship between respiratory viruses and pneumococcus 
in animal models.
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2.1.3.1 In vitro studies
Mucosal inflammation in response to viral infection for many respiratory viruses increases 
host epithelial receptors, depending on the virus and on the cell type, augmenting 
pneumococcal binding and potentially promoting bacterial invasion.67,77 For example,
RSV, HPIV-3 and influenza virus all enhanced pneumococcal adhesion to human 
adenocarcinoma epithelial cells (A549) and to primary human bronchial and primary 
human small airway epithelial cells. RSV and HPIV-3 increased the expression of epithelial 
cell receptors for bacterial adherence by primary bronchial epithelial cells and A549 cells 
but not by primary small airway epithelial cells, and influenza virus did not increase 
receptor expression.77 Human coronavirus NL63-infected human airway epithelial cells 
markedly increased adherence for pneumococcus at day 4 post viral infection, when viral 
replication was maximal.78 Transcription of a set of host cell adhesion molecules was 
enhanced by infection of human pharyngeal cells by RSV, and adherence of pneumococci 
to the host cells was increased by a factor of 1.3- 2.0 in the presence of virus.79 Platelet-
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activating factor (PAF) appears to be a receptor for adherence of S. pneumoniae to 
human respiratory epithelial cells, which is upregulated during RSV infection.80 
Additionally, RSV G-protein expressed on the surface of RSV-infected respiratory 
epithelial cells, was found to bind S. pneumoniae, further promoting bacterial 
adherence.81,82 This increased bacterial adherence to human cell lines infected with RSV 
has been demonstrated for both nasopharyngeal cells and pneumocytes, and for a range 
of serotypes of S. pneumoniae, albeit with variation in degree of adherence between
7 Q o q
serotypes.
As well as RSV, rhinovirus infection has been shown to increase adherence of S. 
pneumoniae to human tracheal epithelial cells via PAF.84 Rhinovirus also increased
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adherence of S. pneumoniae to human nasal epithelial cells, 1.5-fold, and increased 
expression of PAF from the cell lines.85 Human coronavirus NL63 infection of human 
airway epithelial cells increased adherence of 5. pneumoniae, but it was not clear how 
important the PAF receptor is in the process.78
Influenza virus infection does not seem to upregulate host epithelial cell receptors for 
bacterial adherence77 but viral neuraminidase protein is probably important in promoting 
bacterial growth 78 and increases in free sialic acid due to influenza or other virus 
infection have been shown to augment pneumococcal nasopharyngeal biofilm density.86 
Depletion of host sialic acid availability limited influenza-induced pneumococcal 
replication 87 Indeed, not only influenza virus infection, but also application of host 
responses to viral infection to epithelial cell lines or to mice, resulted in transformation of 
pneumococci from a biofilm or planktonic phenotype to a phenotype capable of virulent 
invasion.61
As well as increasing numbers 'Of bacteria adhered to respiratory epithelium, fespiratory 
virus infection has been shown to be associated with reduced clearance of bacteria from 
the respiratory tract. Human monocytes infected with RSV were less able to bind S. 
pneumoniae, showed reduced intracellular killing and reduced production of TNF-a.88
2.1.3.2 In vivo studies
Influenza A infections in infant mice already carrying nasopharyngeal pneumococcus 
increased pneumococcal concentration in the nasopharynx 50-fold, and in the lungs, 300- 
fold.89 Transmission of pneumococcus between infant mice only occurred among those 
infected with influenza A. Influenza A reduced the numbers of pneumococcus required to 
establish pneumococcal pneumonia in mice from 100,000 to 100 colony-forming units
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(CFU) and in turn pneumococcal infection increased established viral titres; influenza 
appeared to reduce the bacterial clearance ability of alveolar macrophages and 
pneumococcal infection enhanced viral release from infected cells.90 Influenza virus not 
only increased pneumococcal nasopharyngeal density and carriage duration in mice, but 
influenza vaccination significantly reduced this excess pneumococcal carriage density.91 
Influenza virus infection in ferrets enhanced not only transmission of pneumococcal 
colonisation from donor ferrets, but considerably enhanced acquisition of pneumococcal 
colonisation in recipient ferrets, and also increased risk of disease, in a pneumococcal- 
strain dependent manner.92 Increased density of pneumococcal colonisation in 
transmitting mice and lipopolysaccharide-induced nasopharyngeal inflammation but not 
neutrophil depletion in receiving mice also enhanced pneumococcal transmission in the 
mouse model.93 In a mouse model of otitis media, influenza A co-infection overcame the 
difference in colonisation propensity and ability to cause otitis media between 
pneumococcal opaque or transparent phase variants.94
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Infection with both RSV and pneumococcus in mice resulted in a higher incidence of 
pneumococcal bacteraemia and a higher bacteraemic pneumococcal concentration than 
in controls.82 RSV infection reduced bacterial clearance and induced functional changes in 
the neutrophil response in mice.95 Human metapneumovirus infection predisposed mice 
to severe pneumococcal pneumonia.96
2.1.3.3 In human children
Frequent carriage of pneumococcus in the first two years of life was associated with 
seroconversion to human metapneumovirus (hMPV)97 but whether hMPV infection 
predisposed to pneumococcal carriage or the other way around is not clear. In a cross- 
sectional study of children attending day-care in Portugal, there was a significant
association between respiratory viral infection (78% of which was picornavirus infection, 
including rhinovirus) and pneumococcal colonisation density.98 Among children with 
radiologically-confirmed pneumonia in Vietnam, nasopharyngeal pneumococcal 
concentration was 15-fold higher with viral co-infection than without viral co-infection 
and the difference was significant for influenza A, RSV and rhinoviruses. This finding was 
not observed among children with lower respiratory tract infection without radiologically- 
confirmed pneumonia.99
2.1.3.4 Summarising respiratory viral -  pneumococcal interactions
We have direct evidence from animal studies and human cell lines that respiratory viral 
infections can increase pneumococcal nasopharyngeal adherence and decrease 
pneumococcal clearance, increasing pneumococcal concentration. We have ecological 
studies linking respiratory viral epidemics with pneumococcal disease, and we have 
evidence that severe pneumococcal pneumonia can follow influenza virus infection in 
pandemics. It mdy even be that respiratory viruses can trigger qbiescent pneumococci N 
colonising the nasopharynx in biofilms to change phase and become invasive. It has been 
postulated that respiratory viral infections may act synergistically with pneumococci of 
capsular or clonal types of lesser invasive potential, leading to IPD with such types.100 
Some have suggested that such viral-bacterial synergy may in fact account for all cases of 
IPD.101
2.1.3.5 Nasopharyngeal concentration and risk of disease
A high pneumococcal concentration in the upper airways may well be a risk factor for 
pneumonia or IPD but it could also be a result of pneumococcal pneumonia. The 
increased pulmonary secretions during pneumonia are expelled upwards by ciliary action
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and either swallqwed or expectorated. This could either seed the nasopharynx with 
pneumococci or provide direct sampling of such secretions during swab sampling.
Colonising pneumococci with invasive potential may have to reach a density threshold in 
the nasopharynx before they can breach the mucosa or spill over into the lungs in 
sufficient numbers to overwhelm the immune defences. Alternatively, the relationship 
between pneumococcal concentration in the nasopharynx and pneumococcal disease 
may be continuous. It may be oversimplifying the situation to consider all pneumococci to 
have the same relationship between nasopharyngeal concentration and likelihood of 
invasion. Respiratory viruses may trigger pneumococcal invasion - if so, do they do this by 
increasing pneumococcal carriage density? Young children are not only more likely to 
carry pneumococcus in the nasopharynx than older children or adults,102 but they are also 
prone to carry a higher concentration of pneumococcus 103 and respiratory viruses are 
frequently present in this age group.5 This high pneumococcal nasopharyngeal 
concentration could be part of the reason that young children are most at risk for
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pneumonia and invasive pneumococcal disease. A higher nasopharyngeal concentration 
of pneumococcal carriage could be part of the reason that children from lower socio­
economic groups or under-resourced countries are at higher risk for pneumococcal 
pneumonia and IPD.
It may be that respiratory viral infection triggering an increase in pneumococcal 
nasopharyngeal concentration coinciding with recent acquisition of an invasive 
pneumococcal serotype is required for invasive disease to occur. However if density of 
pneumococcal carriage or triggering by respiratory viral infection is more important for 
the occurrence of invasion than recent acquisition of a virulent pneumococcal type, then 
duration of carriage increases in importance epidemiologically. Duration of carriage
declines with increasing age in young children, and with the number of carriage 
episodes.65'104 Carriage duration 66 as well as other characteristics of carriage fitness,105 
and invasion potential,34 is associated with serotype.
2.2 Molecular methods to diagnose pneumococcal pneumonia or invasive 
pneumococcal disease
2.2.1 Development of pneumococcal PCR assays
Molecular methods to diagnose pneumococcal pneumonia or IPD have been in 
development for the past three decades.106 127 Some gene targets of nucleic acid 
amplification tests (NAATs) have been found to be non-specific to S. pneumoniae, present 
in non-pneumococcal Streptococcus species.106'125,128 This is perhaps not surprising, given 
the propensity of S. pneumoniae to undergo genetic transformation, using donor DNA 
from other Streptococcus species such as Streptococcus mitis as well as other strains of 
pneumococcus.129'130 A review of diverse studies carried out from 1993 to 2009 to assess 
PCR assays in the diagnosis of IPD from blood describes sensitivity of 57-66% and 
specificity of 88-99%, with specificity varying considerably depending on what sort of 
control groups were used.124 In general, specificity was higher when the control group 
was healthy people than people with suspected but unproven IPD and was higher in 
adults than in children. Poor sensitivity has been thought to be due to low specimen 
volume that can be tested by NAATs, timing of sample collection compared to that for 
blood cultures, PCR-inhibitors and pneumococcal autolysis and DNA degradation from old 
specimens, specimens stored at -20°C, or subjected to freeze-thaw cycles.116'122'125'127
There have been PCR assays developed using the pneumolysin gene p /^105-131'132 the 
surface adhesion protein psaA,125 penicillin-binding protein PBP2b,117 a gene of unknown
function spn9802,122,133 the autolysin gene / y ^ 116-125'134'135 capsular polysaccharide 
biosynthesis gene cpsA136 and bacterial recombinase gene recA.137 Dagan et al found that 
of 202 healthy controls, 35 (17%) were positive for ply PCR from serum samples. Carriers 
of pneumococci were more likely to be ply PCR positive from serum than non-carriers, 
and p/y-positivity was highest among 2-year old children, the group with the highest 
nasopharyngeal pneumococcal carriage. Dagan and colleagues postulated that 
pneumococci or pneumococcal DNA may have been detectable in the bloodstream of 
some children that had escaped immune control in the nasopharynx but were cleared 
successfully without any clinical disease. We now know the pneumolysin gene as a PCR 
target detects not only pneumococcus but also other commensal streptococcal flora and 
Dagan et al's suggestion has received little further attention as a result.106,125
2.2.2 lytA PCR
Although the autolysin gene has been demonstrated in some S. pseudopneumoniae128 
and 5. mitis gehomes,108 the gene sequence can be distinguished from that in S.  ^
pneumoniae.128,138 Most lytA assays have been demonstrated to have 100% analytical 
specificity for S. pneumoniae. At the CDC, a panel of 104 non-pneumococcal isolates 
including 11 non-pneumococcal viridans group streptococci and 10 S. pseudopneumoniae 
were negative by CDC -lytA PCR, although four of the S. pseudopneumoniae isolates were 
positive by the McAvin lytA PCR.125,134 The lytA PCR published by Sheppard et al, was 
negative among all of 39 non-pneumococcal isolates including 18 Streptococcus species 
116 and among all of 49 non-pneumococcal isolates including 22 mitis group 
streptococci.138 The Messmer lytA PCR was negative among all of 51 viridans group 
streptococci, including 16 closely related streptococci that appeared pneumococcus-like 
when originally isolated.120,139 The Nagai lytA PCR was negative among all of 108 non-
pneumococcal cocci, including 23 5. pseudopneumoniae, 5. mitis or 5. oralis strains and 54 
other Streptococcus species.136'140 A summary of these reports can be found in table 2.1 
below. Worldwide experience with the lytA target for identification of IPD cases using 
real-time PCR from whole blood is increasing, with most groups now using the CDC-/ytA 
assay.74'121,141147 It remains possible that the CDC-lytA assay will be demonstrated not to 
have 100% analytical specificity for pneumococcus, but there has been no evidence for 
this to date. Further testing against collections of closely-related, well-characterised non- 
pneumococcal streptococci would be helpful in this regard.
Table 2.1: Summary of published studies examining the specificity of lytA PCR for S. 
pneumoniae against closely related organisms
No. of non- 
pneumococcal No. of S.
streptococci pseudopneumoniae 
Reference lytA PCR assay positive/tested positive/tested
Carvalho etol, JCM 2007 (125) CD C-lytA 0/11 0/10
Carvalho eto/,JCM 2007 (125) McAvin lytA (134) 0/11 4/10
Sheppard et al, JMM 2004 (ii6) Sheppard lytA 0/18
Greve & Moller,vJMM 2012 (138) Sheppard lytA 0/22 N;
Messmer et al, DMID 2004 (139) Messmer lytA 0/51
Park et al, JMM 2010 (136) Nagai lytA (140) 0/54 0/23
Total isolates tested 156 33
2.2.3 Real-time lytA PCR from blood samples in the diagnosis of IPD
It appears that with current specimen handling and DNA extraction techniques, sensitivity 
of the lytA real-time PCR assay is now better than the previous gold standard for IPD, 
blood culture.74'143'144 Specificity is more difficult to assess. In South Africa, lytA real-time
PCR on fresh whole blood detected four times as many cases of IPD as blood cultures
among adults and children, and only missed 1% of cases detected by blood culture, but 
there was no control group and no estimation of clinical specificity.74 In Australia, a lytA 
real-time PCR performed on 1,800 adults presenting to the emergency department
alongside standard blood cultures detected 11 of 11 blood-culture-positive cases of IPD 
and 9 blood-culture-negative cases which may have been IPD (clinical scenario 
compatible with IPD and no other pathogen isolated).141
In Italy lytA real-time PCR from blood was negative among 147 well children, half of 
whom were demonstrably carrying pneumococcus in the nasopharynx15 and in South 
Africa both lytA and psaA real-time PCR's from serum were negative in 100 well children 
with a mean age of 5.8 years, half of whom were carrying pneumococcus in the 
nasopharynx.148 In Sweden, lytA PCR was positive in plasma of 9% of 92 adults with 
community-acquired pneumonia and none (0%) of 91 adult control patients hospitalised
for skin or urinary tract infections, or arthritis or elective surgery, without respiratory
122symptoms.
The lack of a sensitive gold-standard case-definition for IPD, and the use of well children 
or adults who are not the target population for the diagnostic assay, in these types of 
studies, produces a biased estimate of clinical specificity; A more appropriate cbntrol 
group would be children admitted to hospital with possible IPD who are proven not to 
have IPD; such a control group is almost impossible to find because we know that blood 
cultures themselves are insensitive in the diagnosis of IPD.
In Slovenia, lytA PCR was positive in plasma among 32% of 160 children and 23% of 180 
adults with community-acquired pneumonia.146 The authors also ran the assay on 
controls; lytA PCR was positive in plasma among none (0%) of 50 adults being 
investigated for Lyme disease and two (7%) of 29 children with acute febrile illness that 
was not pneumonia and in whom non-pneumococcal infections had been identified. The 
mean age of the childhood controls was 1.5 years, and both control children that were 
lytA PCR positive from plasma carried pneumococcus in the nasopharynx.
2.2.4 Quantitative real-time lytA PCR from blood samples in IPD
Use of quantitative PCR from blood samples as a marker of pneumococcal disease 
severity is also receiving interest, with higher pneumococcal concentrations associated 
with mortality.74'145’147'149 Quantitative real-time lytA PCR from blood might also assist in 
separating children with bacteraemia from children with PCR-positivity in blood 
("DNAemia") from high nasopharyngeal concentration, or escape of pneumococcus into 
the bloodstream without resulting sepsis, if such a phenomenon really occurs. It is 
possible that pneumococcal DNA could be detectable in blood specimens more often 
than we realise. Pneumococcal invasion into the bloodstream may occur more frequently 
than IPD as diagnosed by blood cultures from a clinically ill child occurs, but be controlled 
by complement-mediated bacterial lysis and opsonophagocytosis. The frequency with 
which such a phenomenon might occur would depend on the population carriage 
prevalence and density of carriage, the age structure of the population, the attack rate of 
circulating respiratory viruses, exposure to smoke and pollution, host genetics and the
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circulating bacterial strains.
2.2.5 Nasopharyngeal pneumococcal concentration in the diagnosis of pneumococcal 
pneumonia
A high nasopharyngeal concentration of pneumococcus has been associated with 
pneumonia in HIV-infected adults in South Africa 126 and with radiologically-confirmed 
pneumonia among children in Vietnam99 and Italy.150 In South Africa, high 
nasopharyngeal pneumococcal concentration has been associated with severity of 
pneumococcal pneumonia in HIV-infected adults,151 and with IPD in adults and children 
with pneumonia.152
47
Young children do not expectorate sputum so lower respiratory tract specimens in this 
age group are not easy to collect. Nasopharyngeal swabs, washes or aspirates can be 
used to sample the upper respiratory tract and induced sputum or bronchoalveolar 
lavage are uncommonly performed to access the lower respiratory tract. Detection of S. 
pneumoniae in respiratory tract specimens of infants and young children by culture or 
PCR is very common, as seen in table 2.2; understanding the clinical significance of it in 
the diagnosis of pneumonia is difficult.5'115,146'150,153,154
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There may be a continuum between low-level asymptomatic carriage of pneumococcus in 
the nasopharynges of healthy children, to increased carriage during periods of immune- 
stress or mucosal damage such as during exposure to smoke or viral infection, to local 
mucosal disease such as sinusitis and otitis media, to highest nasopharyngeal 
concentrations associated with pneumonia or IPD. If nasopharyngeal pneumococcal 
concentration by quantitative real-time PCR is greater among children with 
pneumococcal pneumonia than among children with viral respiratory tract infections or 
well children then it might be possible to look for a threshold correlating with 
pneumococcal pneumonia, as has been shown for adults.126'155 It has been assumed in the 
adult study in South Africa, that the increased nasopharyngeal concentration was in the 
causal pathway for pneumococcal pneumonia, which might be the case, but in fact we 
don't know the direction of causality for this association. In Vietnam the median 
pneumococcal concentration in the nasopharynx was 7.8 x 106/mL in children under the 
age of five years with radiologically-confirmed pneumonia compared to 1.3 x 106/mL in 
children with other lower respiratory tract infection, or 7.9 !x 105/mL in healthy children 
(p<0.001 for each comparison), but there was no suitable threshold for potential use as a 
diagnostic assay for pneumococcal pneumonia."
The ideal study to describe the dynamics of the spread of pneumococci in the body from 
healthy carriage through to bacteraemic pneumonia would be a cohort study of healthy 
children with frequent sampling of the nasopharynx and blood, from the asymptomatic 
state, through mild upper respiratory tract illness and into the development of naturally 
occurring pneumonia and pneumococcal bacteraemia. Unfortunately such a cohort 
would have to be extremely large in order to observe a rare event such as IPD in sufficient 
numbers, and the frequency of sampling needed would not be tolerated. A more 
epidemiologically efficient solution would be a series of cross-sectional samples of
suitable populations of children along the continuum outlined above, to describe the 
pneumococcal concentration in the nasopharynx and how this relates to pneumococci 
detectable in the blood.
2.3 Nasopharyngeal pneumococcal concentration and pneumococcal 
conjugate vaccines
As previously noted, there are more than 90 serotypes of pneumococcus, and only some 
of them have the propensity to cause invasive disease. Pneumococcal conjugate vaccines 
have been shown to reduce nasopharyngeal carriage of vaccine serotypes,102'156159 
including in people not themselves vaccinated.160'161 Reduction in carriage among 
vaccinated individuals and less transmission to unvaccinated individuals leads to less 
invasive disease among the unvaccinated as well as the vaccinated. These are indirect 
effects of vaccination -  also known as the herd effect. The herd effect has played a large 
part in overall IPD reduction.18 Pneumococcal conjugate vaccination is thought to bring 
about less carriage of vaccine-types by inducing mucosal immunity but exactly how this 
works is unclear.64 IgG and IgA antibodies to capsular polysaccharide may be present at 
the mucosal surface in response to vaccination, in line with the increase in systemic IgG 
antibody production, but in the mouse model antibodies do not appear to be necessary 
for clearance of pneumococcal carriage.162 The decrease in carriage of vaccine-types 
associated with PCV vaccination may decay with time over subsequent years so that 
mucosal immunity is lost, while immunity to invasive disease is retained.163
Reduction in IPD caused by vaccine-types has been concurrent with an increase in IPD
caused by non-vaccine-types, although in most populations this has not been sufficient to
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negate the overall impact of vaccination on IPD.3,18'20 Serotype replacement disease 
would be particularly a problem if more antibiotic resistant strains replace the vaccine- 
types in circulation. The drop in number of IPD cases in response to vaccination means 
that monitoring the impact of pneumococcal vaccines, whether the currently available 
polysaccharide-protein conjugated vaccines or new generation protein or whole cell 
vaccines, benefits from the use of carriage studies in addition to IPD surveillance; carriage 
is so much more common than IPD that it is easier to study.164 It is possible to separate 
out the direct and indirect effects of vaccination using carriage studies as part of vaccine 
impact monitoring. The vaccine effect on carriage in an individual is a direct marker of 
protection against disease (protection against acquisition, density or duration of carriage 
and protection against progression to disease).64 The indirect effect of vaccination (the 
herd effect) depends on the direct effect on carriage in order to reduce transmission.164 It 
would therefore be useful to examine the impact of vaccination on concentration of 
vaccine-type (VT) carriage, not only on VT carriage prevalence.
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2.3.1 Detecting multiple serotype carriage for vaccine studies
Children can carry more than one serotype of pneumococcus at a time, and do so in up to 
50% of children sampled using current methods,19'165'168 perhaps even up to 67% as 
measured by an Italian group -  although this study used nasopharyngeal swabs collected 
via the oropharynx and a real-time PCR method that could potentially detect capsular 
genes among non-pneumococcal streptococci in addition to those of pneumococcus.163
Historically, multiple serotype carriage was detected by injecting aliquots of saliva 
intraperitoneally into mice. Specimens yielding a pneumococcus were subsequently 
injected into mice pretreated with antiserum to the serotype initially recovered and the 
procedure repeated until no further serotypes were recovered.23 Using this method,
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Austrian reports that Gundel and Okura found in 1933 that 70 of 95 school children were 
harbouring more than one pneumococcal serotype.23 Subsequently, culture of 
nasopharyngeal swabs on 5% blood agar media, with or without gentamicin, was 
favoured as a more practical method for large-scale studies of nasopharyngeal carriage. 
Gentamicin was found to increase the sensitivity of the blood agar plate method for 
throat swabs in the detection of pneumococcus.169 Serotyping more than one colony of 
pneumococcus from culture plates was found to be both labour-intensive and inadequate 
to detect multiple serotype carriage because of the dominance of the prevailing type.170 
This method was standardised by a WHO working group but it was recognised that 
multiple serotype carriage was not readily detected and a call for improved methods was 
made.168
The PneuCarriage project
(http://www.thl.fi/roko/pneumocarr/pneucarriage project.html), an international 
consortium funded by the Gates Foundation, recently set out to establish the optimum
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methods for detection of multiple serotype carriage in order to publish updated 
recommended standard methods.171 Such standardisation is needed if we are to be able 
to measure and compare pneumococcal vaccine effectiveness in different settings around 
the world. Fifteen different methods were studied using a standard set of 81 spiked 
simulated samples, the best five methods being; pneumococcal microarray,166 latex 
agglutination of a sweep from the culture plate,166 restriction fragment length 
polymorphism (RFLP) analysis,172 real-time PCR from cultured isolates142 and real-time 
PCR directly from nasopharyngeal specimens.142,163 These five methods went forward to 
test a set of 260 nasopharyngeal swab samples and in addition traditional serotyping of 
100 colonies was performed for each sample. The gold standard was a serotype found by 
at least two different methods. Among these five methods the best scientific
performance was displayed by the pneumococcal microarray at St George's University 
Hospital in London (http://www.bugs.sgul.ac.Uk/node/l), with 96% sensitivity and 94% 
positive predictive value.171
2.3.2 Assessing pneumococcal carriage concentration in vaccine studies
Carriage density of vaccine-types, assessed by semi-quantitative culture, decreased in the 
vaccine-arm of a PCV-7 randomised controlled trial among a Native American 
population.158 In a cluster-randomised trial in the Gambia, carriage density was also 
measured by semi-quantitative culture and found to decrease for both vaccine and non­
vaccine types after administration of PCV-7.103 Antibodies to polysaccharide capsule were 
higher among individuals from fully-vaccinated than from control (infant vaccination only) 
villages, and increased with age to a plateau at 10 years of age.173 Pneumococcal carriage 
density was highest in the youngest children and decreased with age, beyond the plateau 
in polysaccharide antibody concentration, suggesting such antibodies were not solely 
responsible for the changes in carriage.103 In Kenya, Vaccine-type carriage prevalence 
decreased after PCV-10 was given to toddlers in a randomised controlled trial, however 
concentration of vaccine-type carriage was not assessed.10 Density of nasopharyngeal 
colonisation by pneumococcus is presumably important for both transmission and 
invasive disease 64 but we don't know what the nature of the relationships are.
Carriage prevalence as detected by culture is likely to be an indicator of colonisation 
density, but the relationship between culture positivity and colonisation density by qPCR 
seems to vary by method. In an experimental human pneumococcal carriage model, 
culture of fresh nasal washes from adults was able to detect down to 101 CFU/mL.174,175 In 
Peruvian children sampled by rayon nasopharyngeal swab into skim-milktryptone glucose 
glycerol (STGG) transport media, stored at -70°C, culture was significantly more likely to
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detect pneumococcus at a density of >105 CFU/mL by qPCR.176 By measuring the 
concentration of pneumococcus in a nasopharyngeal sample, whether by a sensitive 
quantitative culture method or by quantitative PCR, we assume we will get more 
information about changes in carriage associated with vaccination or viral infection.
A lytA qPCR will only tell us the overall concentration of pneumococcus in the 
nasopharynx since the autolysin gene is common to all pneumococci and is not serotype- 
specific. It would be worth knowing, not only what the concentration of nasopharyngeal 
colonisation is, but also what the concentration of colonisation with vaccine and non­
vaccine types, and how that changes after vaccination. This is pertinent because we 
expect a direct vaccine effect on vaccine serotypes only, and because of the possibility of 
serotype replacement disease; IPD caused by non-vaccine serotypes. This question could 
be answered with the pneumococcal microarray revealing the relative proportions of 
each serotype present, together with the lytA qPCR. It would also be possible to use a 
singleplex quantitative PCR for each serotype that might be present, as long as the same
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standards could be used to generate each standard curve in the PCR assays. Potential 
difficulties with this latter approach include the fact that capsular gene targets for 
serotyping assays may be found in non-pneumococcal streptococci that are also present 
in nasopharyngeal or oropharyngeal swab samples.177,178
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Chapter Three
3 Initial lytA real-time PCR method validation
3.1 Introduction
The lytA quantitative real-time PCR (lytA qPCR) method used in this work was originally 
developed at the Centers for Disease Control and Prevention (CDC) in Atlanta 125 and was 
developed further by Dr Nicole Wolter at the National Institute for Communicable 
Diseases (NICD) Laboratory in Johannesburg, South Africa. In brief, the method used DNA 
extracted from a standard volume whole blood in a singleplex real-time PCR reaction run 
alongside a set of standards made from DNA extracts of pneumococcal isolates run in 
triplicate in each plate. From the resulting standard curve, the Cycle Threshold (Ct) value 
of the PCR reaction could be converted into a quantity in copies/mL.
Xhe lytA qPCR assay in u^e at NICD was transferred to Kilifi and initial method validation 
was performed to ensure the method had analytical sensitivity and specificity for 
pneumococci found in Kilifi. Methods for making quantitation standards for the assay 
were explored and experiments were performed to choose an appropriate matrix for 
dilution of qPCR standards. The effect of different template volumes for the assay was 
investigated. The lower limit of detection and lower limit of linearity of the assay were 
examined.
The final methods used across the PhD project for whole blood and nasopharyngeal 
samples can be seen in chapter seven: General Laboratory Methods.
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3.2 Analytical sensitivity and specificity
As discussed in detail the chapter two, the lytA target is said to have 100% specificity for 
S. pneumoniae. Having not used the assay in Kilifi before, we first aimed to demonstrate 
analytical sensitivity and specificity on local isolates.
3.2.1 Methods
The lytA PCR method as described in section 7.11 in chapter seven was performed on; the 
type strain of pneumococcus, ATCC 49619, 30 local strains of pneumococcus that had 
caused invasive pneumococcal disease among children in Kilifi, 30 strains of non- 
pneumococcal streptococci from the same collection, and 70 strains of pneumococcus 
from nasopharyngeal carriage studies in Kilifi. DNA extracts for these isolates were a 1:10 
dilution of samples extracted by a simple boilate method, (described in section 7.8, 
chapter seven) which we were using in our laboratory for DNA extraction of invasive 
isolates for the conventional pneumococcal 'serotyping' PCR, adapted from the CDC 
method.179
3.2.2 Results
The type strain of pneumococcus, the 30 local pneumococcal isolates that had caused IPD 
and the 70 carriage isolates, including both serotypable and non-serotypable strains, 
were all successfully amplified by the lytA PCR assay. The 30 non-pneumococcal 
streptococci were not amplified by the assay, giving an analytical sensitivity and 
specificity of 100%, from isolates. The Ct values of these isolates can be seen in Table 3.1.
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Table 3.1: Analytical sensitivity and specificity of lytA real-time PCR for Streptococcus 
pneumoniae in Kilifi
Isolate no. Genus Species/Group Serotype lytA Ct value
36003 Streptococcus viridans group negative
36191 Streptococcus Group F negative
36199 Streptococcus Group D negative
36205 Streptococcus Group B negative
36365 Streptococcus species negative
36679 Streptococcus viridans group negative
36780 Streptococcus viridans group negative
38044 Streptococcus Group F negative
38436 Streptococcus Group D negative
38451 Streptococcus viridans group negative
38461 Streptococcus Group D negative
38526 Streptococcus Group D negative
38527 Streptococcus Group F negative
38585 Streptococcus Group D negative
38783 Streptococcus Group B negative
38794 Streptococcus Group D negative
38795 Streptococcus viridans group negative
38861 Streptococcus Group D negative
39247 Streptococcus Group B negative
39258 Streptococcus Group B negative
39281 Streptococcus Group D negative
39421 Streptococcus viridans group negative
40348 Streptococcus viridans group negative
40818 Streptococcus Group A negative
41274 ^Streptococcus viridans'group \; negative
42122 Streptococcus viridans group negative
42250 Streptococcus Group G negative
42771 Streptococcus Group A negative
44867 Streptococcus viridans group negative
44871 Streptococcus viridans group negative
44929 Streptococcus viridans group negative
41488 Streptococcus pneumoniae 23F 11.50
43188 Streptococcus pneumoniae 18C 11.85
45165 Streptococcus pneumoniae 1 11.93
41078 Streptococcus pneumoniae 23A 11.96
43874 Streptococcus pneumoniae 5 12.14
44608 Streptococcus pneumoniae 5 12.36
42860 Streptococcus pneumoniae 6A 12.45
43969 Streptococcus pneumoniae 1 12.48
43050 Streptococcus pneumoniae 6B 12.53
44261 Streptococcus pneumoniae 1 12.61
44656 Streptococcus pneumoniae 14 12.68
44655 Streptococcus pneumoniae 1 12.84
44527 Streptococcus pneumoniae 14 12.85
43639 Streptococcus pneumoniae 12F 13.19
44371 Streptococcus pneumoniae 14 13.27
44781 Streptococcus pneumoniae 13 13.40
Isolate no. Genus Species/Group Serotype lytA Ct value
44346 Streptococcus pneumoniae 6B 13.62
43429 Streptococcus pneumoniae 19A 13.83
44516 Streptococcus pneumoniae 2 13.83
43203 Streptococcus pneumoniae 6A 13.89
44746 Streptococcus pneumoniae 19F 14.23
43766 Streptococcus pneumoniae 3 14.86
38595 Streptococcus pneumoniae 15A 18.18
36880 Streptococcus pneumoniae 10A 18.28
37423 Streptococcus pneumoniae 4 18.30
39316 Streptococcus pneumoniae 1 18.55
36827 Streptococcus pneumoniae 11A 18.77
38827 Streptococcus pneumoniae 9V 19.04
38379 Streptococcus pneumoniae 5 19.09
40169 Streptococcus pneumoniae 15B 19.18
38039 Streptococcus pneumoniae 13 19.30
37013 Streptococcus pneumoniae 21 37.15
2045 Streptococcus pneumoniae untyped 15.92
3113 Streptococcus pneumoniae untyped 17.49
3201 Streptococcus pneumoniae untyped 18.87
3391 Streptococcus pneumoniae untyped 18.44
30581 Streptococcus pneumoniae nontypable 15.64
30831 Streptococcus pneumoniae nontypable 17.69
31473 Streptococcus pneumoniae nontypable 18.19
31477 Streptococcus pneumoniae nontypable 16.96
31516 Streptococcus pneumoniae nontypable 17.36
32303 Streptococcus pneumoniae nontypable 18.91
34531 Streptococcus pneumoniae nontypable 17.54
34749 Streptococcus pneumoniae nontypable 18.34
34941 Streptococcus pneumoniae  ^nontypable v17.72
34991 Streptococcus pneumoniae nontypable 17.17
35279 Streptococcus pneumoniae nontypable 17.62
35328 Streptococcus pneumoniae nontypable 17.84
35396 Streptococcus pneumoniae nontypable 18.00
35421 Streptococcus pneumoniae nontypable 17.82
35437 Streptococcus pneumoniae nontypable 17.18
44229 Streptococcus pneumoniae 19F 16.40
44231 Streptococcus pneumoniae 8 17.51
44280 Streptococcus pneumoniae 9N 15.78
44282 Streptococcus pneumoniae 6A 18.69
44285 Streptococcus pneumoniae 23F 16.55
44287 Streptococcus pneumoniae 6B 17.75
44291 Streptococcus pneumoniae 3 16.96
44292 Streptococcus pneumoniae 13 19.59
44395 Streptococcus pneumoniae 24F 15.45
44406 Streptococcus pneumoniae 15A 18.42
44408 Streptococcus pneumoniae 18F 17.23
44411 Streptococcus pneumoniae 6A 17.38
44470 Streptococcus pneumoniae 18A 14.95
44503 Streptococcus pneumoniae 23F 16.70
44519 Streptococcus pneumoniae 34 17.20
44615 Streptococcus pneumoniae 21 16.77
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Isolate no. Genus Species/Group Serotype lytA Ct value
44621 Streptococcus pneumoniae 23 B 17.30
44624 Streptococcus pneumoniae 6A 18.98
44672 Streptococcus pneumoniae 15C 16.35
44679 Streptococcus pneumoniae 14 18.23
44691 Streptococcus pneumoniae 15A 16.38
44692 Streptococcus pneumoniae 6B 17.29
44695 Streptococcus pneumoniae 19F 17.54
44716 Streptococcus pneumoniae 13 16.72
44808 Streptococcus pneumoniae 11A 16.53
44810 Streptococcus pneumoniae 5 16.86
44814 Streptococcus pneumoniae 22F 17.59
44818 Streptococcus pneumoniae 35B 18.16
44819 Streptococcus pneumoniae 1 16.78
44820 Streptococcus pneumoniae 16F 17.55
44825 Streptococcus pneumoniae 3 19.58
44830 Streptococcus pneumoniae 7F 17.95
44839 Streptococcus pneumoniae 20 17.13
44910 Streptococcus pneumoniae 11A 15.79
44914 Streptococcus pneumoniae 19C 15.21
44987 Streptococcus pneumoniae 35F 18.32
45013 Streptococcus pneumoniae 6B 18.89
45051 Streptococcus pneumoniae 6A 18.95
45052 Streptococcus pneumoniae 15B 16.99
45057 Streptococcus pneumoniae 18C 15.29
45061 Streptococcus pneumoniae 19A 16.65
45062 Streptococcus pneumoniae 35A 16.25
45079 Streptococcus pneumoniae 23F 17.55
45084 Streptococcus pneumoniae 6B 16.25
45128 Streptococcus pneumoniaev 19F  ^ 16.91
45131 Streptococcus pneumoniae 9V 17.59
45227 Streptococcus pneumoniae 13 16.41
45237 Streptococcus , pneumoniae 10A 15.87
45239 Streptococcus pneumoniae 6A 17.39
45297 Streptococcus pneumoniae 19 F 18.45
90617 Streptococcus pneumoniae untyped 17.32
3.2.3 Conclusions
This initial validation demonstrated that the CDC primers and probe were able to detect a 
range of locally circulating pneumococci in Kilifi with 100% analytical sensitivity and 
specificity. The viridans group streptococci were alpha-haemolytic streptococci from 
blood cultures at Kilifi County Hospital that were not S. pneumoniae because they were 
resistant to optochin, but we were not able to characterize them further. It would have
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been preferable to have well-characterized local isolates of S. pseudopneumoniae and S. 
oralis with which to test analytical specificity, but this has been done at other centres, as 
discussed in chapter two.
3.3 Making standards for quantitative lytA PCR
The work described in this section has been accepted for publication.
3.3.1 Introduction
We set out to explore methods for making in-house standards for the quantitative real­
time lytA PCR assay. Research and Clinical Microbiology laboratories alike are embracing 
qPCR for detection of putative microbial pathogens where simply presence of a target 
organism is insufficient to determine pathogenicity.99'126'147'180'181 For example, 
Pneumocystis jirovecii is known to cause severe pneumonia, but upon the advent of real­
time PCR diagnostics, it was discovered that sensitive qualitative PCR is generally non­
specific. It is frequently positive in well patients or those with another cause of illness. 
Quantitative PCR, however, may predict which samples are indicative of P. jirovecii 
pneumonia.181 Likewise, detection of Streptococcus pneumoniae from respiratory tract 
samples by quantitative real-time PCR may distinguish nasopharyngeal carriage of 
commensal S. pneumoniae from pneumococcal pneumonia.126 There is increasing interest 
globally in quantitative real-time PCR for detection of pneumococcus from respiratory 
tract samples, particularly utilizing the lytA assay. 125426
qPCR requires the use of standards of known concentration, serially diluted to form a 
linear relationship between the quantification cycle threshold (Ct) value and the
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logarithmic value of the standard concentration. Methods for making these standards 
are not always described in publications.182
3.3.2 Methods
One possible method was to make a suspension of pneumococcus, plate out serial 
dilutions of the suspension, perform colony counting, and calculate the concentration of 
the original suspension in colony-forming-units (CFU)/mL from which DNA would be 
extracted for the standards.149 Another method was to extract the DNA from a 
suspension of pneumococcus, measure the DNA concentration in ng/nL, from which the 
concentration in genome-copies/mL calculated based on molarity (using Avogadro's 
number) (personal communication, Nicole Wolter, NICD). These methods are unlikely to 
be equivalent because they assume a single viable bacterial cell produces a single colony- 
forming unit; may be perfectly extracted by DNA extraction methods and will contain only 
one genome, with only one gene copy.183 If they were the same then the ratio of the 
^concentration in CFU/rhL to the concentrationMn genome-copies/mL Would be one. To 
investigate the impact of pneumococcal autolysis, we used Escherichia coli as a 
comparator organism. For the same reason, we used bacterial growth in broth at log 
phase as well as bacterial growth harvested from solid media, to make the starting-point 
suspensions.
S. pneumoniae ATCC 49619 and f. coli ATCC 25922 were grown to log phase in brain heart 
infusion broth, or harvested from an overnight culture plate on blood agar and suspended 
in normal saline, and adjusted to 3.0 McFarland. The suspensions were serially diluted 1:5 
nine times and lOOpL of each of the last three dilutions plated in duplicate on blood agar 
for incubation overnight at 35+/- 2°C in 5% CO2. In addition, lmL of the suspension was 
used for immediate extraction. To estimate CFU/mL, all countable plates underwent
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colony counting on the following day to calculate the concentration of the original
suspension.
DNA was extracted (QIAamp DNA mini kit, Qiagen, Germany) with two elution steps as 
described by the manufacturer to optionally maximise DNA recovery, and DNA 
concentration estimated in ng/pL using the Nanodrop™ spectrophotometer 
(ThermoScientific, USA). Genome copies were estimated using the formula mass = DNA 
size (base pairs) x lmole/6.023e23 molecules x 660g/mole. Twelve experiments were 
performed per organism, by the same operator, on different days.
The ratio of quantities derived from colony counting/DNA concentration (CFU/genome- 
copies) were compared by suspension method and by organism, using the Wilcoxon rank 
sum test.
3.3.3 Results
) The distribution of bacterial concentrations b^ colony counting (mean log [sd] 
concentration for S. pneumoniae 8.4 [0.7] CFU/mL and for E.coli 8.9 [0.4] CFU/mL) was 
wider than the distribution of bacterial concentrations as calculated by DNA 
concentration (mean log concentration for S. pneumoniae 8.9 [0.2] genome-copies/mL 
and for E. coli 8.6 [0.2] genome-copies/mL). The distributions can be seen in Figure 3.1. 
For S. pneumoniae Spearman's rank correlation between the bacterial concentration as 
measured by colony counting and the bacterial concentration as calculated from DNA 
concentration was 0.69 (p=0.014) and for E. coli this was 0.10 (p=0.746). The correlations 
can be seen in figure 3.2. The ratio of quantities derived from the two methods was 
almost never one, and can be seen in Figure 3.3.
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Figure 3.1: Spread of bacterial concentrations of standard suspensions of 5. pneumoniae 
and E. coli. A: Obtained by colony counting in CFU/mL B: Obtained by DNA concentration 
in genome-copies/mL
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Figure 3.2: Poor correlation between methods of measuring bacterial concentration.
Colony counting in CFU/mL and DNA concentration in genome-copies/mL.
The median (IQR) ratio (CFU/genome-copies) for S. pneumoniae combining both culture 
methods was 0.19 (0.1-1.2) and for E. coli was 1.74 (1.1-2.9), p=0.007. For either S. 
pneumoniae or E. coli, there was no difference in the ratio (CFU/genome-copies) whether
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culture on solid media or log phase growth in broth was used to make the suspension, as 
can be seen in figure 3.3.
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Figure 3.3: Ratio of quantification methods. Colony counting/DNA concentration in 
CFU/gepome-copies, by organism and culture-medium. v
3.3.4 Discussion
There was poor correlation between the bacterial concentration as measured by colony 
counting and the bacterial concentration as calculated from DNA concentration.
The ratio of bacterial concentration by colony counting to the bacterial concentration as 
calculated from DNA concentration, whether the measured suspension was made in 
saline from growth on solid media or from broth culture, was lower for S. pneumoniae 
than for E. coli. This supports a possible role of pneumococcal autolysis in lowering the
ratio of concentration in CFU/mL to concentration in genome-copies/mL, because the 
autolysed nonviable cells in suspension could contribute to the quantity measured by 
DNA extraction but not to the quantity measured by colony-counting. Additionally, more 
than one genome may be present per cell, depending on the phase in the cell division 
cycle. It is not realistically possible for a single genome-copy to give rise to more than one 
CFU but ratios of >1 in CFU/genome-copies serve to highlight the difficulty in accuracy 
with either of the measurement methods. DNA concentration may be underestimated 
due to inefficiencies in nucleic acid extraction, nucleic acid degradation or sample 
inhomogeneity or overestimated due to impurities in the extraction process. Colony 
counting could overestimate or underestimate concentration due to sample 
inhomogeneity, delays in plating out suspensions or inaccuracies in counting individual 
colonies.
The lack of a difference between suspension methods for S. pneumoniae implies that log 
phase growth does not sufficiently overcome the problem of autolysed cells in
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suspension, or that pneumococcal autolysis is not the only problem.
The DNA concentration method of quantification was less variable than the colony 
counting method. Poor correlation between methods may be due to inherent differences 
in measuring bacterial cells versus measuring their genomes, rather than simply 
pneumococcal autolysis as it was more pronounced for E. coli than for S. pneumoniae. 
Growing the suspension to log-phase before quantification did not alter the results, but 
the median ratio of concentrations was lower for S. pneumoniae than for E. coli, also 
suggesting that pneumococcal autolysis is not the sole cause of poor correlation between 
quantification methods.
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It was noted that while the DNA concentration method for making standards may appear 
to be a good choice for quantitative real-time PCR in a single laboratory, that there may 
be considerable intra-assay variation between batches of standards by either method. 
What is more, the lack of correlation between methods means that absolute 
quantification of samples between laboratories using different methods would not give 
comparable results.
It is important to be aware that the method used for assigning values to quantitative real­
time PCR standards will affect the results obtained. This is particularly pertinent when 
applying thresholds or cut-offs that rely on quantification from an assay designed in one 
laboratory and then used in another laboratory.
3.3.5 Conclusions
Neither method of preparing in-house standards was considered suitable for the PhD 
objectives, nor for the Pneumonia Etiology Research for Child Health (PERCH) multi-site
V  , V  V  . \
study, because they would not be reproducible across the length of each project, nor 
sufficiently reproducible between laboratories. Instead, it was decided to obtain 
commercially available plasmids containing the lytA target amplicon and serially dilute 
the plasmids for each individual run (rather than storing diluted plasmids). These 
plasmids came from Fast-Track Diagnostics (FTD) in Luxembourg. FTD also measure the 
concentration of the plasmids by Nanodrop, but these are much more pure than whole 
genomic DNA, thus the measurement is more reliable. Each batch of plasmids that FTD 
produce is checked to ensure that the cycle thresholds are reproducible within +/- 2 Ct 
values.
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3.4 Matrix for dilution of standards for lytA qPCR
The intent was to serially dilute the FTD-supplied lytA standards for each lytA qPCR run in 
molecular grade water. Samples of whole blood, of nasopharyngeal swab specimens in 
STGG or nasopharyngeal swab specimens in viral transport medium that were to be run in 
the lytA qPCR assay would be DNA suspended in eluate from the original sample type, 
which could have different properties affecting PCR efficiency compared to the standards. 
In order to ensure this was not the case, FTD lytA plasmid standards were serially diluted 
in molecular grade water, in eluate from whole blood, in eluate from uninoculated STGG 
and in eluate from uninoculated Copan universal transport medium (UTM). The aim was 
to compare Ct values of lytA qPCR from plasmids serially diluted in sample matrix to 
plasmids serially diluted in molecular grade water, for each sample type.
3.4.1 Methods
Uninoculated sterile whole blood, STGG and Copan UTM underwent DNA extraction using 
QIAamp DNA blood mini kits (Qiagen, Germany) as described in the chapter seven for 
blood or nasopharyngeal swabs. Master stock of lytA plasmid standards at 108 copies/mL 
was serially diluted 1:10 four times in molecular grade water and in whole blood eluate 
and each dilution series were run in triplicate in the same PCR plate. lytA qPCR was 
performed as in section 7.9 of chapter seven and mean Ct values plotted. Master stock of 
lytA plasmid standards at 108 copies/mL was serially diluted 1:10 five times in molecular 
grade water and in STGG and Copan UTM eluates and each dilution series were run in 
triplicate in the same PCR plate. Mean Ct values were again plotted for each plasmid 
concentration.
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3.4.2 Results
The mean Ct values for lytA plasmid standards in molecular grade water and in whole 
blood eluate matrix can be seen in figure 3.4.
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Figure 3.4: Standards matrix. Comparison of molecular grade water and whole blood 
eluate as matrix for serial dilution of plasmid standards for lytA qPCR.
The mean Ct values for lytA plasmid standards in moiecuiar grade water and in STGG 
eluate matrix and Copan eluate matrix can be seen in figure 3.5.
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Figure 3.5: Standards matrix. Comparison of molecular grade water, eluate of 
uninoculated STGG and eluate of uninoculated Copan universal transport medium (UTM) 
as matrix for serial dilution of plasmid standards for lytA qPCR.
3.4.3 Conclusions
Molecular grade water was considered to be a reasonable and convenient replacement 
for sample extract matrix for serial dilution of standards for use in lytA qPCR. It was noted 
that unsurprisingly there is more variation in Ct values at lower concentrations of the 
plasmid standard.
3.5 Choosing a template volume for lytA qPCR
The original CDC method for lytA qPCR used 2.5pL of template in the PCR reaction, for 
historical reasons (Bernard Beall, personal communication to David Murdoch). Other 
laboratories have used 6pL144 or lOpL of tem plate .147 Increasing the template volume in
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the reaction may improve the sensitivity of the assay, but increasing it too much could 
result in PCR inhibition. An experiment was therefore performed to see which of 2.5pL, 
5pL or lOpL would perform best with the lytA qPCR protocol.
3.5.1 Methods
Using the lytA PCR method as described in section 7.11 in chapter seven, and maintaining 
the total reaction volume at 25pL, the water was adjusted in the mastermix according to 
the change in template volume. A set of standards was made by serial 1 in 10 dilution in 
molecular grade water of DNA extracted from a suspension of 5. pneumoniae, the 
concentration measured by the colony counting method (further details can be seen in 
the chapter seven, section 7.2). The series of standards in triplicate was run for each of 
the three templates, 2.5pL, 5pL or lOpL, in the same reaction plate.
3.5.2 Results
The mean cycle threshold values for standards run with the three alternative template 
volumes can be seen in table 3.2.
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Table 3.2: Mean Ct values for a series of standards run in triplicate, comparing three
alternate DNA template volumes in lytA qPCR.
Standards Mean Ct for 2.5pL Mean Ct for 5.0|iL Mean Ct for lOpL 
CFU/mL template template template
10e6 23.06 22.37 23.41
10e5 26.80 26.07 27.87
10e4 30.65 29.66 32.32
10e3 34.56 33.67 35.62
10e2 37.34 36.44 39.11
lO e l negative 37.70 negative
3.5.3 Conclusions
As the 5pL template volume gave lower or equivalent Cycle threshold (Ct) values in the 
PCR reaction than the 2.5pL or lOpL template volumes, this volume was chosen to 
continue with. Since the PERCH project chose lOpL as a template volume, and methods 
needed to be standardised across all seven sites, 10pL was used for the whole blood lytA
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qPCR assay, but a 5pL template volume continued to be used for the nasopharyngeal 
samples as these were likely to have a higher bacterial load.
3.6 Lower limit of detection and lower limit of linearity of lytA qPCR
Once satisfied with the standards, experiments were then performed to ascertain the 
lower limit of detection of the lytA qPCR assay, and to establish the linear range.
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3.6.1 Methods
Using the lytA PCR method as described in section 7.11 in chapter seven, the plasmid 
standards were run in triplicate five times, with a fresh 1:10 dilution series made for each 
run from a master stock vial of 108 copies/mL. Two different operators were included.
The standard curves were plotted overlaid and the mean and standard deviation of the Ct 
value for each plasmid concentration plotted with and without the least dilution, of 102 
copies/mL
Subsequently, after the project in chapter nine, nasopharyngeal pneumococcal 
concentration before, during and after respiratory viral infection, was performed, 
standard curves from another 11 runs of lytA qPCR were plotted overlaid and the mean 
and standard deviation of the Ct value for each plasmid concentration were plotted.
The lower limit of detection was defined as the least lytA plasmid concentration that was 
able to be detected 95% of the time and was extrapolated from these two sets of data.
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The lower limit of linearity was defined as the least lytA plasmid concentration at which 
the standard curve remained linear.
3.6.2 Results and Conclusions
The reproducibility of five individual standard curves with lytA plasmids and the mean 
standard curve with standard deviations about each point can be seen in figure 3.6.
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Figure 3.6: Reproducibility of lytA standard curves. A: Five standard curves using 
commercially available lytA plasmid standards. B: Mean standard curve with standard 
deviations around each point. Slope = -3.1 C: Mean standard curve with standard 
deviations around each point, omitting the 102copies/mL standards to demonstrate 
improved linearity, slope = -3.4.
The slope of the mean standard curve was -3.1 with the 102 copies/mL standards 
included, o r -3.4 without these data points. Observation of the standard curves with and 
without the 102 copies/mL data points revealed the lower limit of linearity to be 103 
copies/mL
The lower limit of detection should be defined as the concentration at which 95% of the 
samples can be detected. From these five initial method validation runs, 100% of 15 
plasmid standards at 104 copies/mL were detected, 80% of 15 plasmid standards at 103
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copies/mL were detected and 60% of 15 plasmid standards at 102 copies/mL were 
detected. We could therefore take the lower limit of detection to be approximately 103 
copies/mL or we could extrapolate from these points on a semilog line, which yields a 
lower limit of detection of 5.62xl03 copies/mL
Taking the 11 runs of lytA qPCR data from chapter nine, where nasopharyngeal 
pneumococcal concentration was assessed before, during and after respiratory virus 
infections, the 33 plasmid standards at 104 copies/mL were detected 100% of the time, 
the 33 plasmid standards at 103 copies/mL were detected 85% of the time, and the 33 
plasmid standards at 102 copies/mL were detected 15% of the time. These standard 
curves can be seen in figure 3.7. The lower limit of detection of the assay in this dataset
was again approximately 103 copies/mL, or by extrapolation 4.64xl03 copies/mL. The 
lower lim it of linearity was also 103 copies/mL
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Figure 3.7: Reproducibility of lytA standard curves using plasmid standards during a 
study of pneumococcal concentration from nasopharyngeal swabs in viral transport 
medium. A: Eleven standard curves using lytA plasmid standards. B: Mean standard curve 
with standard deviations around each point.
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Chapter Four
4 Validation of laboratory methods for whole blood specimens
4.1 Introduction
Having performed initial method validation for the lytA qPCR assay, the next step was to 
consider the different specimen types that would be used in the upcoming projects. The 
first specimen type considered was whole blood in EDTA.
Sources of variation in the assay considered included the volume of samples, PCR 
inhibition, and the DNA extraction method.
4.2 Variation in sample volume
All specimens have had DNA extracted from 200pL of blood, unless there is less than 
200pL available, which is sometimes the c&se with sick infants. In this case the volume v
extracted was noted and taken into account in the calculation of pneumococcal 
concentration.
4.3 PCR inhibitors
PCR inhibitors could have been present in some samples. Internal controls could have 
been spiked into all samples, or a human gene target used, and amplified in multiplex but 
this could cause amplification competition and reduce sensitivity of the lytA qPCR, so 
after review of the published literature,116'122'124'125'135'144'145'184 a s  s e e n  jn  table 4.1, and 
discussion with Nicole Wolter from the NICD and David Murdoch it was elected not to do 
this.
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4.4 The DNA extraction method
The DNA extraction method required validation. It was important early on to establish a 
DNA extraction technique for whole blood samples because it was thought that sensitivity 
of pneumococccal PCR from blood would depend significantly on specimen quality and 
handling, and the DNA extraction method. DNA should be extracted from blood while it 
is as fresh as possible, prior to freezing, and the extraction method should be good 
enough to extract even low concentrations of pneumococci.
The options for DNA extraction were constrained by the requirement to share the 
specimens with other research projects such as the PERCH multi-site international study 
and the Kilifi genome-wide association studies, and by limited sample volume.
Method validation for DNA extraction first compared the QIAamp DNA blood mini kit
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* (Qiagen, Germany) manual method, with the ABI PRISM 6100 (Applied Biosystems, Life < 
Technologies, California, USA) semiautomated vacuum method being used by the Kilifi 
genome-wide association project at the time, and the MagNA Pure DNA III (Roche, 
Indianapolis, USA) automated silica bead-based method (which was being considered by 
the PERCH multi-site study team, was the method in use for whole blood DNA extraction 
for lytA qPCR at the NICD, and was available in the virology department in the KWTRP 
laboratory). This work was performed in conjunction with the Kilifi genome-wide 
association project research team. The work led on to a comparison of the Qiagen manual 
method with MagNA Pure extraction from pneumococcal spiked whole blood samples, 
measured by lytA qPCR.
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4.4.1 Comparison of Qiagen manual method with ABI-PRISM-6100 semi-automated 
method and MagNA Pure automated method
4.4.1.1 Methods
Details of extraction protocols for Qiagen and MagNA Pure methods can be seen in 
sections 7.6.1 and 7.4 in chapter seven. The ABI PRISM-6100 method was as follows: 20pL 
of Proteinase K Solution, 80pL of PK Digestion Buffer and 200pL of whole blood sample 
was placed in each well of a 96 deep well plate and mixed by pipetting up and down five 
times. The plate was incubated at 65°C for one hour in a water bath before adding 300pL 
of BloodPrep DNA Purification Solution for a total volume of 600pL per sample. After 
mixing by pipetting again, the plate was loaded onto the instrument for a purification run 
with the settings found in table 4.1.
Table 4.2: Settings for ABI PRISM 6100 semi-automated extraction instrument for DNA 
extraction from whole blood samples.
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Step Description Volume (mL) Position Incubation (s) Vacuum (%) Time (s)
1 Load Samples 600 Waste 0 80 300
2 Add BloodPrep DNA Purification Solution 500 Waste 0 80 400
3 Add BloodPrep DNA Wash Solution 500 Waste 0 80 60
4 Add BloodPrep DNA Wash Solution 500 Waste 0 80 60
5 Add BloodPrep DNA Wash Solution 300 Waste 0 80 60
6 Pre-Elution Vacuum - Waste 0 100 60
7 Touch Off - Waste - - -
8 Elution Solution 1 80 Collection 600 60 120
9 Elution Solution 2 80 Collection 600 60 120
10 Touch Off - Collection - . -
Numbers of whole blood samples in EDTA were as follows, because there was insufficient 
specimen volume to test every sample by all three methods: ABI n=79, MagNA Pure n=31, 
Qiagen n=12. Total DNA extracts from all methods were measured by the Nanodrop
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spectrophotometer (Thermo Scientific, Delaware, USA) for DNA concentration (in r|g/pL) 
and purity.
4.4.1.2 Results
The mean and standard deviation of DNA concentrations obtained by the three methods 
can be seen in table 4.2.
Table 4.3: DNA concentration of extracted whole blood samples by ABI-6100 semi­
automated vacuum extractor, Qiagen manual method and MagNA Pure automated 
extraction instrument.
Extraction
method
N
Mean DNA 
concentration 
ng/pL
Standard
deviation Range
ABI-6100 79 51.44 41.21 3.66 150.80
Qiagen mini kit 12 198.86 148.13 48.52 581.00
MagNA Pure 31 14.63 5.62 5.72 31.28
It'was noted that some samples clogged in the Afel vacuum system, resulting in high 
concentration, low volume DNA extracts.
When measuring DNA concentration with the Nanodrop spectrophotometer, the primary 
indicator of DNA purity is the 260:280 ratio, which should be >1.8. A secondary measure 
of DNA purity is the 260:230 ratio. The 260:280 and 260:230 ratios of extracted whole 
blood samples using the ABI-6100 semi-automated vacuum extractor, the Qiagen manual 
method and the MagNA Pure automated extraction instrument can be seen in table 4.3.
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Table 4.4: DNA purity of extracted whole blood samples by ABI-6100 semi-automated 
vacuum extractor, Qiagen manual method and MagNA Pure automated extraction 
instrument, as measured by the Nanodrop 260:280 and 260:230 ratios.
Extraction
Method
N
Mean
260/280
ratio
Standard
deviation
Range
ABI-6100 79 1.9 0.71 1.41 5.60
Qiagen mini kit 12 1.85 0.06 1.68 1.91
MagNA Pure 31 2 0.19 1.66 2.56
Extraction
Method
N
Mean
260/230
ratio
Standard
deviation Range
ABI-6100 79 0.19 0.13 0.02 0.57
Qiagen mini kit 12 1.43 0.36 0.98 2.15
MagNA Pure 31 0.64 0.16 0.35 1.09
4.4.1.3 Conclusions
The Qiagen manual method gave the greatest DNA concentration as measured by 
Nanodrop, but is not a high-throughput method. The MagNA Pure method gave the most
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pure DNA as measured by Nanodrop. The ABI method gave a good DNA concentration 
most of the time but tended to clog meaning some samples were lost. The Qiagen 
method appeared to be best so far, and it was decided to compare the lytA qPCR results 
from DNA extracted by Qiagen compared to MagNA Pure as a next step.
4.4.2 Comparison of Qiagen manual method with MagNA Pure automated method 
using pneumococcal spiked whole blood samples, measured by lytA qPCR
4.4.2.1 Methods
A heavy (McFarland 3.0) suspension of Streptococcus pneumoniae ATCC 49619, was 
spiked into whole EDTA blood and serial 1:10 dilutions were performed, each dilution was 
extracted by both MagNA Pure and Qiagen methods before undergoing lytA PCR in
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duplicate, and had colony counting performed. Chapter seven, sections 7.4, 7.6.1 and 
7.11, has details for the MagNA Pure and Qiagen extraction protocols and the lytA PCR 
method. The lytA PCR method in use was as described for bacterial isolates.
4.4.2.2 Results
The Ct values of lytA PCR performed on duplicate spiked whole blood specimens 
extracted by the Qiagen manual method and the MagNA Pure automated instrument can 
be seen in table 4.4.
Table 4.5: Ct values from lytA real-time PCR of whole blood extracted by the Qiagen 
manual method or the MagNA Pure automated method.
Colony counting Ct from Qiagen Duplicate Ct from MagNA Duplicate from
CFU/mL extract from Qiagen Pure extract MagNA Pure
lOeO negative negative negative negative
lO e l negative negative negative negative
10e2 37.45 negative negative negative
10e3 35.75 34.65 negative negative
10e4 31.27 31.21 33.14 32.41
10e5 27.39 27.66 29.16 29.16
10e6 v23.89 23.89 V 24.69 24.69
10e7 21.54 21.56 21.57 20.98
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4.4.2.3 Conclusions
The limit of detection using the lytA PCR was 2 log higher from MagNA Pure-extracted 
DNA than from Qiagen-extracted DNA, so the Qiagen method appeared to be more 
sensitive in combination with the lytA PCR than the MagNA Pure method.
At that point in time whole blood specimens being collected on all children who were 
admitted to Kilifi County Hospital and qualified for a blood culture, began being extracted 
using the QIAamp DNA blood mini kit manual method, within three days of collection of 
the specimen.
We next compared the manual Qiagen extraction to automated QIAxtractor extraction -  
also from Qiagen, and using the same chemistry as the manual Qiagen method. The 
experiments included the QIAxtractor as being considered by the genome-wide 
association studies research group for high throughput extraction of frozen stored blood 
samples and the EasyMag extraction method because a subset of these samples were
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included in the PERCH multi-site study which by that stage required automated EasyMag 
extraction as a standard method across sites.
4.4.3 Comparison of manual Qiagen method with QIAxtractor and EasyMag 
automated methods, using pneumococcal spiked whole blood samples.
The aim was to compare the three extraction methods' ability to extract pneumococcus 
from whole blood at a range of concentrations. A secondary objective was to compare 
robustness of the extraction methods using fresh and one month-old blood samples.
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4.4.3.1 Methods
EDTA whole blood was spiked with a 0.5 McFarland suspension of Streptococcus 
pneumoniae ATCC 49619. This was serially diluted 1:10 in fresh whole blood, and 
extracted in duplicate by each of the EasyMag (Bio-Merieux, France) and QiaXtractor 
(Qiagen, Germany) automated instruments and by the Qiagen manual method using the 
QIAamp blood minikit (Qiagen, Germany) (Details of the extraction protocols can be seen 
in chapter seven, sections 7.7, 7.5 and 7.6.1). Extracted DNA was stored at -80°C. Aliquots 
of each spiked sample were retained for one month at 2-8°C and were subsequently 
extracted again by each method, also in duplicate, to check for robustness of the method 
with older samples. lytA PCR was performed according to the description in section 7.9 in 
chapter seven.
4.4.3.2 Results
The lytA PCR Ct values of aliquots of pneumococcus-spiked blood samples from which
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DNA was extracted by three different methods while samples were fresh and again after 
one-month of storage can be seen in figure 4.1.
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Figure 4.1: lytA PCR Ct values of pneumococcus-spiked blood samples processed fresh 
and after one month at 2-8°C
4.4.3.3 Conclusions
Ct values of lytA qPCR from pneumococcal-spiked whole blood samples were comparable 
by the three extraction methods; manual Qiagen, automated QIAxtractor and EasyMag. 
QIAxtractor gave the lowest Ct values, followed by the manual Qiagen method, followed 
by EasyMag. All methods returned linear results over the range of dilutions. DNA 
extracted from fresh samples performed better in the lytA PCR than DNA extracted from 
samples stored at 2-8°C for one month only in the lowest concentrations.
It was notable that the QIAxtractor method uses a 96 well plate and consumables which 
are wasted if less than 96 samples are run at a time, which is a problem for extracting 
from fresh, rather than batched frozen, samples.
A B C D E F G
Serial 1:10 dilutions of pneumococcus-spiked whole blood
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The fresh whole blood samples from all admissions therefore continued to be extracted 
by the manual Qiagen method, within 3 days of sample collection. Blood samples from 
patients also enrolled in the PERCH study additionally underwent EasyMag extraction, but 
this was from frozen blood samples most of the time as the EasyMag instrument had 
technical problems and had to be replaced.
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Chapter Five
5 Validation of laboratory methods for nasopharyngeal swabs in 
viral transport medium
5.1 Introduction
Potential sources of variation in lytA concentration in nasopharyngeal swab samples are 
high compared to blood specimens. DNA extraction, possible PCR inhibition and the 
volume of posterior nasopharyngeal secretions were considered as sources of variation. 
Reproducibility of results was assessed.
5.2 DNA extraction method
For pragmatic reasons, the total nucleic acid (TNA) extracts of the viral transport medium 
(VTM) specimens that bad been performed in the parent study of respiratory virus 
transmission9 were used for objective two, the study of pneumococcal concentration 
before, during and after respiratory virus infection. The method that had been used in the 
parent study was the MagNA Pure (Roche, Indianapolis, USA) instrument, an automated 
magnetic silica bead extraction method, with the MagNA Pure High Performance Total 
Nucleic Acids k it,8 to extract nucleic acids from Copan nasopharyngeal flocked swabs in 
an in-house VTM. The VTM had been made from 5g veal infusion broth (BD Difco, USA), 
lg  bovine albumin fraction V (MP Biomedicals, France), 20mg gentamicin, 400pg 
amphotericin in 200ml of sterile distilled water. Reproducibility of pneumococcal DNA 
amplification from these samples was assessed for the present project using unneeded 
participant samples from the parent study.
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For the study of the performance of lytA qPCR on whole blood, nasopharyngeal 
pneumococcal concentration was assessed as part of the Pneumonia Etiology Research 
for Child Health (PERCH) project. These nasopharyngeal flocked swabs were collected into 
Copan universal transport medium (UTM) (Copan Diagnostics, California, USA) and 
extracted using the EasyMag automated extraction instrument (Bio-Merieux, France).
The aim was to ensure both EasyMag and MagNA Pure LC instruments could successfully 
extract known quantities of pneumococcus from the transport medium used for 
nasopharyngeal swabs that had been collected for viral detection.
5.2.1 Methods
Streptococcus pneumoniae ATCC 49619 was grown on blood agar overnight and a 
suspension made in phosphate buffered saline at an optical density of 0.12 (Biowave 
colorimeter, Biochrom, UK), estimating a concentration of 107 - 108 cells/mL. 140pL of 
the suspension was added to 1260pL of Copan UTM to make a 1:10 dilution, and a further
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five 1:10 dilutions made in UTM, resulting in six different concentrations labelled A to F. 
These were aliquoted such that duplicates of each concentration underwent EasyMag 
extraction and duplicates of each concentration underwent MagNA Pure extraction. 
EasyMag extractions were performed from 400pL of spiked UTM into 110|iL of eluate, 
and MagNA Pure extractions were performed from 200pL of spiked UTM into 60pL of 
eluate, to mimic the PERCH and household viral transmission study methods from which 
it was expected study samples would be drawn. All nucleic acid extracts underwent lytA 
qPCR, as described in section 7.10 of chapter seven.
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5.2.2 Results
Both EasyMag and MagNA Pure were able to extract pneumococcus from UTM to an 
estimated concentration of between 103 to 104 cells/mL. The mean lytA Ct values from 
the duplicate reactions, and the mean quantity of lytA detected adjusted for 
extractionrelution ratio, for each extraction method, can be seen in table 5.1 and figure 
5.1.
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Table 5.1: lytA qPCR results from EasyMag and MagNA Pure extractions of
pneumococcus-spiked Copan universal transport medium samples
Spiked serially 
diluted sample
Expected
quantity
cells/mL
EasyMag 
mean Ct
EasyMag 
mean quantity
MagnaPure 
mean Ct
MagnaPure 
mean quantity
A 10,000,000 23.8 2,041,853 23.7 2,312,376
B 1,000,000 26.8 362,808 27.4 262,896
C 100,000 29.5 65,438 30.8 33,460
D 10,000 34.1 4,280 34.6 4,121
E 1,000 36.6 968 36.9 878
F 100 37.4 651
EasyMag 
mean quantity
MagnaPure 
mean quantity
A B C D E F 
Serial 1:10 dilutions of pneumococcus-spiked viral transport medium
Figure 5.1: Pneumococcal concentration in spiked Copan transport medium, by lytA 
qPCR after EasyMag and MagNA Pure DNA extraction
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5.2.3 Conclusions
EasyMag and MagNA Pure extraction methods for pneumococcal DNA from UTM were 
equivalent within the range of 107-1 0 3 cells/mL. Concentrations obtained by either 
method were slightly less than the approximate expected concentrations, but colony 
counting had not been performed to confirm the expected concentrations.
5.3 The possibility of PCR inhibitors present in nasopharyngeal swab 
samples
It is possible that nasopharyngeal swabs in transport medium contain PCR inhibitors 
inherent to the sample type itself, which cannot be sufficiently tested by spiked samples. 
This inhibition can usually be overcome by diluting the sample, which dilutes the 
inhibitors. Therefore actual samples from the parent viral transmission study used in 
objective two were tested to check for the presence of sample inhibition. If sample 
v inhibition is present then the diluted sample should have the same or lower Ct value than
the undiluted sample, and the amplification curve will be more efficient. It was not 
possible to do this for all samples, due to limitations of sample volume, so a subset was 
tested.
5.3.1 Methods
Seventeen nucleic acid extracts from the household viral transmission study that were to 
be used in the pilot study for objective three were selected as a convenience sample. 
These samples underwent lytA qPCR neat and diluted 1:10 in molecular grade water, as 
described in section 7.10 in chapter seven.
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5.3.2 Results
Fifteen of 17 samples were positive for lytA. On dilution, Ct values increased for 14 of 15 
samples that were positive for lytA, and one sample became negative. These can be seen 
in figure 5.2.
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Figure 5.2: lytA qPCR Ct values of nasopharyngeal swab samples in viral transport 
medium tested neat and diluted 1:10
5.3.3 Conclusions
No evidence of lytA qPCR sample inhibition was noted; all Ct values increased except for 
one that became negative with dilution. Dilution of all nasopharyngeal swab samples 
from the parent viral transmission study before running the lytA qPCR was not 
recommended because some samples that were actually positive might have become 
negative on dilution.
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5.4 The volume of posterior nasopharyngeal secretions sampled
In attempting to measure the nasopharyngeal pneumococcal concentration using a 
nasopharyngeal swab, we are only estimating the true value. In reality all we can measure 
is the pneumococcal concentration in a vial of transport medium. During processing of a 
nasopharyngeal swab collected into transport medium, the sample is vortexed and then 
nucleic acids are extracted from a standard volume of transport medium and eluted into 
a standard volume of eluate. The quantitative PCR then measures the concentration of 
pneumococcus present in the eluate. This concentration can be multiplied by the ratio of 
the eluate to extraction volume, to give the concentration of pneumococcus in the 
transport medium, in copies/mL. This concentration would then need to be multiplied by 
the dilution factor of nasopharyngeal secretion in the transport medium to get the 
concentration of pneumococcus in the nasopharyngeal secretion; this value is not known.
The nasopharyngeal swab can be collected according to a standard method 168 and some
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groups have taken a pragmatic approach of assuming a standard volume of j. -
nasopharyngeal secretion is collected into the transport medium, for example lOOpL of 
nasopharyngeal secretion from a nasopharyngeal flocked swab.185 In reality there will be 
individual variation in the quality and volume of the specimens, both due to the 
collector's technique and to the study participant's degree of coryza. If the swab is not 
collected from the actual posterior nasopharynx, but from the anterior or mid-nares, the 
specimen will not be of adequate quality. If the swab is collected too quickly, it may not 
contain an adequate volume. Any of these problems would lead to less posterior 
nasopharyngeal secretion volume in the transport medium. If a study participant has 
copious coryza, then it is possible the volume put into the transport medium could be 
greater than expected.
To account for this problem in measuring the pneumococcal concentration in 
nasopharyneal secretions, the measurement could be adjusted using a marker of 
sampling variation. One way to achieve this is to measure lytA DNA relative to the 
concentration of DNA from human cells. Quantitative PCR for a gene present in human 
nasopharyngeal squamous epithelial cells would provide an estimate of the concentration 
of human cells present in the sample. Since the nasopharyngeal flocked swab is designed 
to collect posterior nasopharyngeal epithelial cells in order to detect cell-associated virus, 
this would be a good measure of the adequacy of sample collection. Potential limitations 
of this method include amplification competition in a multiplex quantitative PCR, so that 
the target of one set of primers is preferentially amplified. Performing the qPCRs in 
singleplex would avoid this.
A study carried out by swab manufacturers Copan, on adult volunteers, demonstrated 
that the quantity of human beta-actin DNA present in a nasopharyngeal flocked swab 
(NPFS) specimen correlated with the quantity of epithelial cells present, counted directly
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with immunofluorescent stain.186 Other groups have used other reference genes such as 
albumin 187 or RNAseP,188 instead of beta-actin,189 to detect presence of human DNA in a 
clinical sample. A multi-copy human gene, alu,190 was recommended on a European 
Molecular Biology Laboratory (EMBL) quantitative PCR course
(http://www.embl.de/training/events/2012/MIQ12-01/) for this purpose, because of the 
sensitivity of the assay (personal communication, Jim Huggett, LGC, London, UK).
Ideally, the method should be compared against a gold standard. The gold standard 
would be a measure of the true pneumococcal concentration on the posterior 
nasopharyngeal mucosa, which is difficult to achieve. Instead we hypothesised that 
quality of nasopharyngeal sampling would affect the human DNA quantity obtained from
the sample, so that human DNA concentration would increase as quality of sampling 
increases. A secondary hypothesis was that the protein concentration measured 
spectrophotometrically should correlate with the human DNA quantity by quantitative 
PCR.
5.4.1 Methods
Six adult volunteers were sampled from the nasopharynx three times in succession using 
nasopharyngeal flocked swabs in Copan universal transport medium (Copan Diagnostics, 
California, USA). The first swab sampled the anterior nares only, the second swab 
sampled the mid-nasopharyngeal cavity on the other side, and the third swab sampled 
the posterior nasopharynx on the first side of the nose. These swabs were labelled a, b 
and c respectively. In the laboratory, each sample was aliquoted for extraction firstly 
without any vortexing, then briefly vortexed and aliquoted again, and finally vortexed for 
10 seconds before the final aliquot. Each aliquot was labelled x, y and z respectively. 
200pL from kach sampling conditiori was extracted using the MagNA Pure High ■ 
Performance Total Nucleic Acid kit (Roche, Indianapolis, USA) and eluted into lOOpL.
These nucleic acid extracts were then tested using the alu PCR for human DNA 
quantification and the DNA quantity compared to the quality of the nasopharyngeal 
sampling. In addition, each aliquot underwent total protein measurement using the 
Nanodrop (Thermo Scientific, Delaware, USA) and a bovine serum albumin control 
(Biolabs, Maryland, USA).
To choose a human DNA qPCR to account for the potential variability in sampling of the 
posterior nasopharynx a beta-actin real-time qPCR (personal communication, Clayton 
Onyango, KWTRP) was initially tested and compared with the alu real-time qPCR190 and 
the alu PCR was carried on because it gave more efficient amplification curves.
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The alu qPCR method used was as described in section 7.12, chapter seven, except that 
for this experiment the quantity of alu detected from each sample in the plate was 
multiplied by 100/200 (to account for the extraction:elution ratio) and samples were not 
diluted 1:1000. If samples gave inefficient amplification curves they were repeated after a 
1:10 dilution of the nucleic acid extract and if results were similar, omitted from 
subsequent analysis.
The DNA concentration as measured by alu qPCR underwent natural log transformation 
and the difference between the highest quality swab (deepest swab with longest vortex 
time) and the lowest quality swab (anterior nasal swab with no vortex) was calculated for 
each participant. A one-sample t-test was used to compare the mean difference in natural 
log DNA concentration to zero for the change in swab quality. Spearman's correlation was 
applied to the human DNA concentration by alu qPCR and the total protein concentration 
of the sample.
5.4.2 Results v v
The DNA concentration as measured by alu qPCR increased as swab quality improved, for 
all six participants. This can be seen in figure 5.3. The mean change in DNA concentration 
from the lowest to highest quality nasopharyngeal swab collection was a 35-fold increase 
(95% confidence interval 7-183 fold increase), p=0.003. Figure 5.4 shows Spearman's 
correlation co-efficient between DNA concentration as measured by alu qPCR and the 
total protein concentration of the sample.
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Figure 5.3: Human DNA concentration by alu qPCR as swab quality increases among 
adult volunteers
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Figure 5.4: Correlation between human DNA concentration by alu qPCR and protein 
concentration measured by Nanodrop spectrophotometer, by time spent vortexing 
before DNA extraction. A: no vortexing. B: brief vortex. C: prolonged vortex.
5.4.3 Conclusions
The quantity of DNA in the nasopharyngeal swab sample in transport medium as 
measured by alu qPCR, did increase with the quality of sample collection as hypothesised. 
The alu qPCR measurement correlated better with the total protein concentration in the 
vortexed samples than the non-vortexed samples. The alu qPCR measurement is likely to 
be a reasonable measure of the nasopharyngeal sample present in the transport medium 
with which to adjust the pneumococcal concentration to allow for sampling variability. A 
limitation of this experiment is that none of the adult volunteers had purulent nasal 
secretions, which might be expected to impact on results of the alu qPCR in real
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conditions when studying children.
Further method validation was planned for alu qPCR before use in the main study 
objectives; to improve PCR efficiency by removing potential PCR inhibitors by diluting the 
samples before performing alu qPCR, and to assess the reproducibility of alu qPCR.
5.4.4 Testing sample dilution for alu qPCR
The aim was to select the best sample dilution ratio for alu qPCR.
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5.4.4.1 Methods
5.4.4.1.1 Experiment One: 1:10 vs. 1:100 dilutions
Thirty-two nasopharyngeal swab samples from the respiratory viral transmission parent 
study for objective two of this thesis that had been extracted by MagNA Pure with the 
High Performance Total Nucleic Acid kit (Roche, Indianapolis, USA) from 200uL of sample 
into 60uL of eluate were used. A new buffy coat extract was made (details can be found 
in section 7.6.4 of chapter seven) and the DNA concentration measured using Nanodrop, 
to get a higher concentration of total human DNA in the standards, with seven 1:10 serial 
dilutions from 16.1ng/pL. The 32 samples were each run at a 1:10 and a 1:100 dilution, by 
diluting the nucleic acid extracts in molecular grade water, alu PCR primers were as 
previously described in section 7.12, chapter seven, but were used in a mastermix of 
0.75pL forward primer, 0.75pL of reverse primer, 6.25pL of SYBR green (Applied 
Biosytems, Life Technologies, California, USA), 2.25pL of molecular grade water and 2.5pL 
b f template DNA per reaction. Quantitative standards were run in triplicate as were 
negative template controls and a negative extraction control. Cycling conditions were as 
described in the section 7.12, chapter seven. Quantitative results were adjusted for 
dilution factor and for the extraction ratio.
5.4.4.1.2 Experiment Two: 1:100 vs. 1:1000 dilutions
Twenty unneeded nasopharyngeal swab samples in VTM from the parent respiratory viral 
transmission study used objective two were extracted by MagNA Pure with the High 
Performance Total Nucleic Acid kit (Roche, Indianapolis, USA) from 200pL of sample into 
60|iL of eluate. There was insufficient sample volume to use the same samples as in 
experiment one. The standards and controls were as in experiment one above. The 20
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samples were run at a 1:100 and a 1:1000 dilution, by diluting the nucleic acid extracts in 
molecular grade water, alu qPCR was carried out as for experiment one above.
5.4.4.2 Results
5.4.4.2.1 Experiment One: 1:10 vs. 1:100 dilutions
For each pair of results the Ct value was either the same, was shifted to the right as 
expected for a 1:10 dilution factor (a 1:10 dilution factor should shift a Ct value 
approximately three cycles to the right), or the Ct value was shifted to the left with an 
improvement in the efficiency of the amplification curve.
5.4.4.2.2 Experiment Two: 1:100 vs. 1:1000 dilutions
All except one sample (which was unchanged) had a shift in Ct value to the right, with a 
mean shift of 2.25 cycles.
figure 5.5 shows the graphs of the Ct values and the DNA concentration for each pair of 
results comparing 1:10 to 1:100 and 1:100 to 1:1000 dilutions.
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Figure 5.5: Comparing Ct values and human DNA concentration by alu qPCR from DNA 
extracted from nasopharyngeal swab samples after 1:10,1:100 and 1:1000 dilutions. A:
alu qPCR Ct values for 1:10 compared to 1:100 dilutions. B: Human DNA concentration 
obtained for 1:10 compared to 1:100 dilutions. C: alu qPCR Ct values for 1:100 compared 
to 1:1000 dilutions. D: Human DNA concentration obtained for 1:100 compared to 1:1000
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dilutions. Swabs in Experiment 2 (C and D) are different than those in Experiment 1 (A and 
B) due to sample volume limitations.
5.4.4.3 Conclusions
For all samples at least a 1:100 dilution is recommended but for some samples a 1:1000 
dilution is needed. This improves the efficiency of the PCR by diluting out sample 
inhibitors and by not overwhelming the reaction with template. Because the alu target is 
found thousands of times in the human genome, this does not result in samples 
becoming negative and means that the alu PCR is likely to be very sensitive to even very 
small amounts of human specimen being present in sample transport medium.
5.4.5 Reproducibility of lytA qPCR and alu qPCR
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Before commencing work on objective two the reproducibility of lytA and alu qPCRs on 
nasopharyngeal swab samples was assessed.
5.4.5.1 Methods
The same 20 unneeded samples from the parent study of respiratory virus transmission 
as in experiment two of section 5.4.4.1.2 above were used, extracted on three different 
days by three different laboratory technologists, using the MagNA Pure LC instrument 
with the High Performance Total Nucleic Acid kit (Roche, Indianapolis, USA). This was to 
ensure the replicates would be true extraction replicates, and not just PCR replicates.
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5.4.5.1.1 Experiment Three:
The samples were diluted 1:1000 in a two-step procedure and the alu qPCR run as per the 
method outlined in section 5.4.4.1.1 above. The replicate sets were labelled A, B and C, 
and each set was run on a separate plate, with separate mastermix, a separate serial 
dilution of the standard and on a separate ABI-7500 real-time PCR cycler. In addition, the 
lytA qPCR was run on each replicate set, also with separate plates, mastermix, standard 
dilution and cycler. The lytA qPCR method was as outlined in section 7.10 in chapter 
seven.
5.4.5.1.2 Experiment Four:
In an effort to reduce variation introduced by the alu qPCR step, the alu qPCR method 
was modified slightly from experiment three above, in that the 1:1000 dilutions were 
performed in a single step and the reaction mix volume was doubled. The lytA qPCR was 
not repeated.
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5.4.5.2 Results
The lytA Ct values and pneumococcal concentration detected in the three replicates, and 
the mean and standard deviation of the Ct values and of the log transformed 
concentrations of the nasopharyngeal samples can be seen in figure 5.6.
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Figure 5.6: Reproducibility of lytA qPCR. Three extraction replicates of nasopharyngeal 
flocked swabs in viral transport medium. Experiment 3. A: lytA qPCR Ct values. B: lytA 
concentration in copies/mL. C: Mean and standard deviation of lytA Ct values. D: Mean 
and standard deviation of logio lytA concentration in log copies/mL
The olu Ct values, DNA concentration measured by alu qPCR, mean and standard 
deviation of log transformed human DNA concentration, lytA copies/pg human DNA and
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mean and standard deviation of log transformed lytA copies/pg human DNA, for 
experiments three and four, can be seen in figure 5.7.
Hu
ma
n 
DN
A 
qu
an
tity
 i
)g
/u
L
A Reproducibility of olu qPCR Ct values
30]
10-
K '  K<0 A  r p  (?) o f*  <£> £>  n N k *  A4’  0 ?  n ?
4N 4V 4N4N 4n 4  ^4  ^4N 4N 4N 4v 4n 4n 4n 4n 4  ^4  ^4* 4  ^4*
Swab number
B Human DNA concentration
1000* •
• • • • • •100 • .  _ . • .  *
•  *  •10 . •
• • • •
• • • • •
1 • • • • • . *• ©
01. # • • V  •
0.01. *
0.001" ■^ *t ,i,"T">i,,T,,,,,¥ ^ " T l,,lT,,ll,T,,,,^ ^,l1^^^^^ "^r,l,T ,^,Tl,l,T""H"T"
oAjJp c& &  r& j<S> ^  &  r^ > r& r>S 4?
S w a b  n u m b e r
111
oMean and standard deviation of alu qPCR Ct values
30!
20 p
I
lO l|
I
l
I
.cr .cr .cr .<$> .<r *jr .cr .<r .cr .cy .n5 a  vnvv' .n* «n
Swab number
Mean and standard deviation of natural log human DNA concentration
2
Swab number
Figure 5.7: Reproducibility of alu qPCR for human DNA quantification in experiment 
three. Three extraction replicates of nasopharyngeal flocked swabs in viral transport 
medium. Experiment 3. A: alu qPCR Ct values. B: Human DNA concentration. C. Mean and 
standard deviation of alu Ct values. D. Mean and standard deviation of natural log human 
DNA concentration.
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Figure 5.8: Reproducibility of alu qPCR for human DNA quantification in experiment 
four. Three extraction replicates of nasopharyngeal flocked swabs in viral transport 
medium. Experiment 4. A: alu qPCR Ct values. B: Human DNA concentration. C: Mean and 
standard deviation of natural log human DNA concentration.
The mean intra-swab standard deviation of natural log transformed human DNA 
concentration by alu qPCR in experiment three was 1.41r|g/pL, and in experiment four 
was 1.48r}g/pL. This compares with the inter-swab standard deviation in natural log 
human DNA concentration of 1.96r|g/pL, 2.02r)g/|iL and 1.87r|g/pL for each set of 
replicates respectively.
The mean intra-swab standard deviation of natural log transformed pneumococcal 
concentration in lytA copies/pg human DNA was 1.25 copies/pg in experiment three and 
1.14 copies/pg in experiment four. The inter-swab standard deviation in pneumococcal
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concentration in natural log lytA copies/pg human DNA was 2.30 copies/pg, 2.63 
copies/pg and 2.35 copies/pg for each set of replicates respectively, in experiment four. 
The mean natural log pneumococcal concentration per pg of human DNA for each set of 
replicates was 14.93 copies/pg, 12.60 copies/pg and 12.99 copies/pg.
The standard curves for lytA qPCR from these reproducibility experiments are shown in 
chapter three, figure 3.6. For alu qPCR the standard curves from the reproducibility 
experiments are shown in figure 5.9.
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experiments. A: Individual standard curves. B: Mean and standard deviation of Ct values 
for five alu qPCR standard curves.
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The lytA qPCR standard curves from objective two, the study of pneumococcal 
concentration during episodes of viral upper respiratory tract infection, have been been 
shown in chapter three, figure 3.7. The alu qPCR standard curves from objective two can 
be seen in figure 5.10.
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Figure 5.10: Standard curves for alu qPCR from nasopharyngeal swabs in viral transport 
medium from objective two. A: Standard curves from 12 olu qPCR runs. B: Mean and 
standard deviation of Ct values from 12 olu qPCR runs.
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5.4.5.3 Conclusions
Pneumococcus is reproducibly detected by lytA qPCR from nasopharyngeal flocked swabs 
in VTM extracted by MagnaPure. Human DNA concentration by alu qPCR is more variable 
than pneumococcal concentration, and as this variation did not appear to come from the 
quantification standards it probably came from the dilution step, which had been shown 
to be necessary. Pneumococcal concentration adjusted for human DNA concentration 
had reasonable reproducibility, considering extraction replicates.
5.4.5.4 Next steps in human DNA quantification
Since the alu qPCR was not as reproducible as the single target copy lytA PCR, it was 
decided to try two other human DNA targets, with the alu qPCR to fall back on. 
Accordingly, a keratin gene target qPCR and an SFTPC (human surfactant protein C, NCBI 
accession number U02948) gene target qPCR were set up. The keratin gene target came 
from an NCBI BLAST search and primer BLAST was used to design the primers as well as
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the mfold website191 to check the amplicon folding structure. For the SFTPC qPCR, the 
primers came from a published paper,180 and the mastermix recipe and cycling conditions 
were adapted for locally available reagents and instruments. Both PCRs were successful, 
but the SFTPC PCR was pursued because it was working first. The SFTPC qPCR was 
demonstrated to be more reproducible than the alu qPCR and worked for 
nasopharyngeal samples in VTM and in STGG transport media. Unfortunately, when 
initially used for participant samples in the pilot study for objective two, from the 
household study of viral transmission, a half of the samples were completely negative for 
the SFTPC qPCR, presumably because the SFTPC qPCR is not as sensitive to low levels of 
human DNA as the multi-copy target alu qPCR is able to be. This line of work was
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therefore dropped and the alu qPCR was used for human DNA quantification for the 
remainder of the project.
it was decided a priori, to examine objective two, nasopharyngeal pneumococcal 
concentration before, during and after viral URTI, both with and without adjustment for 
human DNA concentration by alu qPCR. Discussion of the effect of the alu qPCR 
adjustment can be found in chapters nine and twelve.
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Chapter Six
6 Validation of laboratory methods for nasopharyngeal swab 
specimens in STGG
6.1 Introduction
Skim-milk-Tryptone-Glucose-Glycerol (STGG) is the WHO-recommended transport 
medium for bacterial culture of nasopharyngeal swabs for pneumococcal carriage.168 This 
sample type was used in objectives one and three.
Sources of variation considered include the DNA extraction method, time during 
transport from the field (following the 2003 WHO guidelines168), and the volume of 
posterior nasopharyngeal secretions in the specimen. The serotype of pneumococcus was 
also considered as a potential source of variation, but it was beyond the scope of this
V  . . V- . V- . V
investigation to examine. ,,
6.2 The DNA extraction method
Potential DNA extraction methods were compared, using spiked samples and several 
different available extraction kits, as part of an intern's project, under the author's 
supervision. Manual methods rather than automated methods were considered, since we 
were not looking for a high-throughput method. The first objective was to choose the 
most appropriate kit for DNA extraction.
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6.2.1 Methods
A suspension of the type strain of S. pneumoniae, ATCC 49619 was made in normal saline 
and adjusted to approximately 108 CFU/mL using a nephelometer (TREK Diagnostic 
Systems, Thermo Scientific, USA). STGG was then spiked with this pneumococcal 
suspension, to three different concentrations (107, 104 and 102 CFU/mL) to mimic patient 
specimens. Both colony counts and DNA extraction were performed on aliquots of the 
spiked specimens. Colony counting was performed by serial 1:5 dilution of the starting 
suspension (the simulated patient sample) with sterile STGG, then from each expected 
countable concentration dispensing in duplicate lOOpL onto a pre-warmed 5% horse 
blood agar plate and spreading it using a wide-mouthed sterile wire loop, allowing the 
plate to absorb the suspension, then turning it upside down and placing in a 5% C02 
incubator at 35°C for 18-24 hours. Colony counting was performed manually the following 
day from all countable plates and a mean concentration for the starting suspension 
calculated.
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DNA extraction was performed from lmL aliquots of the starting suspension using four 
different extraction kits (ZR Fungal/Bacterial DNA Miniprep, Zymo, California, USA; Quick- 
gDNA Miniprep, Zymo, California, USA; Agilent gDNA kit, Agilent, California, USA; QIAamp 
DNA minikit, Qiagen, Germany) according to the manufacturer's instructions, prior to lytA 
qPCR. The experiment was repeated once for the gDNA Zymo kit and twice for the Qiagen 
kit, to check for reproducibility (one repeat sample was spiked at 106 cells/mL instead of 
107 cells/mL). The lytA qPCR method can be seen in section 7.10 of chapter seven, and 
was performed according to lytA qPCR method for nasopharyngeal swab specimens, but 
with standards made from DNA extracted from S. pneumoniae ATCC 49619, measured 
against lytA plasmid standards (Fast-Track Diagnostics, Luxembourg).
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6.2.2 Results
The pneumococcal concentrations by colony counting and the pneumococcal 
concentrations by quantitative PCR, for each concentration and extraction method 
studied, can be seen in table 6.1.
Table 6.1: Pneumococcal concentration from four different DNA extraction kits over a 
range of expected concentrations, by lytA qPCR and by colony-counting, from 
pneumococcus-spiked STGG. STGG = skim-milk tryptone glucose glycerol
Extraction method and PCR quantity
Colony count
expected concentration in lytA
. . .  .. , . , quantity CFU/mLspiked STGG, cells/mL copies/mL
Qiagen mini 10e6 133,080 1,562,500
Qiagen mini 10e4 2,606 1,562
Qiagen mini 10e2 89 16
Qiagen mini 10e7 2,975,580 11,718,750
Qiagen mini 10e4 5,236 11,719
Qiagen mini 10e2 53 117
Qiagen mini 10e7 1,556,000 38,650,000
Qiagen mini 10e4 2,480 38,650
^Qiagen mini 10e2 32 v 387
Bact/Fung Zymo 10e7 ' 44,900 60,000,000
Bact/Fung Zymo 10e4 71 60,000
Bact/Fung Zymo 10e2 negative 600
Agilent 10e7 343,333 3,030,000
Agilent 10e4 353 3,030
Agilent 10e2 18 30
gDNA Zymo 10e7 222,500 5,450,000
gDNA Zymo 10e4 515 5,450
gDNA Zymo 10e2 negative 55
gDNA Zymo 10e7 157,750 65,450,000
gDNA Zymo 10e4 272 65,450
gDNA Zymo 10e2 negative 655
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6.2.3 Conclusions:
The Zymo kits (Zymo, California, USA) failed to extract pneumococcal DNA at the lowest 
concentrations, and the most consistent results were obtained for the QIAamp DNA mini 
kit extractions (Qiagen, Germany).
6.3 Time during transport of specimen after collection
The length of time a nasopharyneal swab in STGG spent traveling back from the field after 
collection, before reaching the laboratory for culture or DNA extraction, might affect 
quantitative results. Different serotypes of pneumococcus might have different survival 
characteristics in the nasopharyngeal swab STGG transport medium. We aimed to detect 
loss of viability of pneumococcus in STGG transport media over eight hours and loss of 
detectable pneumococci in STGG transport media by qPCR over eight hours. Although not
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powered to detect individual differences by serotype, each of the serotypes present in 
the 10-valent pneumococcal conjugate vaccine was included.
6.3.1 Methods:
A QC Type Strain, S. pneumoniae ATCC 49619, and 30 clinical pneumococcal isolates, 
three of each PCV-10 serotype (i.e. 1,4, 5, 6B, 7F, 9V, 14,18C, 19F, 23F) were spiked into 
vials of STGG at five concentrations (106-102 cells/mL) to mimic nasopharyngeal swab 
inoculation. A nephelometer (TREK Diagnostic Systems, Thermo Scientific, USA) was used 
to measure the density of the pneumococcal suspensions prior to spiking, at 0.5 
McFarland. Spiked STGG was held in a cool-box with an ice-pack in a tropical climate for 
eight hours, to mimic specimen transport from the field, as per the WHO
recommendations.168 Aliquots were taken from each vial at 0, 2, 4, 6 and 8 hours for 
culture, and for DNA extraction (QiaAmp DNA minikit, Qiagen, Germany) for qPCR. 
Cultures were performed on lOOpL of 1:5 serial dilutions in STGG of each aliquot in 
duplicate on 5% horse blood agar in 5% C02 at 35°C for 18-24 hours, and the mean colony 
count from all countable plates was taken for analysis. DNA extraction was performed 
from lmL aliquots from each vial, otherwise according to the description of DNA 
extraction using the QIAamp manual method, from nasopharyngeal swabs in STGG, in 
section 7.6.2 in chapter seven.
lytA qPCR was performed as described in lytA qPCR for nasopharyngeal swab specimens 
in section 7.10 in chapter seven, except for the final extraction:elution ratio adjustment, 
and with in-house standards. Standards for lytA qPCR were made by extracting DNA 
(QiaAmp DNA minikit, Qiagen, Germany) from a dense suspension of pneumococcus, 
performing colony counting on the original suspension and making a 1:10 serial dilution 
of the extracted DNA in molecular grade water. Subsequently, the standards were
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calibrated against commercially available lytA plasmid standards (Fast-Track Diagnostics, 
Luxembourg). Data points with <1000 copies/mL by qPCR were dropped from the analysis 
as this was considered to be below the limit of linearity for the qPCR. Linear regression of 
logio-transformed mean counts at two hour intervals in CFU/mL from culture and 
copies/mL from qPCR was performed to look for trends over time. A Wilcoxon signed- 
rank test was used to assess concentration by the culture method in CFU/mL compared to 
qPCR in copies/mL.
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6.3.2 Results
The mean logio concentration of 10 serotypes of pneumococcus recovered from STGG by 
culture and colony counting in CFU/mL and by lytA qPCR in genome-copies/mL over eight 
hours under swab transport conditions can be seen in figure 6.1.
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Figure 6.1: Mean logio concentration of pneumococcus recovered from STGG by culture 
and colony counting in CFU/mL and by lytA qPCR in genome-copies/mL, over 8 hours 
under swab transport conditions, by serotype. Time on the x-axes is in hours.
The overall mean log concentration of pneumococcus recovered from STGG by culture 
and colony counting in CFU/mL and by lytA qPCR in genome-copies/mL, over eight hours 
under swab transport conditions, can be seen in figure 6.2.
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Figure 6.2: Mean logio concentration of total pneumococcus recovered from STGG by 
culture and colony counting in CFU/mL and by lytA qPCR in genome-copies/mL, over 8 
hours under swab transport conditions.
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6.3.3 Conclusions
Over eight hours there was no demonstrable loss in detection of pneumococcus from 
STGG by either colony counting or by quantitative lytA PCR over ten invasive serotypes.
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6.4 The volume of nasopharyngeal secretions in the STGG specimen
Following on from the work on human DNA quantification from the nasopharyngeal swab 
in viral transport medium, the same principles were considered for nasopharyngeal swabs 
in STGG. The mean and standard deviation of Ct values for standards in olu qPCR over ten 
runs performed on different days can be seen in figure 6.3.
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Figure 6.3: Standard curves for alu qPCR from nasopharyngeal swabs in STGG. A: Ct
values for standard curves from 10 individual runs of olu qPCR. B: Mean and standard 
deviation of Ct values for standard curves from 10 individual runs of olu qPCR.
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The specimen quality, sample dilution and reproducibility experiments described in 
chapter five were considered sufficient and not repeated for nasopharyngeal swabs in 
STGG.
It was decided a priori, to examine objectives one and three, the study of nasopharyngeal 
pneumococcal concentration in pneumonia and in health and the study of pneumococcal 
concentration after PCV-10 vaccination, using nasopharyngeal swabs in STGG, both with 
and without adjustment for human DNA concentration by alu qPCR. Discussion of the 
effects of alu qPCR on results and conclusions from objectives one and three, can be 
found in chapters eight, ten and twelve.
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Chapter Seven
7 General Laboratory Methods
7.1 Pneumococcal culture
From stored frozen pure isolates: Streptococcus pneumoniae was cultured on 5% horse 
blood agar for 16-24 hours in 5% CO2 at 35-37°C.
From nasopharyngeal swabs in STGG by the WHO standard method:168 STGG was 
vortexed at 2500rpm for 20 seconds. 10pL of sample was aspirated with a pipette and 
dispensed onto half a 5% horse blood agar with 2.5|ig/mLgentamicin plate and streaked 
with a sterile wire loop. Plates were incubated for 18-24 hours in 5% CO2 at 35-37°C. 
Suspected pneumococcal colonies were subcultured to a 5% horse blood agar plate with 
an optochin disk and incubated for 18-24 hours in 5% CO2 at 35-37°C. Isolates with a zone 
of inhibition vof >14mm to optochin were considered to be S. pneumoniae. Isolates yvith a 
zone of inhibition of 9-13mm to optochin underwent a bile solubility test and were 
considered to be S. pneumoniae if they were bile soluble.
From nasopharyngeal swabs in STGG by the broth enrichment method:165 STGG was 
thawed and vortexed for 10-20 seconds. 200pL of STGG was transferred into 5mL of Todd 
Hewitt broth (Becton Dickinson, MD, USA) supplemented with 5mg/mL yeast extract 
(Becton Dickinson, MD, USA) and lmL rabbit serum (TCS Biosciences, Buckingham, UK). 
The inoculated broth was vortexed and incubated at 35-37°C for 4 hours in 5% CO2 . The 
broth was again vortexed and 10|iL inoculated onto 5% horse blood agar plates with 
2.5pg/mL gentamicin. Plates were incubated for 18-24 hours in 5% CO2 at 35-37°C. S. 
pneumoniae was identified as above.
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Isolates of 5. pneumoniae were serotyped by latex agglutination and the quellung 
reaction, with conventional multiplex PCR 'serotyping' used as an internal quality control.
7.2 Colony counting
Starting suspensions for colony counting were always harvested from fresh overnight 
growth of bacteria on 5% horse blood agar at 35-37°C in 5% CO2 . Colony counting was 
performed by serial 1:5 dilution of the starting suspension in either sterile normal saline, 
phosphate-buffered saline or sterile STGG, up to nine times, labelling tubes A-l. 
Depending on the McFarland standard of the starting suspension, assuming that 0.5 
McFarland is 1.5 x 108 cells/mL (http://www.pro-lab.com/inserts/McFarland.pdf), the 
expected countable concentrations of 30-300 cells per lOOpL were calculated. From 
dilutions E-l lOOpL was dispensed in duplicate onto pre-warmed 5% horse blood agar 
plates and spread using a wide-mouthed sterile, cooled wire loop. The agar plates were 
allowed to absorb the suspension before inversion and placement in a 5% CO2 incubator
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- at 35-37°Cfor 16-24 hours. Colony counting was then performed manually from all 
countable plates and a mean concentration for the starting suspension calculated in 
CFU/mL.
7.3 Serum antibiotic bioassay
20pL of serum was dispensed onto a blank 6mm filter paper disk that had been placed on 
a Mueller-Hinton agar plate streaked evenly with a lawn of Staphylococcus aureus ATCC 
25923 at 0.5 McFarland, and incubated for 18-24 hours at 35-37°C with the agar side up. 
Any zone of inhibition was considered a positive result and indicative of the presence of 
antibiotics in the subject's serum.
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7.4 DNA extraction using MagNA Pure
Whole blood in EDTA tubes was stored at 2-8°C for up to a week before DNA extraction. 
Whole blood samples were extracted using the MagNA Pure LC instrument (Roche, 
Indianapolis, USA) with the MagNA Pure LC DNA Isolation kit III according to the 
manufacturer's instructions. DNA was eluted from 200pL of whole EDTA blood into lOOpL 
of elution buffer. The MagNA pure LC DNA isolation Kit III is optimised for extraction of 
bacterial and fungal DNA. It lyses bacterial cells with lysis buffer and proteinase K, and 
purifies DNA based on magnetic bead technology. DNA binds to the silica surface of the 
magnetic beads in the chaotropic salt conditions of the high ionic strength binding buffer. 
A negative extraction control (molecular grade water) and a positive extraction control 
(supernatant from a BACTEC blood culture bottle positive for Streptococcus pneumoniae 
added to whole EDTA blood) were included in each run. Up to 32 samples, including 
controls, could be run at a time.
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7.5 DNA extraction using QIAxtractor
Whole blood EDTA samples underwent extraction of DNA from 200pL of sample in the 
QIAxtractor (Qiagen, Germany) automated instrument using the QIAxtractor DX kit for 
DNA (reference number 950107 for DX reagents and 950037 for DX plasticware) and Q 
Protocol 'QXT Liquid DNA', according to the manufacturer's instructions. The QIAxtractor 
DNA procedure uses the specific binding of nucleic acids to silica membranes using the 
bind, wash, and elute steps similar to the manual QiaAmp chemistry, but is a vacuum 
system rather than a centrifugation-based system. After nucleic acids in lysates bind to 
the membrane, contaminants are washed away and purified nucleic acids are 
subsequently eluted from the membrane. A negative extraction control (molecular grade
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water) was included in each run. Up to 96 samples, including controls, could be included
in each run.
7.6 DNA extraction using the QIAamp manual method
7.6.1 From whole blood samples
Whole blood in EDTA tubes was stored at 2-8°C for up to 72 hours before DNA extraction. 
DNA was extracted from 200pL of whole blood EDTA using the QIAamp DNA blood minikit 
(Qiagen, Germany) according to the manufacturer's instructions in the QIAamp DNA 
blood mini kit handbook. Working surfaces and pipettes were cleaned with DNA-off and 
70% ethanol. Any sample that was less than 200pL was noted so as to adjust the 
extraction:elution ratio later when calculating the original DNA concentration from the 
quantity obtained by qPCR. 200pL of buffer AL was placed into labelled 1.5mL eppendorf 
tubes and 200pL of whole blood sample added to each tube, with negative controls 
(molecular grade water) at the end. 20(iL of proteinase K was added to the AL-blood 
mixture and vortexed to mix. Samples were then incubated in a heating block or water 
bath at 56°C for 10 minutes. 200pL of ethanol was added to each tube, then vortexed and 
briefly spun in a microfuge to remove droplets from the lid. The total solution was then 
carefully transferred using a pipette onto a QIAamp Mini spin column in a collecting tube, 
avoiding wetting the rim. These were centrifuged at 6000 xg (8000 RPM) for 1 minute at 
room temperature. Columns were removed and placed in a fresh collecting tube and the 
filtrate discarded. 500pL of buffer AW1 was added to each column and centrifuged at 
10,000 x g (13,000 RPM) for 1 minute at room temperature. Again the column was 
removed to a fresh collection tube and the filtrate discarded. 500pL of buffer AW2 was 
then added to the column, centrifuged at 10,000 xg (13,000 RPM) for 3 minutes at room 
temperature, the column removed to a fresh collection tube and the filtrate discarded.
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An additional dry spin at 10,000 xg (13,000 RPM) was then performed for 30 seconds. 
Carefully the column was transferred into a labelled sterile eppendorf tube with the cap 
removed and the collection tube discarded. lOOpL of buffer AE was added onto the 
column membrane and incubated for 5 minutes at room temperature before 
centrifugation at 6000 xg (8000 rpm) for 1 minute. The columns were then discarded and 
the eluted DNA immediately transferred to screw-capped Apex tubes for storage at -80°C. 
Working surfaces and pipettes were cleaned with DNA-off and 70% ethanol after use.
7.6.2 From nasopharyngeal swabs in STGG
Nasopharyngeal swabs in STGG transport medium (NP-STGG) were stored at -80°C and 
thawed on ice for DNA extraction. DNA was extracted from 200pL of STGG using the 
QIAamp DNA minikit (Qiagen, Germany). Before beginning, the working surfaces, racks 
and pipettes were cleaned using DNA-off and 70% ethanol. The thawed STGG tubes were 
vortexed for 20 seconds for proper mixing and immediately 200ul of STGG was pipetted 
into a 1.5mL microfcentrifuge tube. STGG aliquots were centrifuged for 10 minutes at / 
5000 xg (7500 rpm). Using a fine tipped pastette, the supernatant was carefully aspirated, 
without touching the pellets, and discarded. 180pL of Buffer ATL was added to the pellets 
and then 20pL of proteinase K. This was then vortexed until the pellet dislodged from the 
bottom of the microcentrifuge tube. Samples were placed in the thermomixer at 56°C for 
1 hour while shaking at 1000 rpm, or were vortexed 3 times during 1 hour in a heat block 
at 56°C if the shaking thermomixer was not available. After a brief centrifugation to 
remove condensate from the lids, 200pL of Buffer AL was added and the sample pulse 
vortexed 30 times. Samples were incubated at 70°C for 10 minutes, and briefly 
centrifuged again. 200pL of 100% ethanol was added to each sample, pulse vortexed, and 
briefly centrifuged. Using a pipette with lOOOpL barrier tips, the mixture was transferred
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to a QIAamp Mini spin column in a collecting tube without wetting the rim. This was 
centrifuged at 6000 xg (8000 rpm) for 1 minute, the spin column placed in a new 
collection tube and the tube containing the filtrate discarded. 500pL of Buffer AW1 was 
added to each sample, centrifuged at 6000 xg (8000 rpm) for 1 minute, the spin column 
placed in a new collection tube and the tube containing the filtrate discarded. 500pL of 
buffer AW2 was added to each sample, centrifuged at 20,000 xg (14,000 rpm) for 3 
minutes, the spin column placed in a sterile 1.5mL microcentrifuge tube with the cap 
removed and the collection tube containing the filtrate discarded. 60pL of Buffer AE was 
added to each sample and incubated at room temperature for 1 minute before 
centrifugation at 6000 xg for 1 minute. Eluates in the microcentrifuge tube were 
transferred to screw-capped 0.5mL Apex tubes labelled with barcode cryolabels using the 
extract identification number (unique identification for that extraction, as samples could 
be extracted more than once). Extracted DNA was stored at -80°C.
7.6.3 From bacterial suspensions for pneumococcal microarray
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NP-STGG samples were vortexed for 10-20 seconds and 1:10 and 1:100 dilutions were 
made in brain heart infusion broth (Oxoid, UK). 50pL of neat STGG suspension, the 1:10 
and 1:100 dilutions were pipetted onto individual COBA media plates (streptococcal 
selective agar, Oxoid, UK) and spread evenly over the agar surface using sterile L-shaped 
plastic spreaders. Plates were incubated overnight at 37°C in 5% C02. The plate with the 
best high-density of distinct colony growth was selected for processing, and the 
approximate number of alpha-haemolytic colonies recorded. One mL of sterile 
phosphate-buffered saline (PBS) was added to the plate and the surface of the agar 
scraped gently using a sterile L-shaped plastic spreader, to make a suspension of all the 
colonies present. A lmL pipette was used to transfer the resulting suspension to a 1.5mL
eppendorf tube. The suspension was centrifuged at 13,000 rpm for 5 minutes to pellet 
the bacteria. A lysozyme solution in lysis buffer for pre-extraction lysis was freshly 
prepared on each day of use. This consisted of 2190pL of H20, 50pL of 1M Tris-HCI, lOpL 
of 500mM EDTA and 250pL of Triton, fora total of 2.5mL of lysis buffer. Lysozyme (Sigma- 
Aldrich, Switzerland) was then dissolved into the lysis buffer at a concentration of 
20mg/mL. 180pL of lysozyme solution was added to each bacterial pellet and it was 
incubated at 37°C for 60 minutes. Following this pre-extraction lysis, the QIAamp DNA 
mini kit (Qiagen, Germany, catalogue number 51304) was used according to the 
manufacturer's instructions. 20pL of proteinase K and 200pL of Buffer AL was added to 
each sample, which was then mixed by vortexing and incubated at 56°C for 60 minutes. 
Four pL of lOOmg/mL RNase A was added to each sample, mixed by vortexing, incubated 
at room temperature for 5 minutes and briefly centrifuged. Samples were then incubated 
at 70°C for 10 minutes and briefly centrifuged again. 200pL of ethanol was added to each, 
mixed by vortexing and briefly centrifuged. The entire sample was then transferred to a 
QIAamp spin bolumn in a collection tdbe, without wetting thb rim, and centrifuged ajt 
8000 rpm for 1 minute. The filtrate was discarded and the spin column placed in a clean 
collection tube. 500pL of buffer AW1 was added to the spin column and it was 
centrifuged at 8000 rpm for 1 minute. Again the filtrate was discarded and the spin 
column placed in a clean collection tube. 500pL of buffer AW2 was added to each to spin 
column and centrifuged at 13,000 rpm for 3 minutes. The filtrate was discarded and the 
spin column placed in a clean 1.5mL eppendorf tube. This was centrifuged at 13,000 rpm 
for 1 minute to remove any residual ethanol. The spin column was placed in a clean 
1.5mL eppendorf tube. lOOpL of molecular grade H20 was pipetted on to the spin column 
membrane and allowed to stand for 1 minute at room temperature. This lOOpL elution 
volume was reduced for plates with low colony counts, down as far as 20pL for samples
with <10 alpha-haemolytic colonies. Elution was performed by centrifugation at 13,000 
rpm for 1 minute. The eluate containing extracted bacterial DNA was stored at 2-8°C for 
up to 24 hours until the DNA concentration could be measured using the Qubit 
Fluorometer (Life Diagnostics, California, USA) with the Qubit dsDNA high-sensitivity 
assay kit (catalogue number Q32851) and then stored at -80°C until use.
7.6.4 Buffy coat preparation for genomic DNA standards using the QIAamp DNA blood 
mini kit
Two vials of lOmL each of whole blood collected in EDTA were spun at 2500xg for 10 
minutes at room temperature. Using a sterile Pasteur pipette, the buffy coat was 
collected from the middle layer of blood between the clear fraction and the erythrocytes 
from each tube and transferred into a clean 1.5mL eppendorf tube, obtaining 
approximately 1600pL of buffy coat. Twenty pL of proteinase K and 200pL of buffy coat 
extract were placed in each of eight sterile eppendorf tubes. Four pL of RNAse A was 
added to ebch tube and vortexed to mix before incubation at 56°C for 10 minutesV Tubes 
were briefly centrifuged and then 200pL of ethanol added to each. Again tubes were 
vortexed to mix and centrifuged before opening. The contents of each tube were 
carefully transferred into QIAamp mini spin columns and centrifuged at 8000 rpm for one 
minute before transferring the columns into clean collection tubes. Next 500pL of wash 
buffer AW1 was added and centrifugation for one minute at 8000 rpm was repeated. 
Then 500pL of wash buffer AW2 was added and centrifugation at 13,000 rpm was 
performed for three minutes. Fresh collection tubes were applied and a dry spin was 
performed for 30 seconds at 13,000 rpm before transferring the columns to sterile 1.5mL 
eppendorf tubes. Elution buffer at lOOpL was added to each column and incubated at 
room temperature for two minutes. The columns in eppendorf tubes were then
centrifuged at 8000 rpm for one minute to collect the eluted DNA. DNA from all 8 tubes 
was combined, vortexed to mix and the concentration determined using a Qubit 
fluorometer (Life Technologies, California, USA), before storing at -20°C.
7.7 DNA extraction using easyMAG
The NucliSens easyMAG instrument (Bio-Merieux, France) uses silica extraction 
technology for automated isolation of nucleic acids. The sample is pre-processed to 
remove PCR inhibitors and release nucleic acid for isolation, diluted in lysis buffer to 
further remove any PCR inhibition effects and then isolation of total nucleic acid (TNA) is 
performed on the easyMAG instrument. TNA binds to silica particles in the presence of a 
high salt concentration. The silica particles have an iron core. A magnet is then used to 
extract silica particles with bound nucleic acid from solution containing organic sample 
matrix. Once the TNA has been removed from solution it is then purified by washing and 
eluted for downstream analysis.
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Whole blood EDTA sample tubes were inverted gently several times to ensure the sample 
was homogeneous without vortexing. 200pL of whole blood sample was then 
immediately added to the respective labelled eppendorf tubes containing 800|iL of 
Extraction Buffer 3. The entire lmL of whole blood-Extraction Buffer 3 mixture was then 
added to the NucliSENS 2mL lysis buffer tube and vortexed immediately, holding the tube 
midway down the shaft to prevent sample splashing onto the tube cap. 140pL of 
vortexed, undiluted silica was then added to the sample-lysis buffer mix and vortexed 
immediately. The lysed samples were transferred from the NucliSENS lysis buffer 2mL 
tubes (total volume now 3mL) to the sample strips using a Pasteur pipette, without 
causing foam or droplets. A positive (a suspension of S. pneumoniae ATCC 49619 at 
approximately 103 cells/mL in whole blood) and negative (molecular grade water)
extraction control were included at the end of each run. The sample strips were then run 
on the NucliSENS easyMAG using the following parameters: Matrix = Whole blood, 
Protocol = Specific B 2.0.1, Volume = 1 mL (this refers to the 200pL of whole blood plus 
800pL of Extraction Buffer 3 from the pre-processing step), Elute = lOOpL, Type = Lysed, 
Priority = Normal, Lot number = lot of the 2mL lysis buffer. Extracted nucleic acids were 
removed for storage within 30 minutes of the run ending, and stored at -80°C.
7.8 DNA extraction from isolates using the boilate method
DNA extraction directly from bacterial isolates of Streptococcus pneumoniae was 
performed by the simple boilate method. A loopful of pure overnight growth from a 
blood agar plate was suspended in 60pL of Tris-EDTA (TE) buffer in an eppendorf tube, 
capped and placed into a heat block set at 100°C for 10 minutes. Each sample was then 
transferred to the centrifuge for a 10 minute spin at 14,000 rpm. Without disturbing the 
pellet, 50pL of supernatant containing bacterial DNA was pipetted with a barrier tip into a
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labelled cryoviaf for storage at-20°C until use. :
7.9 lytA qPCR on whole blood specimens
lytA qPCR: Forward primer (F373): 5,-ACGCAATCTAGCAGATGAAGCA-3,/ Reverse primer 
(R424):5'-TCGTGCGTTTTAATTCCAGCT-3', Probe (Pb400): 5'-
TGCCGAAAACGCTTGATACAGGGAG-3' (5* FAM; 3' MGB).125 Mastermix containing 12.5pL 
of Gene Expression Mastermix (Applied Biosystems, Life Technologies, California, USA), 
0.5pL of each of the forward and reverse primers and probe, lpL of molecular grade 
water and lOpL of template DNA per reaction. Quantification standards consisting of lytA 
plasmids (Fast-Track Diagnostics, Luxembourg) diluted 1:10 from 107 copies/mL to 102 
copies/mL were run in triplicate on every plate. Negative controls consisting of molecular
grade water were likewise run in triplicate. Cycling conditions of 95°C for 10 min followed 
by 40 cycles of 95°C for 15 sec and 60°C for 1 min were applied on an ABI-7500 real-time 
PCR instrument (Applied Biosystems, Life Technologies, California, USA). Exponential 
amplification curves with a cycle threshold (Ct) value of <40 cycles were considered 
positive and quantified using the standard curve. Standard curves had to have a slope 
between -3.1 and -3.6, for a PCR efficiency of at least 89%, and a correlation of >0.9. This 
was often achieved by omitting the 102 plasmid standard from the calculation, as 
discussed in chapter three, section 3.6. Quantified results were multiplied by a factor of 
0.5, because the extraction was performed from 200|iL of original sample and eluted into 
lOOpLto be used for PCR. Data points with detected pneumococcal concentration below 
the lower limit of linearity and lower limit of detection of the assay were retained in the 
data set, with the understanding that accuracy and precision are affected in that range.
7.10 lytA qPCR on nasopharyngeal swab specimens
lytA qPCR: Forward primer (F373): 5'-ACGCAATCTAGCAGATGAAGCA-3', Reverse primer 
(R424):5,-TCGTGCGTTTTAATTCCAGCT-3/, Probe (Pb400): 5'-
TGCCGAAAACGCTTGATACAGGGAG-3' (5‘ FAM; 3' MGB).125 Mastermix containing 12.5pL 
of Gene Expression Mastermix (Applied Biosystems, Life Technologies, California, USA), 
0.5pL of each of the forward and reverse primers and probe, 6pL of molecular grade 
water and 5pL of template DNA per reaction. Quantification standards consisting of lytA 
plasmids (Fast-Track Diagnostics, Luxembourg) diluted 1:10 from 108 copies/mL to 102 
copies/mL were run in triplicate on every plate. Negative controls consisting of molecular 
grade water were likewise run in triplicate. Cycling conditions of 95°C for 10 min followed 
by 40 cycles of 95°C for 15 sec and 60°C for 1 min were applied on an ABI-7500 real-time 
PCR instrument (Applied Biosystems, Life Technologies, California, USA). Exponential
amplification curves with a cycle threshold (Ct) value of <40 cycles were considered 
positive and quantified using the standard curve. Standard curves had to have a slope 
between -3.0 and -3.7, for a PCR efficiency of at least 86%, and a correlation of >0.9. This 
was often achieved by omitting the 102 plasmid standard from the calculation, as 
discussed in chapter three, section 3.6. Quantified results were multiplied by a factor of 
60/200, because the extraction was performed from 200pL of original sample and eluted 
into 60pL to be used for PCR. Data points with detected pneumococcal concentration 
below the lower limit of linearity and lower limit of detection of the assay were retained 
in the data set, with the understanding that accuracy and precision are affected in that 
range.
7.11 lytA PCR on bacterial isolates
lytA PCR: Forward primer (F373): 5'-ACGCAATCTAGCAGATGAAGCA-3', Reverse primer 
(R424):5/-TCGTGCGTTTTAATTCCAGCT-3', Probe (Pb400): 5'-
TGCCGAAAACGCTTGATACAGGGAG-3' (5’ FAM; 3' MGB). ^M asterm ix containing 12.5pL 
of Gene Expression Mastermix (Applied Biosystems, Life Technologies, California, USA), 
0.5pL of each of the forward and reverse primers and probe, 8.5pL of molecular grade 
water and 2.5pL of template DNA per reaction. A positive control consisting of lytA 
plasmids (Fast-Track Diagnostics, Luxembourg) at 104 copies/mL, or a boilate made from 
Streptococcus pneumoniae ATCC 49619, was included on every plate. Negative controls 
consisting of molecular grade water were run in triplicate. Cycling conditions of 50°C for 2 
minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute were applied on an ABI-7500 real-time PCR instrument (Applied Biosystems, Life 
Technologies, California, USA). Exponential amplification curves with an exponential 
multicomponent rise were considered positive.
7.12 alu qPCR
alu qPCR: Forward primer; CAACATAGTGAAACCCCGTCTCT, Reverse primer; 
GCCTCAGCCTCCCGAGTAG.190 Mastermix containing 12.5pL SYBR green (Applied 
Biosystems, Life Technologies, California, USA), 1.5pL forward primer, 1.5pL reverse 
primer, 4.5pL molecular grade water and 5pL of template DNA per reaction. Standards for 
quantification were made from total human DNA, extracted from a whole blood buffy 
coat preparation using QiaAmp DNA blood mini kit (Qiagen, Germany), the concentration 
measured using a Qubit fluorometer (Life Technologies, California, USA) and serial 1:10 
dilutions made such that the highest standard used was 19ng/pL with six subsequent 
dilutions, all run in triplicate on every plate. Negative controls consisting of molecular 
grade water were likewise run in triplicate. Nucleic acid extracts were diluted 1:1000 in 
molecular grade water before being subjected to alu qPCR because alu is a multi-copy 
gene found thousands of times throughout the human genome. Cycling conditions were 
50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds, 59°C for 1
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minute, followed by a slow ramp to a melt of 95°C for 30 seconds and 59°C for 15 
seconds, on an ABI-7500 (Applied Biosystems, Life Technologies, California, USA). Melt 
curves were examined for all positive samples, with a broad peak at 77-79°C expected.
The quantity of alu detected in the negative template controls was subtracted from each 
sample in the plate, before being multiplied by 1000 (to account for the dilution factor) 
and multiplied by 60/200 (to account for the extraction:elution ratio). Any samples with a 
quantity the same or less than the negative template controls, were repeated at a 
dilution of 1:100 instead of 1:1000.
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7.13 Pneumococcal microarray
DNA extracts were stored at -80°C before shipping frozen to St George's University 
Hospital, London, UK, for microarray analysis.192 Briefly, DNA was fluorescently labelled 
with ULS-Cy3 or ULS-Cy5 with the Genomic DNA ULS Labelling Kit (Agilent, California,
USA). Fluorescently labelled samples were hybridized overnight to the BpG@S SP- 
CPSvl.4.0 microarray at 65°C, according to the Agilent array comparative genomic 
hybridization (CGH) protocol. The microarrays were then washed and scanned with an 
Agilent microarray scanner and intensity data analysed using feature extraction software. 
Intensity data was statistically analysed using a custom Bayesian hierarchical model to 
determine the serotype, or combination of serotypes, present in the sample and assign a 
relative abundance of each serotype detected. (Personal communication, Jason Hinds, St 
George's University Hospital, London, UK).
The serotype is determined by oligos concentrated on capsular locus (cps) genes; taking
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into account all capsular locus genes present. For discrimination of closely related 
serotypes, oligos were designed targeting the functional mutation causing the difference 
in polysaccharide structure, so that all 90 fully-sequenced serotypes could be 
distinguished.16
The genome backbone is determined by oligos targeting all genes in the core and 
accessory genomes of S. pneumoniae TIGR4 and R6, outside of the cps locus. The 
combination of serotype (from the cps locus) and microarray type (from the genome 
backbone) correlates with multi-locus sequence types (MLST) or whole-genome 
sequence-based clustering. Microarray type nomenclature does not apply across different 
serotypes e.g. type 2 serotype 23F does not have the same genome backbone as type 2
serotype 14. Serotype switches can be seen, such as vaccine escape mutants, where the
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genome backbone does not change but the serotype does, as can acquisitions of a new 
strain with the same serotype. The genome backbone can be confounded by multiple 
serotype carriage, depending on the relative abundance and the types present. The 
genome backbone can also discriminate between non-pneumococcal streptococci and 5. 
pneumoniae.
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Chapter eight
8 Objective one: Nasopharyngeal pneumococcal concentration 
in different disease states
8.1 Introduction
Pneumonia is the leading cause of death in children less than five years of age both in 
sub-Saharan Africa and in the world 1 and pneumococcus is the leading cause of 
pneumonia.2 Yet despite having the highest burden of disease, pneumococcal pneumonia 
remains difficult to diagnose in young children. Children do not expectorate sputum for 
sampling, lung aspirates are usually considered too invasive to perform and blood 
cultures are too insensitive. Urinary antigen testing is probably helpful in the diagnosis of 
community-acquired pneumonia in adults,193 but nasopharyngeal pneumococcal carriage 
is thought to cause false-positives in urine antigen testing in children.194 Culture of
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nasopharyngeal swabs reveals pneumococcus among the majority of children under the 
age of five years.195 It has been shown that quantitative methods such as quantitative PCR 
can be helpful in making the diagnosis of pneumococcal pneumonia among adults in 
South Africa 126 and that children with pneumonia had higher nasopharyngeal 
pneumococcal concentration than healthy controls in Vietnam.99 We thought it possible 
that quantitative nasopharyngeal pneumococcal concentration could be the key to 
understanding nasopharyngeal sampling in the diagnosis of pneumonia among children.
Pneumococcal disease is thought to occur soon after nasopharyngeal acquisition of a 
virulent strain of pneumococcus.66 It is plausible, but not proven, that an increase in 
pneumococcal density in the nasopharynx by the virulent strain is the next step which
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then leads to pneumonia or invasive disease. This putative increase in pneumococcal 
nasopharyngeal concentration could be potentiated by presence of a viral upper 
respiratory tract infection (URTI). It is known that viral infections are temporally 
associated with pneumonia,71'73 that viral URTI may directly precede pneumococcal 
pneumonia,75 that respiratory viruses increase nasopharyngeal pneumococcal density, 
transmissibility and invasiveness in mice82,89,95 and increase bacterial adherence to 
respiratory cell lines in vitro.77
If the supposition that an increase in pneumococcal concentration in the nasopharynx is 
the step which then leads to pneumonia or invasive disease is correct, then 
nasopharyngeal pneumococcal concentration ought to be lowest among healthy children, 
increased among children with symptoms of URTI, and highest among children with 
pneumococcal pneumonia. If this is the case, then quantitative methods of sampling the 
nasopharynx could potentially be used as part of the paediatric diagnosis of pneumonia.
A caveat to this is that while Albrich et al were able to set a threshold for nasopharyngeal
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pneumococcal concentration in the diagnosis of pneumonia in adults,126 Vu et al were 
unable to do so in their study of childhood pneumonia.99
It was not practical to study a large cohort of well children through the continuum of 
good health, viral URTI, pneumonia and bacteraemic pneumonia, sampling their 
nasopharynx at each point along the way. Instead we aimed to describe the 
concentration of S. pneumoniae in different groups of children by using the lytA 
quantitative PCR assay on nasopharyngeal swab specimens from the following groups;
(i) healthy children recruited as community controls from a large study of childhood 
pneumonia.
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(ii) children with symptoms of upper respiratory tract infection recruited as community 
controls from a large study of childhood pneumonia.
(iii) children with WHO-defined severe or very-severe pneumonia admitted to Kilifi 
County Hospital from a large study of childhood pneumonia.
It was assumed that children in the latter group, with severe or very severe pneumonia, 
would contain cases of pneumococcal pneumonia.
8.1.1 Hypotheses
Nasopharyngeal pneumococcal concentration is higher in children with WHO-defined 
severe or very severe pneumonia than in children in the community who have URTI 
symptoms. Nasopharyngeal pneumococcal concentration is lowest among children in the 
community who are well.
8.2 Methods
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8.2.1 Sample selection
The samples for this study came from the Pneumonia Etiology Research for Child Health 
(PERCH) project. PERCH is a multi-site case-control study of the causes of pneumonia in 
children aged one month to five years, which took place in Kilifi, Kenya as well as in the 
Gambia, South Africa, Mali, Zambia, Thailand and Bangladesh over 2011-2014. In Kilifi, 
children residing in the Kilifi Health and Demographic Survey System (KHDSS) area 
admitted to Kilifi County Hospital with the syndromes of WHO-defined severe or very- 
severe pneumonia were enrolled from August 2011. Community controls who were well, 
or who had symptoms of acute URTI were age-matched monthly from the KHDSS.196 The 
presence of URTI was defined as cough or runny nose or at least one of; ear discharge,
wheeze, difficulty breathing and at least one of fever or sore throat. In August 2012 after 
one year of enrolment, 70 community controls with URTI, the most constrained group, 
were randomly selected in four age strata; 1-5 months, 6-12 months, 13-24 months and 
25-59 months. Seventy children from the group with WHO-defined severe or very severe 
pneumonia as well as 70 healthy children from the community control group were 
matched for month of enrolment and for age to the controls with URTI.
The selected children were stratified by age because younger children are more likely to 
carry pneumococcus195 and were expected to have higher pneumococcal nasopharyngeal 
concentration.103 Assuming a mean nasopharyngeal pneumococcal concentration of 7 
logio pg/mL in the group with pneumonia and 6 log pg/mL in either of the control groups, 
with a standard deviation of 1.5 logio Pg/mL in both groups,99 and a sample size of 60 in 
each group, a two-sample comparison of means power calculation 197 yielded 95% power 
to detect the 1 log difference in pneumococcal concentration with a significance level of 
0.05. Seventy participants were then selected from each group to allow for missing
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8.2.2 Laboratory methods
Nasopharyngeal swab samples in STGG collected at enrolment into the studies of 
pneumonia were taken from -80°C storage, DNA was extracted using the QIAamp DNA 
mini kit from Qiagen (a full description of the method can be found in section 7.6.2, 
chapter seven). lytA qPCR was performed to quantify pneumococcal load and alu qPCR to 
quantify the amount of human DNA present in the nasopharyngeal swab transport 
medium (sections 7.10 and 7.12 in chapter seven). As most swabs were lytA positive, it 
seemed possible that among the few cases where pneumococci were not detected that 
this might just as easily be attributable to the sensitivity of the assay as to an indication of
true negativity. Additionally, the lower limit of linearity of the assay was at the 
approximate lower limit of detection, 1000 copies/mL, so values <1000 copies/mL could 
be assumed to be inexact. Therefore all swabs with a raw pneumococcal concentration 
(unadjusted for extraction:elution ratio and for human DNA) of less than 1000 copies/mL, 
including negatives, were set to half this value, 500 copies/mL. Data on the lower limit of 
detection of the assay can be found in section 3.6 of chapter three. The pneumococcal 
concentration per pg of human DNA present in the transport medium was then 
calculated.
All children had whole blood samples at enrolment collected into EDTA, DNA extracted by 
either the QIAamp DNA mini kit from Qiagen, or by the EasyMag automated extraction 
instrument from BioMerieux (sections 7.6.1 and 7.7 in chapter seven). These then 
underwent lytA qPCR (section 7.9 in chapter seven) both for the PERCH study, and for 
objective four of this thesis.
As laboratory lead for th'e PERCH study in Kenya'the author had access to additional data 
on the participants; for pneumonia cases this included presence of pneumococcal 
bacteremia by blood culture, presence of pneumococcus in culture of induced sputum, 
administration of antibiotic therapy prior to nasopharyngeal swab collection, and 
presence of radiologically-confirmed pneumonia. Data available for cases and controls 
included evidence of antibiotic use by serum bioassay (section 7.3 in chapter seven); 
growth of pneumococcus from NP-STGG by broth enrichment culture (section 7.1 in 
chapter seven); presence of 33 respiratory viruses and bacteria in a nasopharyngeal 
flocked swab and oropharyngeal swab combined in Copan universal transport medium 
(UTM), extracted using the EasyMag (BioMerieux, France) automated instrument, by 
multiplex real-time PCR (Fast-Track Diagnostics [FTD], Luxembourg). The FTD respiratory
multiplex PCR also included a lytA target. For this analysis, presence of Mycoplasma 
pneumoniae, Chlamydophila pneumoniae or Bordetella pertussis were included in the 
definition of respiratory-virus positive together with the respiratory viruses influenza A, B 
and C, parainfluenza viruses 1, 2, 3 and 4, human metapneumovirus, respiratory syncitial 
virus A and B, coronaviruses OC43, NL63, 229E and HKU1, bocavirus, adenovirus, 
cytomegalovirus, parechovirus/enterovirus and rhinovirus.
8.2.3 Analysis
Log transformation was performed to improve visualisation of the data, but did not 
completely normalise the data so non-parametric analysis of non-transformed data 
proceeded. A Kruskal-Wallis test was used to compare the median pneumococcal load 
between all three groups (pneumonia cases, URTI controls and well controls), and a two- 
sample Wilcoxon rank-sum test for each two-group comparison. The output was box-and- 
whisker plots of logio pneumococcal load by symptomatic group.
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The intention was to analyse the group with WHO-defined severe/very severe pneumonia 
in several strata including: presence or absence of respiratory virus in nasopharyngeal 
samples; finding of pneumococcus from bacterial culture of induced sputum; 
radiologically-confirmed pneumonia; and pneumococcal bacteraemia. The effect of these 
stratified or restricted analyses on the matching for age group and month of enrolment 
was checked by constructing tables of proportions in each group and by using Fisher's 
exact test. Presence of respiratory virus was assumed to have the potential to increase 
nasopharyngeal pneumococcal concentration in both the URTI and pneumonia groups. 
Presence of pneumococcus in bacterial culture of induced sputum, presence of 
radiologically-confirmed pneumonia and presence of pneumococcal bacteraemia were all 
assumed to concentrate pneumococcal aetiology cases among the WHO-defined
pneumonia cases, to improve the likelihood of seeing a difference between this group 
and the control groups.
The variation in pneumococcal concentration by group, age, season, presence of a 
respiratory virus, growth of pneumococcus in bacterial culture of induced sputum, 
radiologically-confirmed pneumonia, antibiotics given prior to sample collection and 
positivity of lytA PCR in whole blood was described using a Kruskal-Wallis or Wilcoxon 
rank-sum test depending on the number of categories of the dependent variable.
In addition a multivariable logistic regression, by backwards stepwise selection, was 
performed in order to adjust for age and month of enrolment in case of loss of matching 
in the stratified/restricted analyses. The likelihood ratio test was used to examine the 
variables in the final model for interactions.
The analysis comparing median pneumococcal concentration between the three 
symptomatic groups was repeated without adjustment for the concentration of human
V; ■ V: ■ V V ■
DNA present in the transport medium for comparison.
The proportion of pneumonia cases and of controls with URTI who had coryza 
documented was compared by chi-squared test.
Statistical analyses were performed in STATA version 11.
8.2.4 Ethical Clearance
The study was approved by the Kenyan National Ethical Review Committee (SSC 1932). In 
the original PERCH study consent was obtained from guardians of all children studied.
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8.3 Results
The lytA qPCR assay was positive among 206/209 (98.6%) of swabs in STGG. By broth- 
enrichment culture 149/209 (71.3%) of nasopharyngeal swabs had grown pneumococcus; 
51/60 (73.9%) of healthy controls, 62/70 (88.6%) of controls with URTI symptoms and 
36/70 pneumonia cases (51.4%), p<0.001. None of the swabs that were lytA qPCR 
negative had grown pneumococcus, but 57 swabs that failed to grow pneumococcus 
were lytA qPCR-positive. Looking at the nasopharyngeal/oropharyngeal swab in UTM, the 
lytA target in the FTD respiratory multiplex PCR was positive in 168/208 (80.8%) samples. 
The distribution of logio-transformed pneumococcal concentration from the 
nasopharyngeal swab in STGG, after setting all lytA results <1000 copies/mL to a value of 
500 copies/mL, adjusting for extraction:elution ratio and for human DNA concentration, 
can be seen in figure 8.1.
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Figure 8.1: Distribution of nasopharyngeal pneumococcal concentration in logio lytA 
copies/pg of human DNA by case-control status.
The variation in median pneumococcal concentration per pg of human DNA present in 
the transport medium in this entire sample set can be seen in table 8.1. The median 
nasopharyngeal pneumococcal concentration per pg of human DNA present in the 
transport medium was 148,148 copies/pg human DNA among pneumonia cases, 415,288 
copies/pg human DNA among controls with URTI symptoms and 265,695 copies/pg 
human DNA among healthy controls. A Kruskal-Wallis test found a statistically significant 
difference between the three groups with a p-value of 0.046. Comparing each group with 
the other, by Wilcoxon rank sum test, only the difference between the cases and the 
controls with URTI symptoms was significant. This can be seen in figure 8.2.
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Table 8.1: Variation in nasopharyngeal pneumococcal concentration by lytA qPCR by 
clinical characteristic
Characteristic n
Median lytA 
concentration 
(copies/pg human DNA) IQR p-value*
Age group:
1-5 months 34 358,129 28,444 1,828,694
0.999
6-12 months 51 298,899 41,854 1,001,807
13-24 months 32 378,638 79,251 971,056
25-59 months 21 265,695 15,473 1,709,503
Month of the year: 
January-March 78 169,243 17,587 985,799
0.114
April-June 47 275,336 12,803 1,742,496
July-September 41 597,780 76,986 1,944,094
October-December 42 319,934 43,957 653,641
Case/control status: 
healthy controls 69 265,695 26,057 980,885
0.046
controls with URTI 70 415,288 76,986 1,742,496
cases of WHO-defined pneumonia 70 148,149 5,795 877,187
Respiratory virus in nasopharynx: 
Absence of respiratory virus 51 223,751 3,773 1,081,401
0.108
Presence of respiratory virus 157 265,695 43,982 1,513,495
Induced Sputum culture: 
Absence of pneumococcus 48 91,608 1,408 625,711
0.142
Presence of pneumococcus 18 460,490 126,181 1,960,489
Chest X-ray:
No radiologically-confirmed pneumonia 41 126,181 16,815 653,641
0.552
Radiologically-confirmed pneumonia 12 v 278,956 5^967 2,040,614
Antibiotics:
No antibiotics given in hospital prior to 
sample collection and antibiotic bioassay 
negative 165 285,389 36,469 1,650,351
0.203
Antibiotics given in hospital prior to sample 
collection or antibiotic bioassay positive 30 207,773 17,587 597,780
lytA PCR from whole blood:
lytA PCR negative from whole blood 175 255,884 26,057 1,059,737
0.199
lytA PCR positive from whole blood 15 398,715 117,685 3,630,154
*Kruskal-Wallis where >2 categories; Wilcoxon rank-sum where 2 categories
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Figure 8.2: Nasopharyngeal pneumococcal concentration among healthy community 
controls, community controls with upper respiratory tract infection (URTI) symptoms,
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and cases of WHO-defined severe or very severe pneumonia. P-values are by Wilcoxon 
rank-sum test. A: Pneumococcal concentration adjusted for the concentration of human 
DNA in the nasopharyngeal swab transport medium. B: Pneumococcal concentration 
without adjustment for human DNA concentration.
The pattern of the pneumococcal concentration across the three groups of healthy 
controls, controls with URTI and pneumonia cases did not change when stratified by 
presence of a respiratory virus in the nasopharynx. This can be seen in figure 8.3.
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Figure 8.3: Nasopharyngeal pneumococcal concentration stratified by presence of a 
respiratory virus. Pneumococcal concentration in logio lytA copies/pg human DNA among 
healthy community controls, community controls with upper respiratory tract infection 
(URTI) symptoms, and cases of WHO-defined severe or very severe pneumonia, stratified 
by presence of a respiratory virus by multiplex PCR of a combined nasopharyngeal and 
oropharyngeal swab specimen. P-values are by Kruskal-Wallis test.
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Cases from whom S. pneumoniae was grown in culture of induced sputum samples did 
not have a statistically significant difference in quantity of pneumococcus in the 
nasopharynx than controls. Controls did not have induced sputum collected. The 
distribution can be seen in figure 8.4.
Restricting cases to those with radiologically-confirmed pneumonia did not substantially 
alter the distribution of results, as can be seen in figure 8.4.
None of the cases had pneumococcal bacteraemia diagnosed by blood culture.
When pneumonia cases were restricted to only those who had not yet received antibiotic 
therapy in hospital and who had no evidence of antibiotic use on a serum antibiotic 
bioassay, and controls were restricted to those who had no evidence of antibiotic use on 
the bioassay, the differences in nasopharyngeal pneumococcal concentration between 
groups were reduced and the overall pattern was similar. This can be seen in figure 8.4. 
There was no statistically significant difference between groups overall (p=0.173),
V ■ V ■ V: V .
between healthy and URTI controls, between healthy controls and pneumonia cases, or 
between URTI controls and pneumonia cases.
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Figure 8.4: Nasopharyngeal pneumococcal concentration, restricted analyses.
Pneumococcal concentration in logio lytA copies/pg human DNA among healthy 
community controls, community controls with upper respiratory tract infection (URTI) 
symptoms, and cases of WHO-defined severe or very severe pneumonia. A: Pneumonia 
cases were restricted to those with growth of S. pneumoniae on culture of induced 
sputum. B: Pneumonia cases were restricted to those with radiologically-confirmed 
pneumonia. C: Controls were restricted to those without evidence of antibiotic use by the 
serum antibiotic bioassay and cases of pneumonia were restricted to those w ithout 
evidence of antibiotic use by the serum antibiotic bioassay and without antibiotics having 
been given in hospital prior to sample collection.
159
Repeating the analysis without adjusting the pneumococcal concentration for the amount 
of human DNA present in the specimen transport medium gave similar results. The 
median log nasopharyngeal pneumococcal concentration was 138,281 copies/mL among 
pneumonia cases, 1,079,054 copies/mL among controls with URTI symptoms and 376,047 
copies/mL among healthy controls. The Kruskal-Wallis test yielded a p-value of 0.017 
between the three groups. Comparing each group with the other, only the controls with 
URTI symptoms were significantly different from either the pneumonia cases or the 
healthy controls. This can be seen in figure 8.2.
The distribution of the proportions of each age group across healthy controls, controls 
with URTI and pneumonia cases was not significantly different; after stratification for 
presence of respiratory virus; on restriction to presence of pneumococcus on culture of 
induced sputum among cases; on restriction to radiologically-confirmed pneumonia 
among cases; and on restriction to cases and controls without evidence of antibiotic use. 
These can be seen in table 8.2.
\; , \; . V; . V  ■ V ■
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Table 8.2: Effect of stratification and restriction on matching by age and month of 
enrolment. A: Stratification by presence of respiratory virus. B: Restriction to cases with 
culture of pneumococcus from induced sputum. C: Restriction to cases with 
radiologically-confirmed pneumonia. D: Restriction to cases and controls with no 
evidence of antibiotic use prior to sample collection.
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A
No respiratory virus
n Healthy % Healthy n URTI % URTI
Age group at enrolment controls controls controls controls n Cases % Cases
1-5 months 6 33.3 5 31.3 5 31.3
6-12 months 5 27.8 3 18.8 2 12.5
13-24 months 4 22.2 3 18.8 2 12.5
25-59 months 3 16.7 5 31.3 7 43.8
Fisher's exact p=0.762
With respiratory virus
1-5 months 11 22.0 12 22.2 12 22.6
6-12 months 20 40.0 23 42.6 23 43.4
13-24 months 12 24.0 13 24.1 14 26.4
25-59 months 7 14.0 6 11.1 4 7.6
Fisher's exact p=0.981
No respiratory virus
n Healthy % Healthy n URTI % URTI
Month of enrolment controls controls controls controls n Cases % Cases
Aug 2011 0 0 0 0 1 6.2
Sep 2011 2 11.1 1 6.3 0 0
Oct 2011 2 11.1 3 18.8 2 12.5
Nov 2011 3 16.7 2 12.5 3 18.8
Dec 2011 1 5.6 1 6.3 0 0
Jan 2012 0 0 1 6.3 4 25
Feb 2012 4 22.2 2 12.5 1 6.3
Mar 2012 3 16.7 2 12.5 2 12.5
Apr 2012 1 5.6 1 6.3 0 0
May 2012 v 0 v 0 0 v 0 1 6.3
Jun 2012 1 5.6 2 12.5 1 6.3
Jul 2012 1 5.6 0 0 1 6.3
Aug 2012 0 0 1 6.3 0 0
Fisher's exact p=0.850
With respiratory virus
Aug 2011 3 6 4 7.4 2 3.8
Sep 2011 0 0 1 1.9 2 3.8
Oct 2011 3 6 3 5.6 3 5.7
Nov 2011 4 8 4 7.4 4 7.6
Dec 2011 1 2 1 1.9 2 3.8
Jan 2012 9 18 8 14.8 5 9.4
Feb 2012 2 4 4 7.4 5 9.4
Mar 2012 8 16 9 16.7 9 17
Apr 2012 2 4 2 3.7 3 5.7
May 2012 5 10 6 11.1 5 5.7
Jun 2012 6 12 5 9.3 6 11.3
Jul 2012 5 10 6 11.1 5 9.4
Aug 2012 2 4 1 1.9 2 3.8
Fisher's exact p=1.000
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B
Cases restricted to those with induced sputum culture of pneumococcus
n Healthy % Healthy n URTI % URTI 
Age group at enrolment controls controls controls controls n Cases % Cases
1-5 months 17 25 17 24.3 4 22.2
6-12 months 25 36.8 26 37.1 8 44.4
13-24 months 16 23.5 16 22.9 4 22.2
25-59 months 10 14.7 11 15.7 2 11.1
Fisher's exact p=0.999
Cases restricted to those with induced sputum culture of pneumococcus
n Healthy % Healthy n URTI % URTI
Month of enrolment controls controls controls controls n Cases % Cases
Aug 2011 3 4.4 4 5.7 1 5.6
Sep 2011 2 2.9 2 2.9 0 0
Oct 2011 5 7.4 6 8.6 1 5.6
Nov 2011 7 10.3 6 8.6 1 5.6
Dec 2011 2 2.9 2 2.9 1 5.6
Jan 2012 9 13.2 9 12.9 1 5.6
Feb 2012 6 8.8 6 8.6 2 11.1
Mar 2012 11 16.2 11 15.7 4 22.2
Apr 2012 3 4.4 3 4.3 1 5.6
May 2012 5 7.4 6 8.6 1 5.6
Jun 2012 7 10.3 7 10 2 11.1
Jul 2012 6 8.8 6 8.6 2 11.1
Aug 2012 2 2.9 2 2.9 1 5.6
Fisher's exact p=1.000
. V  .
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c
Restricted to radiologically-confirmed pneumonia in cases
n Healthy % Healthy n URTI % URTI
Age group at enrolment controls controls controls controls n Cases % Cases
1-5 months 17 25 17 24.3 4 33.3
6-12 months 25 36.8 26 37.1 3 25
13-24 months 16 23.5 16 22.9 1 8.3
25-59 months 10 14.7 11 15.7 4 33.3
Fisher's exact p=0.704
Restricted to radiologically-confirmed pneumonia in cases
n Healthy % Healthy n URTI % URTI
Month of enrolment controls controls controls controls n Cases % Cases
Aug 2011 3 4.4 4 5.7 1 8.3
Sep 2011 2 2.9 2 2.9 0 0
Oct 2011 5 7.4 6 8.6 0 0
Nov 2011 7 10.3 6 8.6 3 25
Dec 2011 2 2.9 2 2.9 0 0
Jan 2012 9 13.2 9 12.9 0 0
Feb 2012 6 8.8 6 8.6 1 8.3
Mar 2012 11 16.2 11 15.7 4 33.3
Apr 2012 3 4.4 3 4.3 1 8.3
May 2012 5 7.4 6 8.6 1 8.3
Jun 2012 7 10.3 7 10 0 0
Jul 2012 6 8.8 6 8.6 1 8.3
Aug 2012 2 2.9 2 2.9 0 0
Fisher's exact p=0.998
D
No antibiotics by bioassay or given in hospital
n Healthy % Healthy n URTI % URTI 
Age group at enrolment controls controls controls controls n Cases % Cases
1-5 months 15 25.0 13 20.6 8 19.5
6-12 months 20 33.3 24 38.1 18 43.9
13-24 months 15 25.0 15 23.8 9 22.0
25-59 months 10 16.7 11 17.5 6 14.6
Fisher's exact p=0.973
No antibiotics by bioassay or given in hospital
n Healthy % Healthy n URTI % URTI
Month of enrolment controls controls controls controls n Cases % Cases
Aug 2011 2 3.3 4 6.3 1 2.4
Sep 2011 1 1.7 1 1.6 1 2.4
Oct 2011 2 3.3 6 9.5 2 4.9
Nov 2011 7 11.7 5 7.9 3 7.3
Dec 2011 2 3.3 2 3.2 2 4.9
Jan 2012 9 15 8 12.7 5 12.2
Feb 2012 6 10 6 9.5 4 9.8
Mar 2012 8 13.3 9 14.3 6 14.6
Apr 2012 3 5 3 4.8 2 4.9
May 2012 5 8.3 5 7.9 6 14.6
Jun 2012 7 11.7 7 11.1 3 7.3
Jul 2012 6 10 5 7.9 5 12.2
Aug 2012 2 3.3 2 3.2 1 2.4
Fisher's exact p=1.000
V ■ . ■ V • V;
On multivariable logistic regression, seen in table 8.3, not very much variation in 
nasopharyngeal pneumococcal concentration was associated with the variables 
examined, in keeping with the findings from the stratified or restricted analyses. Only the 
6-12 month age group in the presence of a respiratory virus, had a significantly different 
(higher) pneumococcal concentration than the youngest age group, and July 2012 had 
samples with higher concentration than other months.
"Runny nose" also known as coryza, was part of the definition of URTI symptoms but 
could also be present among cases. It was present among 60/70 (86%) controls with URTI 
symptoms and among 33/69 (48%) pneumonia cases, pcO.OOl.
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8.4 Discussion
Pneumococcal concentration in the nasopharynx of children admitted to hospital with 
WHO-defined severe or very severe pneumonia was not higher than community controls 
with or without symptoms of URTI. In fact, control children with URTI symptoms had 
slightly higher nasopharyngeal pneumococcal concentration than those hospitalised with 
pneumonia. The difference between groups, while statistically significant, is not great, 
with median pneumococcal loads all within half a log of one another and considerable 
overlap in distributions.
This finding differs from that of Vu et al in Vietnam where swabs were all collected before 
commencing antibiotic treatment," and it was initially thought this might be due to 
antibiotic use among children with pneumonia. Restriction of the pneumonia group to 
cases who had had a swab collected before commencing antibiotic therapy in hospital 
and who hadvno evidence of prior antibiotic use in a serum antibiotic bioassay, and v 
restriction of the control groups to those who had no evidence of antibiotic use in the 
bioassay, only somewhat attenuated the variation between groups, with loss of statistical 
significance. There may be residual confounding by antibiotic use that we were not able 
to detect. We have previously shown that the antibiotic bioassay is more sensitive from 
urine than from serum, but is harder to perform, because of the difficulty in collecting 
urine from hospitalised sick children prior to administration of antibiotic therapy 
(unpublished data). PCR-based methods such as the lytA real-time qPCR ought to be less 
susceptible to alteration by antibiotic use than culture-based methods, but this may 
depend on timing of antibiotic use. A course of oral antibiotics in the community in the 
days prior to study enrolment and sample collection would be expected to have more of
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an effect on qPCR estimation of nasopharyngeal pneumococcal concentration than would 
an intravenous antibiotic dose in hospital within minutes to hours of sample collection.
Another possible explanation of our findings is that significantly more control children 
with URTI symptoms than those in the pneumonia group had documented coryza, and 
coryza may have made it easier to detect pneumococci from a nasopharyngeal swab, so 
that estimation of nasopharyngeal pneumococcal concentration was relatively elevated. 
However, we did try to adjust for this possibility with the alu qPCR and, this does not 
explain the fact that healthy controls, none of whom had coryza, had a similar median 
nasopharyngeal pneumococcal concentration to the pneumonia group.
Stratifying the samples by presence of a respiratory virus, M. pneumoniae, C. pneumoniae 
orB. pertussis, did not markedly alter the distribution of the nasopharyngeal 
pneumococcal concentrations by group. We can suppose that a respiratory virus in the 
context of an URTI may have been both causing coryza and stimulating an increase in the 
carried nasopharyngeal pneumococfcal concentration, makihg it easier to detect. A ; 
respiratory virus or 'atypical' bacterial pathogen in the context of pneumonia may have 
been causing pneumonia alone, without any pneumococcal aetiology. In the Vietnamese 
study presence of a respiratory virus increased pneumococcal nasopharyngeal carriage 
concentrations among cases of pneumonia carrying pneumococcus 15-fold, but presence 
of respiratory viruses among control children was not reported."
Pneumococcal pneumonia may be becoming less common than is recognised, due to the 
introduction of the pneumococcal conjugate vaccine in Kenya in 2011 and to the 
amelioration of poverty in Kilifi District over time,196 so that the WHO-defined syndrome 
of severe or very severe pneumonia probably did not include many cases of true
pneumococcal pneumonia. In fact, this syndromic definition may have included children
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with heterogenous conditions other than pneumonia but who were severely unwell, 
which is a limitation of this sample set.
Restricting cases to those from whom S. pneumoniae was grown in culture of induced 
sputum, or to those with radiologically-confirmed pneumonia, and so might reasonably 
be expected to be more likely to have had pneumococcal pneumonia, still did not reveal 
any statistically significant variation to the distribution of nasopharyngeal pneumococcal 
concentration among cases and controls. This may have been partly due to loss of power. 
Restricting cases to those with radiologically-confirmed pneumonia and growth of 
pneumococcus from induced sputum might be expected to better concentrate true cases 
of pneumococcal pneumonia but this would have led to further loss of power and so 
would need to have been done before initial sample selection. There is not much 
published experience with culture of sputum from young children in the diagnosis of 
pneumonia, but a study in Finland found that induced sputum sampling from children 
with pneumonia was possible, yielded mostly high quality samples, and culture of induced
\; ■ V ■ V: ■ .
sputum was useful in determining likely aetiological pathogens, including Streptococcus
154pneumoniae.
In a study of paediatric community-acquired pneumonia with RSV or Rhinovirus infection 
by Esposito et al in Italy, children with alveolar pneumonia on chest X-ray had higher 
nasopharyngeal pneumococcal loads by lytA qPCR than children with non-alveolar 
pneumonia, but controls without pneumonia were not studied.150 For those with RSV 
infection, the mean pneumococcal nasopharyngeal concentration with alveolar 
consolidation was 4.5 logio copies/mL compared to 3.8 logio copies/mL without alveolar 
consolidation (p=0.04). For those with rhinovirus infection, the mean pneumococcal
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concentration with alveolar consolidation was 4.2 logio copies/mL and without was 3.4 
logio copies/mL (p=0.03).lso
In Vietnamese children, the median pneumococcal concentration among those with 
radiologically-confirmed pneumonia was 7.8 x 106/mL, among those with other lower 
respiratory tract infection was 1.3 x 106/mL and among healthy children was 7.9 x 
105/m L." Like the study by Vu et al in Vietnam, the Italian study by Esposito et al was 
unable to identify a cut-off concentration to aid in the diagnosis of pneumococcal 
pneumonia (in this case of mixed viral-bacterial aetiology) perhaps partly because mixed 
viral-pneumococcal pneumonia may also present without alveolar consolidation visible 
on paediatric chest X-ray. The concentrations obtained by Esposito et al were lower than 
those in our study, which were in turn lower than those measured in Vietnamese 
children. However, it is not appropriate to directly compare concentrations obtained by 
real-time PCR without calibrating the PCR standards between assays so this is likely to be 
artefact.
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In a study of HIV-infected adults with community-acquired pneumonia in South Africa, 
the mean nasopharyngeal log lytA qPCR copy number was 6.0 logio copies/mL among 
patients with a diagnosis of pneumococcal pneumonia compared to 2.7 logio copies/mL 
among patients without a pneumococcal diagnosis and 0.8 logio copies/mL among well 
HIV-infected controls (p<0.001).126 The differences between these groups are 
considerably greater than those in the published paediatric studies discussed above and 
in our study, presumably because adults, even adults with HIV infection, have a lower 
nasopharyngeal pneumococcal concentration than young children, in the absence of 
pneumococcal pneumonia.
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Another South African study, in which 49% of 400 study participants with acute lower 
respiratory tract infection, and nasopharyngeal carriage of pneumococcus by qPCR, were 
children <5 years of age, 3% were older children and the remainder were adults, found 
that nasopharyngeal carriage density >1000 copies/mL was associated with invasive 
pneumococcal pneumonia.152 The authors also found that respiratory virus co-infection 
was associated with nasopharyngeal pneumococcal carriage density with an adjusted 
odds ratio of 1.7 (95% confidence interval 1.1-2.6). This study combined adults and 
children, making it difficult to compare the results to other studies, and for these analyses 
took only subjects with lower respiratory tract infection carrying pneumococcus. The 
density threshold of >1000 copies/mL may have been different for children than for 
adults if the study had been analysed in age strata. Additionally, invasive pneumococcal 
pneumonia was defined by lytA PCR on blood, which as discussed in chapter eleven of 
this thesis, does not have good specificity for IPD among children.
In our study, adjusting the pneumococcal concentration in the nasopharynx for the
V  , V . V ,
amount of human DNA present in the swab transport medium, to allow for poor 
swabbing technique or copious coryza, did not substantially alter the results or the 
conclusions that can be drawn from them.
A striking feature of this work was the finding that almost all nasopharyngeal swabs in 
STGG were positive for lytA qPCR (98.6%) with only two swabs from cases of pneumonia 
and one swab from a control participant testing as negative. The corresponding 
nasopharyngeal/oropharyngeal swabs in UTM tested in the FTD respiratory multiplex PCR 
that also included a lytA target had a lower positivity (80.8%); this PCR also allowed 
positives up to 40 amplification cycles but there were differences in swab transport 
media, extraction methods and the PCR was multiplex. Given the widespread positivity of
nasopharyngeal swabs in STGG for lytA PCR, it was thought reasonable to call all swabs 
positive, with all swabs less than the lower limit of detection set to half that value. This 
supposes that all children in our population carry pneumococcus in the nasopharynx to 
some degree, and challenges our previous belief that carriage prevalence among children 
<5 years of age in Kilifi is 66%, by WHO standard culture.168'195 We could have taken the 
opposite approach, and called all swabs with less pneumococcus than the lower limit of 
detection negative, which would have been more conservative. Of course, it is not 
unexpected that PCR would be more sensitive than culture for pneumococcus, since PCR 
can detect non-viable organisms, but it does change the paradigm to consider that all 
children in our population might be carriers. If carriage as defined by PCR positivity of NP- 
STGG, is present in all children, then it is not useful to predict transmission or invasion or 
progression to pneumonia. Density of carriage by qPCR is the natural progression of this 
chain of thought but in this study at least, nasopharyngeal pneumococcal concentration 
was not associated with admission to hospital with WHO-defined pneumonia among 
children less than five years of age. The ideal study design to answer this question would 
be a longitudinal study with frequent sampling, of large enough numbers to enable 
follow-up until pneumonia occurs; such a study is impractical.
Quantification of nasopharyngeal pneumococcal concentration does not hold promise as 
a useful technique for diagnosing pneumococcal pneumonia among children under the 
age of five years in Kenya. In our population, nasopharyngeal pneumococcal 
concentration among children with symptoms of upper respiratory tract infection was 
actually higher than among children hospitalised with pneumonia. In Vietnam and Italy, 
nasopharyngeal pneumococcal concentration was higher among radiologically-confirmed 
pneumonia cases than cases of other lower respiratory tract infection, and in Vietnam,
than among healthy controls. Neither of these studies actually had a control group with
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URTI symptoms for direct comparison with our study and the populations are likely to be 
different in other ways; Italy is a high-income country compared to Kenya and South-East 
Asian countries like Vietnam appear to have considerably less pneumococcal disease than 
countries in sub-Saharan Africa (seen in chapter eleven). All the paediatric studies 
mentioned, including ours, found considerable overlap in the distribution of 
nasopharyngeal pneumococcal concentrations by study group, in contrast to the South 
African studies of adults, in whom it appears to be easier to set a threshold to distinguish 
nasopharyngeal carriage associated with pneumococcal pneumonia.126
In summary, we found that among Kenyan children under five years of age, 
nasopharyngeal pneumococcal carriage as detected by PCR is very common and is not 
greater in children with WHO-defined pneumonia than among controls. Residual 
confounding by antibiotic use may have hampered our ability to detect high 
nasopharyngeal pneumococcal concentrations among pneumonia cases and the WHO 
syndrome of pneumonia may not have included many cases of true pneumococcal
V ■ ■ V ■ V ■
pneumonia. Carriage is likely to be augmented by the presence of upper respiratory tract 
viral infection, potentially accounting for the highest pneumococcal concentrations being 
seen among the controls with symptoms of URTI.
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Chapter Nine
9 Objective two: The dynamics of pneumococcal concentration 
in the nasopharynx during symptomatic viral upper 
respiratory tract infection
9.1 Introduction
A link between viral infection and bacterial pneumonia has been established in many 
populations, notably during Influenza pandemics,75'198 and ecological studies also lend 
support.73 Animal models have confirmed the transmissibility and density of 
pneumococcal nasopharyngeal carriage increases during viral respiratory infection 82'89' 
91,95 and basic science experiments demonstrate the upregulation of receptors for 
bacterial adherence and reduced bacterial clearance during the inflammatory response 
associated with viral infection.77'83 85'88'95 fnfluenza virus, or host factors in response to v 
influenza virus, have been shown to disperse pneumococci from biofilms, potentiating 
invasion.61
In Peru, a recent study has found the risk of nasopharyngeal pneumococcal acquisition 
increased post influenza or parainfluenza acute respiratory illness in children <3 years of 
age.199 While associations do not prove causality, it is widely accepted clinically that viral 
respiratory tract infections can lead to bacterial pneumonia. Increased nasopharyngeal 
pneumococcal concentration has been demonstrated in humans with pneumococcal 
pneumonia 126 but it is not clear whether the pneumococcal pneumonia has caused the 
increase in nasopharyngeal pneumococcal concentration or the other way around.
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It is biologically plausible that a rise in pneumococcal nasopharyngeal concentration 
associated with acquisition of a viral infection could increase the likelihood of progression 
to pneumococcal pneumonia or invasive pneumococcal disease (IPD). If this is the case, 
then the concentration of pneumococci in the nasopharynx should increase following 
viral infection and decrease again after the viral infection is cleared. It is not clear how 
long the augmented risk period for development of pneumococcal disease is subsequent 
to viral infection. Some ecological studies have found significant associations between 
peak viral detection and peak IPD with a lag of one week to one month, others have 
found associations without applying a lag.71'73
We set out to study the prediction that acquisition of a respiratory viral infection is 
associated with an increase in pneumococcal nasopharyngeal concentration in young 
children, and if so, that nasopharyngeal pneumococcal concentration returns to baseline 
after the viral episode is over. A recent study of respiratory viral transmission among 
households in the rural Kilifi district of Kenya enabled us to investigate this question.9
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Many studies are now using quantitative PCR to address differences in concentration of 
pathogens associated with carriage and disease states,126'180,181 making standardization of 
sample collection and laboratory methodology vital.64 This is fairly straightforward for 
sample types such as whole blood, where the specimen volume from which DNA is 
extracted is known. For samples such as nasopharyngeal secretions, the specimen 
volume is much more variable; all that can be known for sure is the volume of transport 
medium from which DNA is extracted, not the volume of the clinical specimen within the 
transport medium. Factors such as increased nasopharyngeal secretions (as are often 
seen in viral upper respiratory tract infections) may increase the volume of human 
specimen collected with a nasopharyngeal swab and deposited in the vial of transport
medium. Factors such as participant discomfort during swabbing, or poor training or 
monitoring of swab collectors may result in an inefficiently collected swab and a 
decreased volume of human specimen deposited in the vial of transport medium. Such 
differences would be expected to introduce bias, which could be corrected by an 
adjustment for the quantity of human DNA present in the transport medium of a 
nasopharyngeal swab. This is not a perfect adjustment, as it assumes a constant 
relationship between human DNA and specimen volume, whereas there is variation in 
cellularity of coryza in reality. Further data and discussion regarding the adjustment by 
human DNA concentration can be found in chapter five, section 5.4.
9.2 Methods
The setting for this study is a pre-existing project consisting of samples from a household 
study of viral transmission; "Who Acquires Infection from Whom" (WAIFW).9 Under this 
parent protocol, nasopharyngeal flocked swab (NPFS) specimens were collected twice
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weekly irrespective of symptoms and stored in viral transport medium (VTM) during a 
single respiratory syncytial virus (RSV) season for six months from all members of 47 
households with at least one infant and a sibling.8 These households were rural Kenyan 
households in Kilifi County. A household was defined as people living in the same 
compound and sharing a common cooking arrangement. See figure 9.1 for results of RSV 
testing from one household as an example (figure supplied by Patrick Munywoki). 
Multiplex real-time PCR was performed on all samples to detect RSV A/B, adenovirus, 
rhinovirus and coronaviruses NL63, E229 & OC43 (in a sub-sample of the parent study 
these had been found to be the most prevalent viruses in circulation throughout the six 
month period)8. Additionally, five households were tested for influenza A/B/C, human 
metapneumovirus, parainfluenza viruses 1-4, and Mycoplasma pneumoniae. These five
households also underwent rhinovirus typing of all samples positive for rhinovirus by 
sequencing of the VP4-VP2 junction (unpublished data -  Clayton Onyango).200 Rhinovirus 
typing was necessary in order to be able to distinguish episodes of rhinovirus infection; 
rhinovirus was so commonly detected that without typing, strains belonging to the same 
episode could not be differentiated from other strains. This is demonstrated in figure 9.2.
05
£1
E(D
E
sz
wOco
co'CO
T—
CO
05
CNh-
CM,
wo
CN
CO
CNT-'
CN
05T-
T-wOT~CO
05
wo
co
0o ooQO oo o0 0o o o0o oo 0
oo o oQ oO oo o0 o0 0o oo o0 o0 ooo oo oo 0o oo o0 oo o
o o o
OOOOOOOOOOO
CDO c o o o o o o o o o o o o o o o o o  
o o o o o o o o o o o o o o o o o o o  oo  
o  o  
00 o o o
o o o  © o o o o o o o o o o o o o o o o o  
o o o o o o o o
OOO OOQOOO o o o  o o o o o o o o  
o oo  c o  o o o o o o o o  o o o o o o o o  
o o o o o o
O O OO OO O 0 0
O OOOOOOOO 0 0 (0 0 0  o o o o o  
O OOO OO OO O OOO OO o  oo o  oo  
OOO OOOOOOOO  
OOQG o  OOOO
OOOOO OOOOOOOOOO OOOO 
OOOO OOOOOOOOOOOOOOOOO  
OO OO OO OO OO OOO O O OOO oo  
OOOO OOO OOO OOO o o o o o
o o o o o o o o  _
OOOO oo c o  o o o o o O o o o o  
OOOOOOOOOO o o o o o  o o o o o
o  oo o  oo oo  o o  oo o  o  o  
00 o o o  o o o o o  
OOOO o o o  o o o o o o o  
o o  o o  oo oo  o o  oo o  o  o  OOO OO o o
OO OO OO OO O OOOO O O OOO OO OO 
OO OO OO OO OO OOO O O OOO CO oo
o o  o o o o o
o o o o o  OO OOOOO o o  OO OO oo  
O OOOO OOO OOO OOOOO OOOO 
OOOOOOOO
o o o o o  OOO OOOOO 0 0 0  OOOO
OOOO
c Q D O  0 0 0 0 0 0 0 0 0 0
O O O O  O OO OO OQ
ooooooocQ
OO OOO OOO OO
OOOOOOOO  
OOOOOOOO  
O O O O O O O O O O O O O O O O O
O O O O O O O O O O O O O O O O O  
OOO O O O O O O O O O O *
ooooo
OO OOOOOoooooooo ooo ooo ooo oooooooo
O O O O  Q D O O O O  
^OOOOOOOOOOo ooo
OOOOO  
O OOOOOOO
OOOO
0 0  OO DO
CO OOOOc-ooooo:.o □□ 30D CO 00
OOOOOO
oo ooo ooo |VI
T
Dec'09 Jan Feb Mar Apr 
Date of Sample
May Jun'IO
o sample neg o RSV A
Figure 9.1: Nasopharyngeal swab sampling from all members of a rural Kenyan 
household twice weekly over a 6-month period. Samples negative for respiratory 
syncytial virus (RSV) are shown in green, samples positive for RSV are shown in red. The 
size of the circle corresponds approximately to the viral concentration. Figure by Patrick 
Munywoki.
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Figure 9.2: Rhinovirus typing enabled identification of episodes of rhinovirus infection 
for study. A: Nasopharyngeal swab sampling from all members of a rural Kenyan 
household twice weekly over a 6-month period. Samples negative for rhinovirus are 
shown in green, samples positive for undifferentiated rhinovirus are shown in red. B: The 
same household as in A; rhinovirus types are each allocated a different colour. Rhinovirus 
typing has allowed identification of different episodes of rhinovirus infection. Figure by 
Patrick Munywoki.
We selected episodes of RSV and rhinovirus infections to study. Influenza virus was not 
included because the sampling timeframe did not occur during the Influenza season and 
there were only two detected influenza episodes meeting the selection criteria. Both RSV 
and rhinovirus have been shown to increase pneumococcal adhesion to human 
respiratory epithelial cells, and while RSV has the most evidence for association with 
pneumonia,5 rhinovirus is the most common upper respiratory tract virus found in most 
populations.
9.2.1 Defining Episodes of Viral Infection
Episodes were defined by the temporal association of symptoms of upper respiratory 
tract infection (URTI) with the detection of RSV or rhinovirus in at least two swabs over a 
period of 14 days among children under the age of five years. An episode began with the 
first positive swab and was terminated at the last positive swab if there were no further 
positive swabs from the child over 14 days. All swabs in between the positives were 
counted as part of the episode, regardless of positivity. To optimise specificity swabs had 
been defined as positive if the real-time PCR cycle threshold value for respiratory viruses 
was <35.201
Only episodes with symptoms of URTI at some point during the episode were considered; 
such symptoms were coryza, cough or sore throat. Within a single household, one child 
could have two or more episodes of infection with the same virus, and different children 
couia be infected sequentially throughout the household. In this study, for each virus, 
only the episode frorri the first child to be infected per household wa)s selected, although 
if more than one child became infected with the same virus simultaneously, or if a single 
child was the first to be infected in their household for both RSV and rhinovirus, or for 
more than one rhinovirus type, all of those episodes were selected. These criteria were 
applied to ensure that true episodes of viral infection were selected, recurrent episodes 
were avoided, and that pneumococcal transmission was less likely to have already 
occurred prior to acquisition of the viral infection, assuming pneumococcus may have 
been transferred along with the virus from child to child in the household.202
Swabs from two weeks prior to the onset of the episodes, all swabs during the episodes 
and two weeks after the end of the episodes were initially chosen in order to study the 
change in pneumococcal concentration before, during and after viral infection, but the
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'after' swabs were extended to four weeks when initial pilot data was considered. A 
flowchart outlining the swab selection criteria can be seen in figure 3. The STATA code 
used to perform viral episode selection can be found in Appendix A; this code was written 
in conjunction with Patrick Munywoki.
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Swabs collected twice weekly from 
all members of 47 households over 6 
months; 17,687 swabs
Include only participants 
<5 years of age at start 
of study: 5,281 swabs
Episode of infection defined as:
at least 2 positive swabs within 14 
days,
only swabs with a Ct value <35 for 
RSV or typed rhinovirus called 
positive
Include negative swabs that lie 
between 2 positive swabs as part of 
the episode of infection
71 RSV episodes 
33 rhinovirus episodes
Include if URTI symptoms on at 
least 1 occasion during episode
64 RSV episodes 
22 rhinovirus episodes
Only the first episode/s of infection for 
each virus per household included
(>1 episode if >1 participant started 
>de on the same ds 
same household)
38 RSV episodes 
18 rhinovirus episodes
I
f  Study swabs 2 weeks before, all swabs 
during and swabs 4 weeks after the first 
symptomatic viral infection in a child <5 
years in each household*
37 RSV episodes 
16 rhinovirus episodes
Figure 9.3: Flowchart describing the selection of viral episodes to examine from the 
parent study. URTI = upper respiratory tract infection. *One RSV episode was excluded due to it being a 
prolonged relapsing infection that by the criteria above would have meant swabs "after" the episode would 
still have been positive for RSV. Two rhinovirus episodes were excluded because the very first swabs 
collected in the study were positive so it was impossible to accurately define the episodes.
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9.2.2 Laboratory Methods
Total nucleic acids had previously been extracted from all samples using the MagNA Pure 
LC (Roche, Indianapolis, USA) automated instrument with the Roche high performance 
Total Nucleic Acids kit.8 These extracts were used to run the multiplex respiratory PCR in 
the parent study and stored frozen at -80°C. The same extracts were used to run the lytA 
qPCR for pneumococcal quantification and the alu qPCR for human DNA quantification as 
part of this study. These PCR methods have been described in sections 7.10 and 7.12 in 
chapter seven.
Pneumococcal concentration in the nasopharynx was taken as the pneumococcal 
concentration per pg of human DNA present in the transport medium of the 
nasopharyngeal swab. For the analysis, swabs with <1000 copies/mL of lytA detected, 
including swabs with no lytA detected, were assigned a value of 500 copies/mL before 
adjustment for alu concentration on the basis that all such swabs were below the lower 
limit of detection and lower limit of linearity of the pneiimococcal assay. v
9.2.3 Statistical methods
A pilot study of nine episodes of viral infection was carried out to inform the main 
analysis. Swabs during, two weeks before and two weeks after a convenience sample of 
episodes of symptomatic viral infection among children <5 years old were included, and 
both lytA qPCR and alu qPCR were carried out as above. The pilot results were 
summarized as a box and whisker plot of the pneumococcal concentration per pg of 
human DNA present in the swab transport medium and can be seen in figure 9.4. Median 
pneumococcal concentration before, during and after viral infection was compared using 
a Kruskal-Wallis rank test. Pneumococcal concentration was greater during or after viral
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infection than before viral infection, p=0.022. Although there was no significant 
difference in pneumococcal concentration between the swabs collected during and after 
viral infection, viral co-infection was common and there appeared to be heterogeneity in 
pneumococcal concentration between individuals. It was therefore decided to extend the 
period for sampling after the viral infection from 2 weeks to 4 weeks for the main 
analysis, to concentrate on differences at the individual level, and to allow for 
confounding by presence of viral co-infection. In order to account for changes in 
nasopharyngeal pneumococcal concentration at the individual, rather than the 
population level, the analysis was refined. The mean natural log concentration of the 
"before" swabs was subtracted from the "during" swabs, for each individual viral episode. 
Similarly, the mean natural log concentration of the "during" swabs was subtracted from 
the "after'' swabs for each episode. These differences, when exponentiated, yield the 
geometric mean fold change in pneumococcal concentration between each state. A one- 
sample, two-sided t-test (ie. compares the difference to nil) was used to assess statistical 
significance in the mean fold chang^ with a p-value of <0.05 considered good evidence to 
reject the null hypothesis. As there were only nine episodes in the pilot study, the results 
of this analysis were not statistically significant, but the direction of change was 
consistent with the hypothesis; an 11.2-fold increase in pneumococcal concentration 
during viral infection, p=0.0996, and a 0.5-fold decrease in pneumococcal concentration 
after viral infection, p=0.3246.
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Figure 9.4: Nasopharyngeal pneumococcal concentration in lytA copies/pg of human 
DNA, before, during and after symptomatic viral upper respiratory tract infection (URTI) 
among nine children in a pilot study. The box and whisker plot shows the median, 
interquartile range and range for each swab category.
Power was calculated using a one-sample comparison of mean to a hypothesized value 
(in this case, 0) in STATA l l . 197 The power calculation revealed that the estimated number 
of episodes needed to detect a 3-fold change in pneumococcal concentration between 
viral infection periods, using a standard deviation in natural log pneumococcal 
concentration of 2.9 obtained from the pilot study, with 75% power and a significance 
level of 0.05, was 49. The predicted sample sizes needed for different levels of power and 
different effect sizes can be seen in table 9.1.
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Table 9.1: Sample size calculation. Predicted sample sizes needed for different levels of 
power and different effect sizes.
Fold-change in geometric 
mean pneumococcal 
concentration
0.9 0.85
Power
0.8 0.75 0.7
2-fold 186 159 139 123 110
3-fold 74 63 55 49 43
4-fold 46 40 35 31 27
5-fold 35 30 26 23 21
6-fold 28 24 21 19 17
Of the potential confounders considered for the main analysis, namely the number of 
children in the household, the number of smokers in the household, age of the child, 
poverty level, cooking fuel type, whether cooking was done inside or outside, hygiene 
(consisting of toilet type and water source), recent use of antibiotics and presence of viral 
co-infection, oniy the iast couia be a confounder because it varied within episodes for 
individual children. Although it would have been scientifically stronger to restrict the 
analysis to episodes without any co-infected swabs, this would have entailed dropping 
almost all the data because co-infection was so common. Therefore to examine the 
potential role of co-infection, the individual level analysis for the main study was 
repeated restricted to swabs without presence of viral co-infection (rather than episodes 
without presence of viral co-infection).
A t-test with unequal variances was used to assess whether the differences in mean log 
pneumococcal concentration during and before a viral episode were significantly different 
for RSV and rhinovirus.
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9.2.4 Ethical Clearance
The study was approved by the Kenyan National Ethical Review Committee (SSC 1932). In 
the original viral transmission study consent was obtained from guardians of all children 
studied.
9.3 Results
The main analysis consisted of 47 households (five of these households had subtyped 
rhinovirus episodes from the parent study), of which there were 53 viral episodes for 
analysis, consisting of 42 individual children and 804 sampling visits. Fifty-one viral 
episodes had swabs available from both before and during viral infection; 37 episodes of 
first RSV infection and 14 episodes of first rhinovirus infection in a household during the 
study period in a child <5 years of age. Of these, 28 and 12 episodes of RSV and rhinovirus 
infection, respectively, rerpained once the analysis was restricted to swabs not co­
infected with other viruses. Of 804 selected sample visits, 785 had nasopharyngeal 
respiratory PCR results available from the parent study. For another 62 swabs, the sample 
was missing or had been used up in previous analyses, leaving 723 swabs available for 
pneumococcal PCR. By lytA qPCR 675/723 swabs (93.4%) were positive for 
pneumococcus. Of these, 23/723 swabs had insufficient sample for alu qPCR, and 2 were 
negative for human DNA by alu qPCR, leaving 698 swabs with both lytA and alu qPCR 
results for the main analysis. Individual plots of pneumococcal concentration before, 
during and after RSV and Rhinovirus infection can be seen in figure 9.5, these are 
illustrative examples; plots for every episode can be found in Appendix B. These plots 
additionally show the samples that were co-infected with another virus; 271/785 (35%) 
were co-infected.
The mean fold change in pneumococcal concentration, with and without adjustment for 
human DNA concentration for RSV and rhinovirus are in table 9.2. There was not a
statistically significant difference between the viruses, p=0.250, so the mean fold change 
in pneumococcal concentration is also presented combined to improve power and 
precision. Pneumococcal concentration rose during viral infection, 3.8-fold if adjusted for 
the quantity of human specimen present in the transport medium, 7.5-fold if not 
adjusted, p<0.001 for either method. Pneumococcal concentration fell after viral 
infection, but this was not statistically significant. The differences in adjusted 
pneumococcal concentration during and before viral infection, and after and during viral 
infection can be seen in figure 9.6.
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Figure 9.5: Nasopharyngeal pneumococcal concentration in lytA copies/pg of human 
DNA, before, during and after examples of episodes of symptomatic upper respiratory 
tract infection (URTI) with RSV or rhinovirus in children <5 years old. The y-axis of each
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graph is in logio scale. The swab numbers on the x-axes are consecutive twice-weekly 
swabs. Where a swab was not collected or the sample was unavailable, the bar is missing. 
Where a swab was not missing but did not have detectable pneumococcus by lytA qPCR, 
it is marked zero. For RSV episodes, swabs collected during the episode are marked in 
red, for rhinovirus these are blue. Swabs two weeks before and four weeks after each 
viral episode are black. Bars marked with an asterisk indicate swabs that were co-infected 
with another respiratory virus by multiplex PCR.
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Figure 9.6: Differences in individual mean nasopharyngeal concentration. The
differences between individual mean nasopharyngeal pneumococcal concentration in 
natural log lytA copies/ug human DNA 'during' and 'before' viral upper respiratory tract 
infection (URTI), and between concentration 'after' and 'during' viral URTI. A difference of 
0 indicates no change in pneumococcal concentration with the change in viral status.
Data to the right of the 0 line indicate an increase in pneumococcal concentration, data to 
the left indicate a decrease.
9.4 Discussion
There is considerable inter and intra-individual heterogeneity in the concentration of 
pneumococcus in the nasopharynx of children under the age of 5 years in rural Kenya.
The main finding in this study, the 4-fold increase in nasopharyngeal pneumococcal 
concentration, is small but is statistically significant. If the probability of invasion
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increases with an increase in pneumococcal nasopharyngeal concentration, then this 4- 
fold increment in bacterial concentration with viral infection may contribute to the 
augmented likelihood of bacterial pneumonia or invasive pneumococcal disease among 
children with viral infections. Additionally, the increase in bacterial concentration with 
viral URTI is very likely to contribute to person-to-person transmission of pneumococcal 
carriage.
The changes in pneumococcal concentration with viral infection appeared to be more 
marked for RSV than for rhinovirus, but there was not a statistically significant difference 
between the viruses. RSV may indeed have a stronger relationship with changes in 
nasopharyngeal pneumococcal concentration than rhinovirus but we were not powered 
to detect this.
The Peruvian study did not measure the bacterial concentration present, but did look at 
acquisition of pneumococcal serotypes that were not present in the nasopharynx one 
Vnonth prior, and found'that acquisition of a neW serotype of pneumococcus was 
associated with influenza or parainfluenza virus related acute respiratory illness but not 
with an RSV or rhinovirus associated illness.199 We did not have enough episodes of 
influenza to look for a rise in pneumococcal concentration associated with influenza 
illness in our study.
Adjusting nasopharyngeal swab specimens for the concentration of human DNA present 
in the swab transport medium resulted in a reduction in the effect size measured. This is 
biologically plausible, because symptomatic viral infection can be expected to increase 
nasopharyngeal secretions, resulting in a greater volume of sample collected into the 
swab transport medium. Without adjusting for this increased volume, a falsely elevated
nasopharyngeal pneumococcal concentration could be inferred from the sample. Two of
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our nasopharyngeal swab samples were found to contain no human DNA; pneumococcal 
DNA was not detected in these samples either. These swabs were omitted from the 
analysis as "missing" rather than included as samples negative for pneumococcus, 
because it is unlikely the swabs were truly collected from the human nasopharynx, 
despite training and monitoring of swab collectors.
Strengths of this study include the extensive swab collection; 17,687 swabs were 
collected from 47 households over a six-month period, requiring considerable community 
co-operation. This is the first study we are aware of where rhinovirus sub-typing was 
available, enabling the study of rhinovirus episodes. The study would have been 
impossible without the sub-typing because so many different rhinoviruses were present 
that defining the individual episodes could not have been done otherwise. Adjusting the 
pneumococcal concentration for the amount of human DNA present in the sample meant 
that children who had a higher pneumococcal yield due to the presence of copious nasal 
secretions were accounted for. It also meant that poor swab technique, if problematic
v . v . v , v . v
for some samples, would not bias the results.
This study does have some limitations. Despite high compliance from the nearly 500 
occupants of the studied households, there were only 53 first viral episodes from children 
<5 years old available for analysis; 37 RSV episodes and 14 rhinovirus episodes had swabs 
collected both before and during episodes. Numbers were reduced further when the 
analysis was restricted to swabs without viral co-infections, as such co-infections were 
very common. Naturally, we could not test the swabs for all possible viral co-infections 
and therefore there may well have been further confounding that we could not detect.
Data on recent antibiotic use was limited, with only antibiotics given out by the study
field team or local healthcare clinic recorded. However, the study field team noted that
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antibiotics were generally otherwise inaccessible to the study population. It remains 
possible that we were unable to adequately account for this potential confounder. If this 
was the case, you would expect it to have an effect of potentially reducing pneumococcal 
concentration during the symptomatic viral episode, which would reduce our ability to 
see an association between viral infection and increased pneumococcal concentration.
It was beyond the scope of this study to serotype the Streptococcus pneumoniae isolates 
carried among these children, and would in any case have resulted in too much loss of 
power to stratify by serotype, but it is possible that the rise in pneumococcal 
concentration associated with viral infection could be serotype-dependent.
The effect of a modest rise in pneumococcal concentration with acquisition of 
symptomatic viral infection in terms of risk of transmission or invasion depends on 
whether the relationship between nasopharyngeal pneumococcal concentration and 
transmission or invasion is linear, sigmoid or more complicated, if the relationship is 
linear, then a 4 or 7-fold rise cannot have <3 great effect. If the relationship is sigmoid, /
there may be a threshold effect, in which case it depends where the threshold for 
transmission or invasion lies relative to the distribution of nasopharyngeal pneumococcal 
concentration in the population. If the respiratory viral infection triggers the 
pneumococcus to switch from opaque phase in a biofilm to transparent phase, expressing 
genes enabling invasion, as well as increasing the pneumococcal concentration as 
discussed in chapter two, this would be likely to potentiate the effect on invasive risk.
How much of this increased risk of invasion is due to an increase in pneumococcal 
concentration and how much is due to changes in gene expression we do not know. Any 
increase in risk of transmission is more likely to be due to the increased nasopharyngeal 
pneumococcal concentration itself. We also do not fully understand the relative
contributions of serotype and strain. Certainly some serotypes are more invasive than 
others, and virulence factors other than capsule also play a role.25,63
In conclusion, there is a detectable rise in pneumococcal concentration in the 
nasopharynx of children who acquire symptomatic viral infection, particularly with RSV. 
There may be a less marked decrease in pneumococcal concentration after the episode of 
viral infection but we have been unable to demonstrate this conclusively. The modest 
increase in pneumococcal concentration may be an important contributing factor to the 
development of bacterial pneumonia or invasive pneumococcal disease among children 
with preceding viral respiratory tract infections at a population level.
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Chapter Ten
10 Objective three: The dynamics of pneumococcal concentration 
in the nasopharynx after immunisation with pneumococcal 
conjugate vaccine
10.1 Introduction
Invasive pneumococcal disease (IPD) has been largely controlled in developed countries 
by the introduction of pneumococcal conjugate vaccines/8'20 and encouraging data is 
emerging from resource-poor countries where such vaccines have been instituted.3'12,203 
The effect of the vaccine is due not only to a direct effect among vaccinated infants, but 
also to an indirect, or herd effect, among older children and adults who are protected by 
a reduction in circulating invasive serotypes; less carriage 156 159 and less transmission of 
vaccine-types.1^ 0,161 Serotype replacement disease is caused by pneumococcal serotypes 
not covered in the vaccine in use.20 The carriage prevalence and invasive potential of 
serotypes occupying the nasopharyngeal niche in place of the vaccine-types and the 
virulence and drug-resistance of such non-vaccine-types determine the degree of the 
problem that serotype replacement causes. Together with the fact that IPD is now an 
uncommon condition in vaccinated populations, making it more difficult to study, this 
means that nasopharyngeal carriage studies are an important part of monitoring the 
impact of pneumococcal conjugate vaccines.164
Detection of multiple serotype carriage can be difficu lt166'170'171 and has not always been 
performed, hindering pre and post-vaccine surveillance efforts.165,166 Children carry more 
than one serotype of pneumococcus at a time, and probably do so in up to 50% of
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cases.19'165'167 The pneumococcal microarray at St George's University Hospital in London 
(http://www.bugs.sgul.ac.Uk/node/l) has been assessed by the PneuCarriage project 
(discussed in chapter two) as being one of the best methods in the world for accurate 
detection of multiple serotype carriage.171
Density of vaccine-type and non-vaccine-type carriage has seldom been reported, but 
semi-quantitative carriage density of vaccine-types decreased in the vaccine-arm of a 
PCV-7 randomised controlled trial among a Native American population 158 and among 
Gambian villagers in a cluster-randomised trial of PCV-7.103 As discussed in chapter nine, 
we assume that nasopharyngeal colonisation density is important for both pneumococcal 
transmission and invasion, but we don't know whether the relationship is linear or 
whether there is a threshold effect. Nor do we know where the population range for 
carriage density lies relative to these.
In Kenya, we carried out a randomized controiied triai of the immunogenicity, 
reactogenicify and impact on carriage of PCV-10 among Kenyan children aged 12-59 
months (the PCV-10 Reactogenicity, Immunogenicity and Safety study in Malindi 
[PRISM]).10 Six months after vaccination, carriage prevalence of vaccine-type 
pneumococci as assessed by standard culture was 21% in recipients of two doses of PCV- 
10 compared to 31% in controls (p = 0.04). Previous work in Kilifi has demonstrated a 
seasonal increase in prevalence of pneumococcal carriage at the end of the wet season, 
usually around July.195 In the PRISM study, total pneumococcal carriage prevalence by 
culture was 66% (95% confidence interval [Cl] 59-72%) among controls at the 
commencement of the study in January and 72% (95% Cl 66-79%) at the end of the study 
in July. Multiple serotype carriage and concentration of vaccine-type carriage was not 
assessed in the PRISM study.
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Carriage prevalence is probably a marker of nasopharyngeal pneumococcal 
concentration, but we assume that quantification of colonisation should give a more 
accurate picture of the dynamics of pneumococcal carriage with vaccination.
The autolysin gene is common to all pneumococci so quantitative lytA PCR (qPCR) can 
only tell us the total concentration of pneumococcus. In this study we also asked what the 
concentration of carriage with vaccine-types (1,4, 5, 6B, 7F, 9V, 14,18C, 19F, 23F) and 
non-vaccine types was, and how that changed after vaccination. We aimed to answer this 
question using quantitative lytA PCR together with a pneumococcal microarray revealing 
the relative proportions of each serotype present. This objective was examined by 
studying samples from subjects enrolled in the PRISM study.10
10.2 Methods
In the parent PRISM study, participants were sampled by rayon nasopharyngeal swab 
(Medical Wire Company, UK) in skim-milk tryptone glucose glycerol (STGG) transport
V; v  V; V ; .
medium before, and at 30, 60, 90 and 180 days post PCV-10 in two different schedules. 
Culture was performed in real time for S. pneumoniae, H. influenzae and S. aureus in our 
laboratory and STGG was stored frozen at -80°C. For this sub-study, swabs collected prior 
to vaccination (day 0) and at days 30, 60, 90 and 180 from all children aged 12-23 months 
who were enrolled in dosing schedule group A (PCV-10 vaccine at day 0 and day 60) were 
selected; these were 47 children. One child dropped out of the study after day 30 and his 
swabs were excluded from the analyses.
DNA was extracted from 200pl of thawed STGG using the QIAamp DNA minikit (Qiagen, 
Germany) as described in section 7.6.2 in chapter seven. This nucleic acid was then used 
for the pneumococcal lytA qPCR (section 7.10 in chapter seven). Because only seven 
swabs were negative for lytA by qPCR, and three of these were positive by culture, all
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swabs that tested at or below the limit of detection for lytA qPCR (1000 copies/mL) were 
set at 500 copies/mL, including the negatives. As well as the lytA qPCR, STGG samples 
underwent a quantitative alu PCR (section 7.12, chapter seven) for human DNA to adjust 
the lytA concentration for the proportion of transport medium that was actual human 
specimen. The pneumococcal PCR was then expressed in copies of lytA per pg of human 
DNA.
In addition, STGG was cultured on streptococcal selective agar (Oxoid, UK) and the 
resulting growth harvested and suspended in phosphate-buffered saline for further DNA 
extraction using the QIAamp DNA minikit with a pre-lysis step (section 7.6.3, chapter 
seven). This DNA was used for the pneumococcal microarray, described in section 7.13 of 
chapter seven. The microarray was carried out at St George's, University of London. At St 
George's, they have tried using the microarray without the culture step, extracting DNA 
directly from STGG and amplifying it before proceeding with the microarray, but have 
found that sensitivity for detecting minor serotypes is lost with that method, and so
V ■ V: ■ V: V:
recommend the culture step (personal communication, Jason Hinds, St George's 
University Hospital).
10.2.1 Analysis
The pneumococcal microarray gives the relative abundance of each serotype present and 
considerably enhances detection of multiple serotype carriage; the lytA qPCR yields the 
total concentration of pneumococcus. It is then possible to calculate vaccine-type (VT) 
and non-vaccine-type (NVT) pneumococcal nasopharyngeal concentration for each swab 
for which there is microarray serotype data, using the proportion for each serotype (from 
the microarray) of the total concentration (by lytA qPCR). Swabs without growth of 
pneumococci for microarray typing were missing the VT and NVT proportions but the
total concentration by lytA qPCR was available, as PCR was more sensitive than culture. In 
order to better understand the missing data, the pneumococcal concentration by lytA 
qPCR was compared for samples that grew and did not grow pneumococcus, and 
variables potentially associated with growth of pneumococcus were examined by logistic 
regression with pneumococcal concentration in strata formed by quintiles.
The distribution of the total pneumococcal concentration at each time point was 
examined using the results of the lytA qPCR (adjusted for human DNA concentration) in 
all swabs.
In order to assess changes in VT and NVT pneumococcal concentration overtime post­
vaccination, a range of methods was explored in order to address limitations of the 
dataset. These limitations included missing VT and NVT data for samples that did not 
grow pneumococcus on culture for microarray but were lytA qPCR positive; many 0 
values in VT or NVT concentration eg. from swabs that contained oniy NVT (and therefore 
"0" VT) or swabs that contained only VT (and therefore "0" NVT) and the timing of the 
study over January to July being in line with seasonal increases in pneumococcal 
prevalence so that we may have confounding by season.
1) A visual display of all data. Firstly all data was displayed visually; stacked area charts to 
present all serotype data for each individual study participant, and the log lytA 
concentration for all pre-vaccine and combined post-vaccine swabs.
2) Changes in VT and NVT pneumococcal concentration with time, for swabs with 
microarray data. Secondly, VT and NVT pneumococcal concentrations, from swabs that 
had microarray serotype data, were studied by time point with Wilcoxon signed rank 
tests used to compare median concentrations. The differences between concentrations of
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pre-vaccine swabs and paired swabs collected six months later were calculated and 
analysed using a sign test. Total pneumococcal concentration was analysed in the same 
way, but from all swabs, using lytA qPCR data alone, as microarray serotype data was not 
needed.
3) Changes in VT and NVT pneumococcal concentration with time, with imputed data for 
swabs missing microarray data. Data were re-analysed after imputing the proportions of 
VT and NVT for swabs positive by lytA qPCR but without serotype data from microarray. 
To impute data, the median VT concentration over the median NVT concentration among 
swabs yielding VT or NVT pneumococcus at each time point was used to generate a 
VT/NVT ratio for each time point. This ratio was then applied to the total pneumococcal 
quantity by lytA qPCR to yield the relative VT and NVT quantities for 58 swabs that were 
missing serotype data. The median VT and median NVT concentrations of all swabs that 
underwent microarray were not used, because several of the median VT concentrations 
by time point were 0.
V ■ V: V; V .
4) The ratio of median VT to median NVT concentration. Changes in VT and NVT 
concentrations over time were probably confounded by seasonality. To avoid this, a 
different approach using the ratio of VT to NVT pneumococci was utilized, strengthening 
the analytic findings. Taking the ratio of the median VT concentration to the median NVT 
concentration at each time point described in 3) above, the change in log VT:NVT ratio by 
time point was examined using linear regression.
5) Individual ratios of VT:NVT concentration. Individual ratios of VT:NVT concentration 
were determined for study participants with multiple carriage of pneumococcal serotypes 
that included both VT and NVT serotypes. A Wilcoxon signed-rank test was used to
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compare the median ratios between day 0 and each other swab collection time point 
until day 180 post-vaccine.
6) Serotype-specific analyses. The serotype-specific pneumococcal concentration at each 
time point was examined for the six most common serotypes, a Wilcoxon signed-rank test 
used to compare paired median concentrations by time point and a rank-sum test used to 
compare median pre and post-vaccine concentrations.
The microarray, in addition to providing the relative abundance of each pneumococcal 
serotype present, assesses the genome backbone of each serotype. A subtype for each 
serotype is assigned based on genes in the genome backbone, independent of the 
capsular locus. Further details on the microarray analysis can be found in section 7.13 of 
chapter seven.
Finally, the analysis of changes in VT, NVT and total pneumococcal concentration from 
swabs that had microarray serotype data (analysis 2, above) was repeated without
V • V: ■ V: •
adjusting pneumococcal concentration for the concentration of human DNA present in 
the nasopharyngeal swab transport medium.
10.2.2 Ethical Clearance
The study was approved by the Kenyan National Ethical Review Committee (SSC 1932). In 
the original PRISM study consent was obtained from guardians of all children studied.
10.3 Results
Figure 10.1 details the samples available for study. By lytA qPCR, 97% of all swabs were 
positive so, for the purposes of analysis, all swabs were assumed to be positive at all time
points, at varying concentrations. By microarray, which involved an initial culture step, 
36/46 (78%) subjects were carrying pneumococcus at day 0,40/45 (89%) at day 30, 27/46 
(59%) at day 60, 33/46 (72%) at day 90 and 36/45 (80%) were carrying pneumococcus at 
day 180.
48/230 swabs did not 
grow at iall for microarray J
5/230 swabs growth was 
not SPN by microarray
3/230 swabs did not grow 
sufficiently for microarray
2/230 swabs were not 
retrieved for microarray
172 swabs with 
microarray 
serotype data
1 child dropped out after day 30: 
n=230 swabs
7/230 swabs were negative for 
lytA qPCR (3/7 were culture 
positive)
Assume all lytA qPCR results 
are positive at half lower limit 
of detection if <1000 copies/ 
mL, including negatives
47 children aged 12-23 months received 
PCV-10 at day 0 and day 60 with swabs 
collected at days 0, 30, 60,90 & 180.
58 swabs lytA positive but 
no microarray serotype 
data, 172 swabs with 
both lytA concentration 
and serotypes by 
microarray
Figure 10.1: Samples available for study
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The proportions at each time point carrying any vaccine-type, only non-vaccine-types, 
and no pneumococcus at all, by microarray, can be seen in table 10.1. As this was a sub­
study of the original PRISM study three years earlier, in which nasopharyngeal swabs had 
been cultured for pneumococcus using the WHO standard method 168 in our laboratory, 
we also had those original results with which to compare the culture step for microarray. 
The culture for microarray and the original swab culture three years previously both 
yielded pneumococcus in 154/230 swabs, both were negative for pneumococcus for 
47/230 swabs, and were discordant for 29/230 swabs. Of the discordant swabs 11 grew 
pneumococcus originally but failed to do so for microarray and 18 swabs yielded 
pneumococcus by culture for microarray but had not done so originally by the standard 
WHO method.
Table 10.1: Proportion of swabs carrying any vaccine-type, only non-vaccine-type, or no 
pneumococcus, by culture step and microarray analysis
Time point n Vaccine-type Non-vaccine-type No pneumococcus
v (days) \ pneumococcus \ pneumococcus v
0 46 18 39% 18 39% 10 22%
30 45 18 40% 22 49% 5 11%
60 46 12 26% 15 33% 19 41%
90 46 17 37% 16 35% 13 28%
180 45 17 38% 19 42% 9 20%
Of the 154 swabs that grew pneumococcus on both occasions, 139 were concordant 
serotypes and 15 were discordant serotypes. Of the 15 discordant serotypes, nine were 
concordant to serogroup level and six were not. Therefore 148/154 (96%) swabs with 
growth of pneumococci were concordant to at least serogroup.
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The swabs that did not yield viable pneumococci for serotyping by microarray had lower 
pneumococcal concentration by lytA qPCR (median 4.04 log copies/pg human DNA, IQR 
3.51-4.55 log copies/pg human DNA) than the swabs that did grow pneumococci, 
(median 5.19 log copies/pg human DNA, IQR 4.60-5.92 log copies/pg human DNA) 
p<0.0001. This is illustrated in figure 10.2.
In multivariable logistic regression; gender, age at time of swab collection, recent 
antibiotic use (within 30 days), month of swab collection, number of smokers in the 
household, mid-upper arm circumference, source of drinking water and type of cooking 
fuel were not associated with culture positivity but pneumococcal concentration by lytA 
qPCR was significantly associated (data not shown). The proportion culture positive in 
strata of lytA concentration can be seen in figure 10.3.
SH
o .>.co
i s -
Micorarray culture positive
logJyta_alu 
Microarray culture negative
log. ,lyta_alu
Figure 10.2: Distribution of nasopharyngeal pneumococcal concentration in logio lytA 
copies/pg human DNA for swabs that did and did not grow pneumococci on culture in 
preparation for microarray.
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lytA c^oncentration copies/|ig human DNA
Figure 10.3: Proportion of nasopharyngeal swabs that were positive on culture for 
pneumococcus by five strata of pneumococcal concentration by lytA qPCR.
In order to assess changes in total, VT and NVT pneumococcal concentration over time 
post-vaccination, a range of methods was explored; here the results are presented in the 
same order as the analytic methods were discussed above.
1) A visual display of all data. Examples of the visual representation of serotype-specific 
nasopharyngeal pneumococcal concentration across time, by individual study participant, 
can be seen in figure 10.4. There are two graphs, A and B, presented for each individual 
child. Graphs marked "A" are of nasopharyngeal pneumococcal concentration in lytA 
copies/pg of human DNA over the six months post vaccination and demonstrate the 
dominance of the principal serotype and the impressive changes in concentration that 
occurred within individuals. Graphs marked "B" are of logi0-transformed nasopharyngeal 
pneumococcal concentration in logi0 lytA copies/pg of human DNA and reveal the degree 
of multiple carriage that occurred and the relative concentrations between individuals.
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"Unknown" serotypes seen on these charts are indicative of swabs for which the lytA 
qPCR was positive, but culture for microarray was not, so that we are lacking serotype 
data for those swabs. Graphs for every study participant can be found in Appendix C.
The log lytA concentration for all day 0, pre-vaccine swabs, and the log lytA concentration 
distribution for all day 30, 60, 90 and 180, post-vaccine swabs can be seen in figure 10.5.
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Figure 10.5: Pneumococcal concentration, in logio lytA copies/pg human DNA, in 230 
nasopharyngeal swabs from 46 children before vaccination (day 0) and after vaccination 
(days 30, 60, 90 and 180 since vaccination) with PCV-10.
2) Changes in VT and NVT pneumococcal concentration with time for swabs with 
microarray data. Log-transformed VT, NVT and total pneumococcal concentrations over 
time can be seen in figure 10.6; data are log-transformed for ease of display but p-values 
are a non-parametric paired analysis of untransformed data, so as not to lose the zero 
quantities. Here the paired analysis of individuals at day 0 and day 30, at day 0 and day 
60, at day 0 and day 90 and at day 0 and day 180 reveals no significant changes in VT 
pneumococcal concentration, but significant increases in NVT pneumococcal 
concentration. Total pneumococcal concentration likewise increases significantly over 
time. The analysis for VT and NVT concentration is restricted to data from swabs that 
were culture positive for microarray, in order to assign serotype, and does not include
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data from swabs that were lytA qPCR positive but microarray negative. The differences in 
VT, NVT and total pneumococcal concentration between day 0 and day 180 are displayed 
in figure 10.7 and a sign test demonstrates no change in VT concentration, a significant 
increase in NVT concentration and an overall increase in pneumococcal concentration 
over the six-month period post vaccination.
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Figure 10.6: Logi0-transformed total, vaccine-type and non-vaccine type 
nasopharyngeal pneumococcal concentration over time. Time point 1 = day 0, time point 
2 = day 30, time point 3 = day 60, time point 4 = day 90 and time point 5 = day 180 since 
vaccination with PCV-10. Data were logi0-transformed for display only. P-values were a 
non-parametric paired analysis of untransformed data. Pneumococcal concentration was 
in lytA copies/pg human DNA.
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Figure 10.7: Differences in vaccine-type, non-vaccine-type and total nasopharyngeal 
pneumococcal concentration between day 0 and day 180 post-vaccination with PCV-10.
Pneumococcal concentration was in lytA copies/pg human DNA.
3) Changes in VT and NVT pneumococcal concentration with time with imputed data for 
swabs missing microarray data. The analysis was repeated with imputed data for the 58 
swabs that were positive by lytA qPCR but microarray serotype data was not available.
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The ratio of median VT concentration over the median NVT concentration among swabs 
yielding VT or NVT pneumococcus at each time point was used to impute data. Several of 
the median VT concentrations by time point were 0, so the median VT and median NVT 
concentrations of all swabs that underwent microarray were not used, as can be seen in 
tables 10.2 and 10.S. The Wilcoxon signed-rank paired analysis of the dataset including 
imputed data again revealed no change in VT pneumococcal concentration and a 
significant increase in NVT pneumococcal concentration with time post-vaccination. 
Figure 10.8 shows the changes in VT and NVT concentration over time for all 46 swabs 
including the imputed data.
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Table 10.2: Median vaccine-type (VT) and non-vaccine-type (NVT) nasopharyngeal 
pneumococcal concentration among swabs that had vaccine-types detected by 
microarray analysis and swabs that had non-vaccine-types detected by microarray 
analysis, which involves an initial culture step. Pneumococcal concentration was in lytA 
copies/pg human DNA.
median median
Days since N VT N NVT
vaccination (VT) concentration (NVT) concentration
0 18 51,372 24 21,219
30 18 284,397 31 88,520
60 12 260,145 20 94,808
90 17 129,922 25 99,523
180 17 221,241 27 293,745
Table 10.3: Median vaccine-type (VT) and non-vaccine-type (NVT) nasopharyngeal 
pneumococcal concentration among all swabs that underwent microarray analysis.
Pneumococcal concentration was in lytA copies/pg human DNA
median median
Days since N VT N NVT
vaccination_____(VT) concentration (NVT) concentration
0 36 756 36 13,486
30 40 0 40 35,199
60 27 0 27 55,063
90 33 6 33 18,047
180 36 0 36 117,193
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Figure 10.8: Logi0-transformed vaccine-type (VT) and non-vaccine-type (NVT) 
nasopharyngeal pneumococcal concentration overtime, including imputed data.
Imputed data was for swabs with total pneumococcal concentration available by lytA 
qPCR, but proportion VT and NVT not available because of no or insufficient growth on 
culture for microarray analysis. Time point 1 = day 0, time point 2 = day 30, time point 3 
day 60, time point 4 = day 90 and time point 5 = day 180 since vaccination with PCV-10. 
Zero values were set to 0.1 and data were logi0-transformed for display only. P-values 
were a Wilcoxon signed-rank paired analysis of untransformed data. Pneumococcal 
concentration was in lytA copies/pg human DNA.
4) The ratio of median VT to median NVT concentration. An alternative method of 
analysis looked at the ratio of VT to NVT concentrations. This could be done overall for 
the whole dataset, taking a ratio of the median VT concentration to the median NVT
concentration for swabs yielding VT or swabs yielding NVT, or on an individual basis using 
individual participants with multiple serotype carriage. The ratio of median VT:NVT 
concentrations fell by 69% over the six months post vaccine and this can be seen in figure 
10.9. The log of this ratio declined significantly with a p-value of 0.036.
Ratio of median VT: median NVT
0
0 30 60 90 180
D a y s  s in c e  v a c c in a t io n
Figure 10.9: The ratio of median VT to median NVT pneumococcal concentration in the 
nasopharynx. The median values were taken from swabs with VT pneumococcal growth 
or NVT pneumococcal growth on culture for microarray analysis at each time point since 
PCV-10 vaccination.
5) Individual ratios of VT:NVT concentration. There were 65 swabs with multiple serotype 
carriage, and of those, 37 had carriage of both VT and NVT pneumococci. These 37 swabs 
differed from the entire dataset only in that they were more likely to come from homes 
containing multiple smokers and from participants with lower mid-upper arm 
circumference (MUAC). This can be seen in table 10.4. A box plot of the log ratio of VT to 
NVT quantities can be seen in figure 10.10. Statistical significance was not demonstrated.
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Table 10.4: Characteristics of swabs containing both vaccine-type (VT) and non-vaccine- 
type (NVT) pneumococcal carriage compared to all other nasopharyngeal swabs.
VT & NVT 
multiple carriage
n/37 (%)
All other 
swabs
n/193 (%) p-value
Days since vaccination 0.717
Day 0 6 16 40 21
Day 30 9 24 37 19
Day 60 5 14 41 21
Day 90 9 24 37 19
Day 180 8 22 38 20
Female 14 38 91 47 0.298
Firewood as cooking fuel
type 37 100 193 100 NA
Source of drinking water § 0.395
Borehole 0 0 5 3
Dam 13 35 52 27
Pond 6 16 14 7
Protected well 1 3 14 7
Rainwater 0 0 5 3
Stream/river 2 5 8 4
Unprotected well 15 41 95 49
Smokers in household § 0.003
none 30 81 135 70
1 1 3 39 20
2 3 v 8 17 9 v
3 3 8 2 1 .;■<
Antibiotic use within 30 days 0 0 15 8 0.138
mean (sd) mean (sd) p-value
Age (months) 20.0 
MUAC(cm)H 14.4 
H mid-upper arm circumference, § Fisher's exact
4.4
0.99
20.4
14.9
3.8
1.16
0.597
0.021
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Figure 10.10: Logio ratio of vaccine-type (VT) to non-vaccine-type (NVT) pneumococcal 
concentration in the nasopharynx among 37 swabs carrying both VT and NVT 
pneumococcus, by time point. Time point 1 = day 0, time point 2 = day 30, time point 3 : 
day 60, time point 4 = day 90 and time point 5 = day 180 since vaccination with PCV-10.
6) Serotype-specific analyses. Serotype concentration over time for the six most common 
serotypes, 6A, 19F, 23F, 15B, 14 and 6B, can be seen in figure 10.11. The numbers for 
each serotype were small and statistically significant changes were not detected for any 
of the individual serotypes.
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Figure 10.11: Nasopharyngeal pneumococcal logio concentration by the six most 
common individual serotypes among over time. Time point 1 = day 0, time point 2 = day 
30, time point 3 = day 60, time point 4 = day 90 and time point 5 = day 180 since 
vaccination with PCV-10. Pneumococcal concentration was in lytA copies/pg human DNA.
Repeating analytic method 2), without adjusting pneumococcal concentration for human 
DNA present in the swab transport medium, revealed no significant changes in VT
pneumococcal concentration, a significant increase in NVT pneumococcal concentration,
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and no significant change in total pneumococcal concentration over time post 
vaccination. Log-transformed VT, NVT and total pneumococcal concentrations overtime, 
without adjustment for human DNA concentration, can be seen in figure 10.12.
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Figure 10.12: Logio-transformed total, vaccine-type and non-vaccine type 
nasopharyngeal pneumococcal concentration overtime. Time point 1 = day 0, time point 
2 = day 30, time point 3 = day 60, time point 4 = day 90 and time point 5 = day 180 since 
vaccination with PCV-10. Data were logio-transformed for display only. P-values were a 
non-parametric paired analysis of untransformed data. Pneumococcal concentration was 
in lytA copies/mL without adjustment for the concentration of human DNA present in the 
nasopharyngeal swab transport medium.
10.3.1 Pneumococcal microarray
In three study participants, microarray types generated from the genome backbone were 
different even when the same serotype apparently persisted in carriage. Specifically, 
participant 138 had a microarray type 4 /  capsular serotype 6A at day 0 and day 30 but 
this became a microarray type 3 /  capsular serotype 6A at day 60 and day 180. Participant
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141 likewise had a microarray type 4 /  capsular serotype 6A at day 60 and day 90, but a 
microarray type 9 /  capsular serotype 6A at day 180. Finally, participant 107 had a 
microarray type 1 /  capsular serotype 6B at day 30 and a microarray type 2 /  capsular 
serotype 6B at day 60.
10.4 Discussion
Total pneumococcal nasopharyngeal concentration increased in the six months post PCV- 
10 vaccination. Vaccine-type pneumococcal nasopharyngeal concentration did not 
change significantly over this time period. Non-vaccine-type pneumococcal
nasopharyngeal concentration increased significantly at the same time. These results held 
true regardless of whether we looked at only the culture-positive swabs with serotype 
data by microarray, or whether we looked at all swabs including imputed data for those 
that were not able to be typed by microarray.
The ratio of median VT concentration to median NVT concentration fell by 69% over the 
same time period. Taken together, the results of these analyses are compatible with a 
vaccine effect on nasopharyngeal concentration of vaccine serotypes. It has been clearly 
demonstrated that pneumococcal conjugate vaccines decrease prevalence of vaccine- 
type carriage, both in the PRISM study10 and elsewhere.156 158 Density of vaccine-type 
carriage decreased with vaccination in a Navajo population in the USA,158 and in the 
Gambia, although in the latter study non-vaccine-type carriage also decreased at the 
same time.103
A major limitation of this study is the lack of microarray data for control children without 
vaccination, to adequately address confounding by seasonality. Pneumococcal carriage 
prevalence in Kilifi increases from January to July, with a peak just after the April-July 
rainy season.195(204 if microarray data for control children were available, we may have 
been able to demonstrate a relative decrease in vaccine-type pneumococcal 
concentration in vaccine recipients compared to controls, and would have been able to 
quantify the decrease. However, the lack of an increase in vaccine-type pneumococcal 
concentration when total pneumococcal nasopharyngeal concentration increased with 
the pneumococcal season is plausibly explained by vaccine effect. We cannot rule out a 
reason other than seasonality for the increase in total pneumococcal and NVT 
pneumococcal concentration over the studied time-period, such as a carriage epidemic of 
NVTs. Studying the total, VT and NVT concentrations over the same time period among
controls would assist in understanding whether seasonality is the explanation and 
whether VT pneumococcal concentration really does decline in vaccinees relative to 
controls.
We assessed the differences between paired swabs collected pre-vaccine and swabs 
collected 6 months later, in VT, NVT and total pneumococcal concentration. It may be 
more relevant to assess ratios of such paired swabs to detect changes that might affect 
individual disease risk post-vaccine. We were limited to the assessment of differences 
rather than ratios by the large number of zero quantities in the data (90 of 169 swabs 
contained 0 lytA copies/pg human DNA of VT pneumococci and 45 of 169 swabs 
contained 0 lytA copies/pg human DNA of NVT pneumococci). Differences may still be 
relevant; the graphs of untransformed nasopharyngeal pneumococcal concentration by 
serotype for individual children marked "A" in Appendix C demonstrate that large linear 
changes in concentration do occur-and these may be important for transmission or 
disease risk.
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We did not have sufficient data to demonstrate changes in individual serotypes overtime 
after PCV-10 vaccination by paired analysis. To investigate whether the vaccine has an 
effect of reducing the concentration of newly-acquired colonisation with individual 
vaccine-types, even if it does not entirely prevent acquisition with those types, a larger 
dataset allowing a paired comparison of serotype-specific concentration would be 
needed.
Looking at the ratio of VT to NVT pneumococcal concentration gets around the problem 
of seasonality, as we do not expect season to influence VT or NVT relative concentrations. 
However, of 65 swabs demonstrating multiple carriage by microarray, only 37 
demonstrated multiple carriage with both VT and NVT pneumococci present. These 37
swabs were not significantly different from all other swabs except that they were more 
likely to come from children with a slightly lower MUAC and from homes with multiple 
smokers. The ratio of VT:NVT did appear to decrease with time, but numbers were too 
small to be able to prove statistical significance. In order to increase the number of swabs 
contributing data for analysis we computed a ratio of median VT to median NVT 
concentrations using swabs containing VT or NVT. This ratio does not include the swabs 
with no VT or those with no NVT quantity (for example, a swab with 100% NVT quantity 
yields a 0% concentration for VT) as seen in tables 10.2 and 10.3 because several median 
concentrations would have been 0. The log ratio of median concentrations, VT:NVT, fell 
significantly across time after vaccination with PCV-10. The shape of the curve for VT:NVT 
ratio across time was similar for the analysis using median concentrations from all carriers 
as for the restricted analysis using 37 individual swabs with multiple carriage of VT and 
NVT, seen in figures 10.9 and 10.10.
Another limitation of these data is the 58 swabs that were positive for lytA by qPCR but
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did not yield pneumococcus on culture for microarray serotyping. It is known that the 
autolysin gene may exist in non-pneumococcal streptococci, such as Streptococcus 
pseudopneumoniae, so we might suspect that these nasopharyngeal swabs were 
detecting non-pneumococcal species.108,205 However, as analytical specificity of lytA PCR 
has been demonstrated by several authors, as seen in table 2.1 of the introduction, and 
as we used the CDC-revised primer and probe sequences 125 and further validated them 
ourselves on 70S. pneumoniae and 30 non-pneumococcal streptococcal species from 
Kilifi, we assumed specificity for pneumococcus. The Kilifi data can be seen in section 3.2, 
chapter three, and further discussion of the specificity of the lytA assay for 
pneumococcus can be found in section 2.2.2 in chapter two. It is also possible that the 
PCR assay was detecting non-viable pneumococci, since some of the swabs that did not
grow pneumococcus for microarray typing had grown pneumococcus two years 
previously when the original study was carried out. Imputing data was possible using the 
ratio of median VT quantity to median NVT quantity among positive swabs from the 
pneumococcal microarray at each time point; applying this ratio to the concentration of 
pneumococcus found by lytA qPCR for swabs lacking microarray data. Analysing the 
changes in VT and NVT concentrations across time using the model with imputed data did 
not change the conclusions drawn from the analysis without imputed data.
Pneumococcal conjugate vaccines are being rolled out to more and more of the world 
that needs them, and more countries are beginning to monitor impact of the vaccines. 
Additionally, new-generation pneumococcal vaccines that are not serotype-specific are 
being developed and tested. Studies using nasopharyngeal carriage as the endpoint 
instead of IPD are proposed; taking the vaccine effect on carriage to be a marker of direct 
protection against pneumococcal disease at the individual level.64 Pneumocarr, a Gates- 
funded initiative to advise on the use of nasopharyngeal pneumococcal carriage as the
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endpoint for vaccine studies, have suggested that pneumococcal acquisition, duration of 
carriage and density of carriage are important parameters to consider.164
If the vaccine effect on carriage includes reduction in density of carriage, this will be 
important to detect. The degree of importance will depend on the relationship between 
carriage density and transmission and between carriage density and invasion, which we 
do not yet fully understand. The relevance of duration of carriage for invasive disease 
depends on whether we believe that invasion occurs only within a month of new 
acquisition of carriage, but the relevance of duration of carriage for transmission is clear.
Methods that detect multiple serotype carriage are also important to get the full 
picture.171 Serotype replacement in carriage can be unmasking or true replacement. Our
data illustrate the use of nasopharyngeal pneumococcal concentration in addition to 
detection of multiple serotype carriage pre and post vaccination. The graphs by individual 
study participant in figure 10.4 and Appendix C demonstrate the amazing complexity of 
pneumococcal dynamics by serotype post vaccine; multiple serotype carriage, dominance 
of the prevailing type, variation in serotype-specific concentration both within individuals 
over time and between individuals. These analyses also reveal the inherent difficulties in 
studying the density of carriage. Paired analysis of serotype-specific nasopharyngeal 
pneumococcal concentration in swabs before and after vaccine is constrained by the zero 
concentrations that are present in such data. Restricting the analysis to the small subsets 
of swabs that are positive for specific serotypes, or to swabs that are positive for either 
VT or NVT alone, constrains the power of the analyses and ignores the information 
contained in negative swabs. Negative swabs can contain important information as part 
of a pair, such as the acquisition of a VT where there was no VT previously, or the loss of a 
VT where there was previously a VT present.
V ■ \ ;  • V
The pneumococcal microarray, a powerful tool for demonstrating multiple carriage, 
relative abundance, and genetic relatedness of pneumococci, is currently limited to swabs 
that are culture-positive with pneumococci. The requirement for a culture step in the 
standard microarray workflow is a major limitation of the methodology both because it 
creates an artificial step in the data, where swabs with a lower pneumococcal 
concentration are less likely to grow and be included in the microarray, and because we 
cannot be sure that the relative concentrations of bacteria detected in the microarray are 
the same as they were in the original swab. It is possible to extract DNA directly from the 
nasopharyngeal swab specimen, and amplify it for use in the microarray, but this method 
has been shown to be less sensitive for detecting minor serotypes and multiple carriage 
than use of the culture amplification step (personal communication, Jason Hinds).
Recently, serotype-specific quantitative PCRs have been developed for many 
pneumococcal serotypes,142'167 but there will still be swabs that are negative for any given 
serotype under study. Even when aggregating serotype-specific data into VT and NVT 
there are still swabs that are negative for all vaccine-types or for all non-vaccine types, so 
the issue of dealing with quantitative data with medians at or close to zero remains. 
Serotype-specific PCRs performed directly from nasopharyngeal or oropharyngeal swabs 
are also troubled by problems with lack of specificity for pneumococcus, as non- 
pneumococcal streptococci may harbour pneumococcal capsular genes.167,177
The nasopharyngeal swabs in this study had a very high prevalence of pneumococcal 
carriage as determined by lytA qPCR. Aliquots of uninoculated STGG were used as 
negative extraction controls and taken through all the lab procedures, remaining 
negative. As discussed, we assume the CDC's lytA assay that we used is specific for 
pneumococcus. This leads to the question; what is pneumococcal carriage? In the mid­
last century, this was the ability of a nasal aspirate or saliva to grow pneumococcus in the 
peritoneum of a mouse, more recently it has been growth of pneumococci on blood agar 
with gentamicin from a nasopharyngeal swab, the WHO standard method.168
Austrian recognised that very different surveillance results ensued from different 
methods of culture for pneumococcus.23 Austrian also stated that Gundel found in 1933 
that "60% of humans could be shown to carry pneumococci if examined appropriately 
and that, if studied over time, this fraction would approach 100%."23 Swab positivity in 
our study of 12-23 month old infants over 6 months was 75% of swabs by culture and 
microarray, yet 97% of swabs tested positive by lytA qPCR. We expect that PCR might be 
more sensitive than culture, because of the ability to detect non-viable organisms. We 
may be detecting pneumococcus at levels that do not constitute carriage as we know it.
Most pneumococcal carriage data from around the world is culture prevalence, using 
methods similar to the WHO standard method.168 There are some data available using 
lytA qPCR to compare with ours; a study of Peruvian children <35 months of age found 
carriage among 60.1% by culture compared to 77.4% by PCR, but they used a different 
cut-off for PCR-positive than we did, setting a Ct value of <35 of 40 cycles as positive 
whereas we took all amplification curves up to cycle 40 as positive.176 It can be more 
difficult to call positives from amplification curves occurring late in the amplification 
cycles of real-time PCR, because it is more difficult to see whether true exponential 
amplification is taking place. Late positive curves may also be occurring close to or below 
the reliable lower limit of detection or linearity, limiting accurate quantification.
However, calling all such curves negative may be ignoring true low positives. Various 
strategies such as performing PCR replicates and calling positives only on samples that are 
positive from 2/2 or 2/3 replicates may be employed but low-level positives below the 
limit of detection win stocnasticaiiy iesi as negative sometimes — and likewise some 
negatives may 'becofne' low positives if repdat testing is employed.v
Among 17-month old infants in Fiji vaccinated with PCV-7, carriage prevalence was 57%, 
but 69% in indigenous Fijians, by lytA PCR.206 This group used a cut-off of 5 x 103 genome- 
copies/mL for positives, and tested samples in duplicate, requiring both results to be 
positive for a sample to be called positive. In Dutch primary school aged children, older 
than our study population, 88% were found to be carrying pneumococcus in saliva, by 
culture-enriched PCR.167 Among Nigerian infants <9 months of age assessed prior to 
introduction of the pneumococcal conjugate vaccine, 90% of infants were carrying 
pneumococcus by culture.207 Likewise in The Gambia, by culture, 90% of 11-month old 
infants carried pneumococcus, and 100% carried pneumococcus at some point during the 
12-month study.208
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Our swab positivity rate was 75% by culture for microarray, varying from 59% to 87% of 
swabs at any time point, and 97% by lytA PCR, varying from 91% to 100% by time point. 
This may be similar to prevalence among infants in The Gambia or Nigeria, but it would be 
interesting to know what the PCR-positivity would have been among those populations.
In fact, even the culture for microarray gave slightly different results in this study than the 
original culture done by the WHO standard method two years previously. There were 29 
discordant swabs; the 11 that grew originally but failed to do so for this study may have 
not survived freeze-thaw cycles and 18 swabs yielded pneumococcus by culture for 
microarray but failed to do so originally by the standard WHO method. These may have 
been due to the WHO standard method of selecting a single colony for identification and 
serotyping; it would be possible to miss a pneumococcal colony with that technique 
compared to the DNA extraction from a sweep suspension of all growth on the plate for 
microarray. Previous work in our laboratory demonstrated 98% sensitivity of 
pneumococcai cuiture from frozen compared to fresh nasopharyngeal swabs in STGG, but 
swabs were onlyTrozen for 2 months, cdmpared to three years in the current study.209 J
The microarray gives us additional data to consider. The genome backbone of the 
pneumococci studied can be used to examine the relatedness of the isolates. We can see 
that some serotypes that appear to persist over time in an individual, are in fact not the 
same clone, so that replacement has occurred with the same serotype. Such information 
would not be available from a traditional culture-based study, unless whole genome- 
sequencing was applied to the cultured isolates, nor from a serotype-specific qPCR-based 
study.
In summary, vaccine-type pneumococcal nasopharyngeal concentration did not change 
over six months post PCV-10 among Kenyan children aged 12-23 months. At the same
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time, non-vaccine-type and total pneumococcal concentration increased in line with 
possible seasonal changes in pneumococcal carriage prevalence. This is compatible with a 
relative effect of vaccine on VT compared to NVT concentration, but controls are needed 
to confirm and quantify the effect. Such control samples were collected in the parent 
PRISM study and permission is being sought to extend the microarray analysis to these 
samples. If there were no effect of vaccine, then we would expect to see similar changes 
over time in the control arm as in the vaccine arm reported here, ie. no change in VT 
concentration, and an increase in total pneumococcal and NVT concentration over the 
six-month period.
The ratio of median VT to median NVT pneumococcal concentration decreased by 69% 
over the six months post-vaccine. This is likely to have been a vaccine effect on VT relative 
to NVT concentration.
Coionisation density ano tne errects or coionisation density on transmission and invasion 
may vary by serotype^yet large datasets are heeded to examine effejcts by individual 
serotype. Simplifying serotype-specific data into VT and NVT still leads to complications in 
analysis, with many zero values and median values at or close to zero; prevalence 
contributes significantly towards quantitative data. The data are not normal but log- 
transformation leads to loss of true zero concentrations, so non-parametric analyses are 
needed.
Carriage defined by pneumococcal real-time PCR cannot be directly compared with 
carriage defined by standard culture. Measuring serotype-specific density of colonisation 
for vaccine studies will be challenging and a lot of thought needs to go into planning 
analyses for such studies. Cross-sectional surveys will be easier to analyse than
longitudinal studies using quantitative microarray data but paired analysis of longitudinal
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data is epidemiologically stronger. We need to continue to innovate ways to describe 
pneumococcal dynamics in the nasopharynx.
Chapter Eleven
11 Objective four: Pneumococcal DNA quantification in blood as a 
diagnostic method for invasive pneumococcal disease
11.1 Introduction
Pneumococcal disease is the leading cause of childhood vaccine-preventable death in the 
world.11 Diagnosis of invasive pneumococcal disease (IPD) for either epidemiological 
studies or clinical care is difficult; a minority of cases are detected by blood culture even 
under ideal conditions;12 sputum is not spontaneously produced by young children; it is 
problematic to differentiate carriage from disease using culture of nasopharyngeal
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samples; diagnostic serology is insensitive.in children and in any case needs paired 
sampling;13 and urinary antigen tests are not sufficiently specific for use in young 
children.194 It is presumed this lack of specificity of urinary antigen tests among children is 
due to nasopharyngeal pneumococcal carriage; swallowing of nasopharyngeal secretions, 
absorption of pneumococcal polysaccharide in the gut and excretion in urine 15 - and 
perhaps intermittent transient benign bacteraemia.14
Pneumococcal nasopharyngeal colonisation is a prerequisite for pneumonia and IPD.64'67 
Recent acquisition of an invasive strain of pneumococcus is thought to be the event that 
leads to invasive disease if immune mechanisms fail.66 67 This is based largely on a 
longitudinal study by Gray et al, where in fact only three of the 31 pneumococcal
infections that occurred were IPD, the remainder being otitis media. Three-quarters of
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the pneumococcal infections in the study by Gray et ol occurred within a month of 
acquisition of a new strain of pneumococcus in the nasopharynx. Young children are not 
only more likely to carry pneumococcus in the nasopharynx, but they may carry a higher 
density of pneumococcus than older children or adults.103 Both the higher prevalence of 
carriage and a higher density of pneumococcal carriage in the nasopharynx could 
potentially contribute to children from populations with low socio-economic opportunity 
being at higher risk for pneumococcal pneumonia and IPD; these could also contribute to 
a lack of specificity in the diagnosis of IPD.
Progress in molecular methods to diagnose IPD has been slow, with several gene targets 
of NAATs being non-specific to S. pneumoniae due to its close homology with related non- 
invasive species.106 125 A review of heterogenous studies of molecular methods to 
diagnose IPD from blood samples carried out over 1993 to 2009 describes sensitivity of 
57-66% and specificity of 88-99%. Specificity depended on what sort of control groups 
were used.124 Poor sensitivity has been thought to be due to low specimen volume that
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can be tested by NAATs, PCR-inhibitors and pneumococcal autolysis and DNA degradation 
from old specimens or specimens stored at _20°C.116'122'125'127
Most pneumococcal PCR assays now use the autolysin gene lytA,125 but assays using the 
pneumolysin gene ply were common initially.106,127 Other pneumococcal gene targets 
include the surface adhesion protein psaA125 a gene of unknown function spn9802,122 the 
capsular polysaccharide biosynthesis gene cpsA136 and the bacterial recombinase gene 
recA,137 Dagan and colleagues suggested that pneumococcal DNA may be detectable in 
the bloodstream of healthy individuals who do not develop clinical disease, from 
pneumococci which directly invaded the blood from the nasopharynx or which entered 
the bloodstream phagocytosed by lymphoid cells.106 However, they were using the
pneumolysin gene as a PCR target, that we now know detects not only pneumococcus but 
also other commensal streptococcal flora. This has meant that the concept of 
pneumococcal DNA being readily detectable in the bloodstream of young children who 
remain completely well has not received as much consideration in the scientific 
community as it might have done. Non-pneumococcal commensal streptococcal flora are 
not uncommon blood culture contaminants in young children,210 presumably because 
infants' skin is frequently in contact with their saliva, but they should otherwise not be 
expected to be detected in blood samples either.
lytA has been shown to be a specific gene target for identifying pneumococcus for PCR 
assays,116'125'136,138'139 and although the autolysin gene has been found in some 5. 
pseudopneumoniae128 and S. mitis genomes,108 it can be differentiated from that in S. 
pneumoniae.128,138 Experience with the lytA target for real-time PCR assays in the 
diagnosis of IPD from blood samples is increasing,15'74'121'141145 particularly with the CDC's 
lytA assay published in 2007.125 Further discussion of the analytical specificity of this assay
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can be found in section 2.2.2 of chapter two. The sensitivity of lytA real-time PCR is now 
probably better than blood culture, the traditional gold standard for the diagnosis of IPD, 
with attention to specimen management and use of modern DNA extraction 
methods.74'143,144 Clinical specificity has been harder to measure, particularly among 
children, the population who most need an improved diagnostic assay. In Italy lytA real­
time PCR from blood was negative among 147 well children with a median age of 4.9 
years, half of whom were colonised with pneumococcus in the nasopharynx by PCR of 
nasopharyngeal swabs.15 In South Africa real-time lytA PCR from serum was negative in 
100 well children with a mean age of 5.8 years, half of whom were colonised with 
pneumococcus in the nasopharynx by culture.148 In Slovenia, lytA real-time PCR was 
positive from plasma among two (7%) of 29 children with a non-pneumonia acute febrile
illness for which a non-pneumococcal cause was identified, with a mean age of 1.5 
years.146 Both the children who tested positive were colonised with pneumococcus. As 
blood cultures are themselves not a sensitive gold-standard assay with which to define 
IPD, it is not surprising that real-time PCR could detect cases that are blood culture 
negative. This does make it difficult to assess specificity of PCR in the diagnosis of IPD 
because it is not easy to define a suitable group of true negatives among children who are 
actually the target population for the diagnostic assay -  ie. sick children who might have 
IPD. The use of healthy children or adults as control populations is likely to produce a 
biased estimate of clinical specificity.
Quantitative real-time pneumococcal PCR has been used from respiratory specimens to 
separate colonisation from disease126 and from blood as a marker of disease 
severity.74,145'147,149 Quantitative PCR (qPCR) using the lytA target on blood samples might 
help us separate children with IPD from children with PCR-positivity in blood due to 
nasopharyngeal pneumococcus advancing into the bloodstream without resulting in
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sepsis, if such a phenomenon really occurs.
11.1.1 Objective
To investigate the test parameters of lytA qPCR on paediatric blood specimens in the 
diagnosis of invasive pneumococcal disease in diverse populations in the developing 
world.
11.2 Methods
There were two sets of samples available to assess the test parameters of lytA qPCR on 
blood as a diagnostic test for IPD. The first was the Kilifi set of samples, all paediatric 
medical admissions to Kilifi County Hospital from September 2010 until November 2013;
and two control groups consisting of healthy children and children with upper respiratory 
tract infection symptoms in the community.5
The second was the Pneumonia Etiology Research for Child Health (PERCH) case-control 
sample set, consisting of children 1 month to 5 years of age enrolled in an international 
multi-site case-control study of causes of pneumonia. The PERCH sites included Kilifi in 
Kenya as well as sites in The Gambia, Mali, Zambia, South Africa, Bangladesh and 
Thailand. Children were enrolled from August 2011 until late 2013 or early 2014, 
depending on the site.
11.2.1 Kilifi sample set
The Kilifi set of samples came from 8,158 children <13 years of age; 536 community 
controls from the Kilifi arm of the PERCH study (both with and without symptoms of 
upper respiratory tract infection), 557 cases of WHO-defined severe or very severe 
pneumonia admitted to Kilifi County Hospital (KCH) and included in the PERCH study, 
6,996 general medical admissions to the paediatric service at KCH, and 69 convenience 
controls without pneumonia enrolled under non-PERCH studies of pneumonia. The total 
numbers of paediatric admissions to KCH, the paediatric medical admissions (excluding 
accidents, surgical cases, a history of poisoning, and fresh burns) and those providing 
consent for collection of blood for research, can be seen in figure 11.1. Samples were 
collected from November 2010 until November 2013, but were limited to June 2011 until 
November 2013 for controls. The 69 convenience controls were collected during the 
piloting of the PERCH study control selection system in June-August 2011 or were 
collected during the PERCH study but outside the PERCH age limits so were not included 
as PERCH data. All controls lived within the Kilifi Health and Demographic Surveillance 
System (KHDSS) s ite196 and were sampled in the community, matched by age and month
of enrolment to cases of WHO-defined severe or very severe pneumonia admitted to 
KCH. As the pneumococcal conjugate vaccine was introduced to Kenya in January 2011, 
along with a catch-up campaign for children <5 years of age in Kilifi County, most samples 
were collected after the introduction of vaccine.
Controls Cases
Included in Kilifi analysis
536 Qiagen 
DNA extract 
available
7,246 not in 
PERCH study
566 PERCH 
study cases
751 community 
controls enrolled in 
PERCH study
10,735 medical admissions
7,812 sufficient blood collected
8,829 consenting medical admissions
557 Qiagen 
DNA extract 
available
6,996 Qiagen 
DNA extract 
available
EasyMag DNA extract 
available, included in PERCH 
multisite analysis
69 convenience 
controls enrolled in 
non-PERCH studies of 
pneumonia
11,144 paediatric admissions to KCH 
1 Nov 2 0 1 0 -2  Dec 2013
Figure 11.1: Overlap of cases and controls in the two sample sets: paediatric admissions 
to Kilifi County Hospital (KCH) and Pneumonia Etiology Research for Child Health 
(PERCH) multi-site study samples, including Kilifi. Samples in the Kilifi analysis underwent 
DNA extraction by the Qiagen manual method; samples in the PERCH analysis, including 
Kilifi samples, underwent DNA extraction by the EasyMag automated instrument; samples 
in both sample sets were extracted by both methods.
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Administration of antibiotics prior to sample collection (n=l,260), presence or absence of 
pneumococcus in the nasopharynx by culture or PCR (n=2,401) and HIV status (n=5,855) 
were available for some participants. Numbers with available data varied because clinical 
and laboratory parameters were introduced in a stepwise fashion as the PERCH study was 
developed and incorporated into existing Kilifi pneumonia surveillance.5 Additionally, 
children otherwise meeting the PERCH inclusion criteria of WHO-defined severe or very 
severe pneumonia, but who were outside the PERCH study age limits (1-59 months) or 
catchment area (the KHDSS) were included in Kilifi pneumonia surveillance. 
Administration of antibiotics in hospital was recorded and a serum bioassay was 
performed during pneumonia aetiology studies. Details of the serum antibiotic bioassay 
may be found in section 7.3 of chapter seven. Antibiotics were considered as having been 
administered prior to sample collection if the clinical records indicated this or if the serum 
antibiotic bioassay was positive.
A whole blood specimen was collected into EDTA from consenting medical paediatric
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admissions alongside a blood culture and standard admission blood tests. Controls had an 
EDTA blood sample collected but not a blood culture. The EDTA blood sample was 
collected into a dedicated tube for DNA extraction, with the aim of extracting DNA within 
72 hours of sample collection, and samples were kept refrigerated at 2-8°C until 
extraction. All samples were extracted using the QjaAmp DNA blood mini kit from Qiagen 
(section 7.6.1 in chapter seven). Extracted DNA was frozen at -80°C until undergoing 
quantitative lytA PCR as described in section 7.9 of chapter seven.
11.2.2 PERCH sample set
The PERCH sample set consisted of 8,981 children 1-59 months old, cases being those 
admitted to hospital with symptoms meeting the WHO syndromic definition of severe or
very severe pneumonia, and age and time-matched community controls without 
pneumonia at each of the seven sites.4 The WHO definition for severe pneumonia is 
cough or difficulty breathing, with lower chest wall indrawing. Very severe pneumonia is 
defined as severe pneumonia plus any of; central cyanosis, difficulty in 
breastfeeding/drinking or vomiting everything, convulsions/lethargy/unconsciousness or 
head nodding. The cases and controls from Kilifi that came from within the KHDSS, were 
1-59 months of age and fell between 15th August 2011 and 15th November 2013, were 
also included in the PERCH all-site dataset. Pneumococcal conjugate vaccine (PCV) had 
been introduced as PCV-10 in Kenya in January 2011, PCV-7 in the Gambia in August 
2009, PCV-13 in the Gambia in April 2011, PCV-13 in Mali in March 2011, PCV-7 in April 
2009 in South Africa, PCV-13 in June 2011 in South Africa, and PCV-10 in Zambia in July 
2013. Thailand and Bangladesh had not introduced pneumococcal conjugate vaccines. All 
PERCH samples were extracted using the EasyMag automated extraction instrument 
(section 7.7, chapter seven). PERCH samples extracted by EasyMag were done In batches 
for Ibgistical reasons and thb time from sample collection to DNA extraction.varied 
considerably.
The subset of PERCH samples that were from Kilifi had therefore been extracted by two 
methods, the QIAamp DNA blood mini kit manual spin-column method and the EasyMag 
automated extraction instrument. Extracted DNA from whole blood samples underwent 
lytA qPCR (section 7.9, chapter seven). All Ct values <40 were considered positive, as long 
as an exponential amplification curve was present. Results of lytA qPCR from the Qiagen 
extraction are included in the Kilifi dataset and results of lytA qPCR from the EasyMag 
extraction are included in the PERCH all-site dataset.
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The samples from all other PERCH sites followed the same protocols for EasyMag 
extraction and lytA qPCR as those in Kilifi, but were run in the individual site laboratories, 
with standardised quality control procedures and external quality assurance.
11.2.2.1 Nasopharyngeal culture and PCR in PERCH
Nasopharyngeal flocked swabs in STGG (NP-STGG) transport medium underwent broth 
enrichment and culture on blood agar plates containing gentamicin to select for 
pneumococcus. Further details of broth enrichment culture can be found in section 7.1 of 
chapter seven.
Nasopharyngeal flocked swabs and oropharyngeal swabs were collected and combined in 
Copan universal transport medium (NP/OP-UTM), underwent extraction using the 
EasyMag automated instrument, and multiplex PCR using the Fast-Track Diagnostics 
respiratory 33-plex quantitative real-time PCR, which includes a lytA target (Fast-Track
Diagnostics, Luxembourg).
V ■ V:. v . \;.
11.2.2.2 Blood cultures
Blood cultures were performed using the BACTEC 9050 automated blood culture system 
in Peds Plus bottles from BACTEC (Becton Dickinson, NJ, USA). Positive blood cultures 
were gram-stained, sub-cultured and organisms were identified using standard 
microbiological procedures.
11.2.3 Analysis
The analysis of the Kilifi dataset informed the analysis of the PERCH all-site data.
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11.2.3.1 Kilifi data analysis
Characteristics of cases/general admissions and controls in the Kilifi sample set were 
compared using a Wilcoxon rank-sum test or chi-squared test as appropriate.
lytA qPCR data was categorised as a binary variable, either positive or negative, and 
compared to blood cultures as the gold standard, to assess the sensitivity of lytA qPCR in 
the diagnosis of IPD. Specificity was assessed among community controls, who were well 
or had symptoms of upper respiratory tract infection, so were very unlikely to have IPD.
A quantitative comparison of pneumococcal concentration in whole blood between 
participants admitted to hospital and community controls was carried out. lytA qPCR 
results on whole blood were examined by presence or absence of pneumococcus in the 
nasopharynx as detected by culture or multiplex PCR.
As the lytA qPCR assay was found to have poor specificity in the diagnosis of IPD, further 
investigation of assay performance was carried out. A receiver operating characteristic 
(ROC) curve was created for Ct values from the lytA qPCR, using IPD cases according to 
blood culture to set the true positives and community controls to set the true negatives. 
The ROC curve was used to set a cut-off to optimise sensitivity and specificity of lytA qPCR 
for the diagnosis of IPD. This cut-off was used to create categories of lytA qPCR results; 
negative, weak-positive and strong-positive. Weak-positive results were positive results 
with a Ct value above the cut-off, strong-positive results were positive results with a Ct 
value below the cut-off. Weak and strong-positive lytA qPCR results were then analysed 
by sample collection date, extraction run, PCR run and laboratory technician.
Univariable and multivariable logistic regression were used to assess variables associated
with weak positives or strong positives by lytA qPCR. Variables associated with outcome
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at a p-value of <0.1 in univariable analysis, or that were considered important for the 
model, were included in multivariable analysis models by backwards stepwise selection. 
Biologically plausible interactions were assessed using the likelihood ratio test. Weak- 
positive samples were analysed relative to negative samples and strong positive samples 
were analysed relative to weak-positives and negatives combined, assuming that weak 
positives may have been false positive samples.
The ROC curve was then re-created in the subset of Kilifi participants less than five years 
of age, using the raw lytA quantity from the qPCR, unadjusted for extractiomelution ratio, 
as this is standardised across PCR runs, unlike the Ct value which may vary run to run. 
Potential cut-offs were assessed from this Kilifi ROC curve to apply to the PERCH all-site 
dataset.
The lytA concentration values from whole blood samples that had been extracted by both 
the QIAamp DNA biood mini kit and the Easyivlag instrument, were iogio-transformed and 
plotted ih a scatterplot and a z-thst for binary data was performed. For illustrative 
purposes only, negative values were assigned a value of 1 prior to log transformation for 
the scatterplot.
11.2.3.2 PERCH data analysis
Analysis of the PERCH dataset began by assessing between-site differences in positivity 
and concentration of lytA from whole blood. Descriptive analyses were performed: the 
whole blood lytA concentration by site and case-control status; participant characteristics 
by case-control status with chi-squared test for differences between cases and controls; 
and the distribution of lytA concentration by participant characteristics with the Wilcoxon 
rank-sum test for binary data and the Kruskal-Wallis test for categorical data of more than
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two categories. The correlation between nasopharyngeal pneumococcal concentration 
and whole blood pneumococcal concentration for positive samples was assessed using 
Pearson's pairwise correlation co-efficient and displayed as a scatterplot with a line of 
best fit by linear regression.
Two potential cut-offs from the Kilifi under-five years of age dataset were selected from 
the ROC plot based on maximising sensitivity and specificity. One of the cut-offs was also 
noted as being close to the lower limit of detection and linearity of the assay. This cut-off 
was used to define weak-positive and strong-positive samples for lytA qPCR in the PERCH 
all-site dataset.
To explore associations with strong positivity or weak positivity univariable logistic 
regression was performed for weak-positive outcome and strong-positive outcome and 
variables selected based on a p-value <0.1, biological importance for the model, and 
avoidance of collinearity. Multivariable logistic regression was performed by backwards 
stepwise selection, for weak-positive and strong-positive outcome. Strong-positive 
samples were compared with weak-positive samples and negative samples combined; 
weak-positive samples were compared with negative samples only. For each model, 
biologically plausible interaction terms with a significance level of <0.05 by the likelihood 
ratio test were included in the model. Whenever observations were dropped from the 
model due to perfect prediction, Firth logistic regression was employed.
The sensitivity and specificity of a strong positive outcome were calculated for each site in 
the PERCH dataset and these were plotted in a ROC plot with 95% confidence intervals. A 
chi-squared or Fisher's exact test, as appropriate, was used to assess heterogeneity in 
sensitivity and specificity between sites.
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The number of extra diagnoses of IPD that could be made in the PERCH study by 
employing the cut-off for lytA qPCR, in addition to those diagnoses made by blood 
culture, was calculated.
11.2.4 Ethical Clearance
The study was approved by the Kenyan National Ethical Review Committee (SSC1932). In 
the original studies consent was obtained from guardians of all children studied.
11.3 Results
11.3.1 Kilifi results
11.3.1.1 Characteristics of cases and controls in Kilifi
There were 8,158 samples with lytA qPCR results in the Kilifi dataset, among children 
from the first day of life to 13 years of age. Age, Hi'v positivity, days from specimen 
' collection until DNA extraction, antibiotic use prior to sample collection, nasopharyngeal 
carriage of pneumococcus as detected by culture of NP-STGG, and carriage as detected by 
culture of NP-STGG or multiplex PCR of NP/OP-UTM, and blood culture positivity for S. 
pneumoniae can be seen in table 11.1. The 63 children that had IPD as defined by a blood 
culture that grew S. pneumoniae, had a median age of 2.8 years (IQR 1.1 -  4.4 years, 
range 3 days -13.5  years).
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Table 11.1: Characteristics of general admissions and controls in the Kilifi sample set
Controls 
Median IQR
Cases/General admissions 
Median IQR p-value*
Age (months) 13.2 6 25.2 15.6 3.4 46.8 0.355
Days from specimen collection to DNA extraction§ 2 1 3 2 1 3 <0.001
n N (%) n N (°/o)
Female 284 605 (47) 3,182 7,553 (42) 0.021
HIV positivity 2 478 (0.4) 407 6,786 (6.0) <0.001
Antibiotics prior to sample collection 13 551 (2.4) 270 1,068 (25.3) <0.001
Carriage of pneumococcus by culture 470 600 (78) 953 1,879 (51) <0.001
Carriage of pneumococcus by culture or PCR 528 595 (89) 1,324 1,806 (73) <0.001
Blood culture positive for S. pneumoniae - - - 63 7,396 (0.9) -
*Wilcoxon rank sum for comparison of medians, chi-squared test for comparison of proportions
§the distribution of days from specimen collection to DNA extraction was slightly longer for cases than for controls
11.3.1.2 lytA qPCR positivity among cases and controls in Kilifi
Of 605 controls, 31 (5.1%) were lytA qPCR positive from whole blood and of 7,553 PERCH 
cases and general admissions, 305 (4.0%) were lytA qPCR positive. The breakdown by 
participant group can be seen in table 11.2. The differences between groups were not 
significant, with a chi-squared p-value of 0.398. Specificity of lytA qPCR was therefore 
estimated at 94.9% among the 605 controls. Sensitivity of lytA qPCR estimated against 
IPD as defined by blood culture positivity among cases and general paediatric admissions 
was 39/63 (62%).
Table 11.2: lytA PCR positivity from blood samples by participant group in the Kilifi 
sample set. PERCH = Pneumonia Etiology Research for Child Health.
lytA positive (%) Total
PERCH controls 29 5.4 536
PERCH cases 25 4.5 557
General admissions 280 4.0 6,996
non-PERCH controls 2 2.9 69
Total 336 4.1 8,158
247
11.3.1.3 lytA qPCR quantitative data in Kilifi
The distribution of logio-transformed lytA concentration for all positive samples by 
participant group, including cases of IPD as defined by blood culture, can be seen in figure 
11.2. The median lytA concentration among controls with a positive lytA qPCR was 2.51 
(IQR 2.07-3.21) logioCopies/mL and among pneumonia cases and general admissions was 
2.33 (IQR 2.02-3.10) logio copies/mL, rank-sum p-value 0.656. The distribution of logio 
lytA concentrations in blood by participant characteristics can be seen in table 11.3. 
Concentration varied by blood culture positivity as expected, and by DNA extraction 
period, but w ithout a discernable trend. The whole blood logio lytA concentration by 
nasopharyngeal carriage status, for general admissions and pneumonia cases and for 
controls, can be seen in figure 11.3.
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Figure 11.2: Distribution of logio-transformed lytA concentration in logio copies/mL, in 
blood samples in controls, in cases/general admissions and in invasive pneumococcal 
disease (IPD) in the Kilifi sample set. IPD was defined by growth of S. pneumoniae from a 
blood culture. IPD cases are a subset of cases/general admissions.
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Table 11.3: Logio-transformed lytA concentration in logio copies/mL, in blood samples, 
by participant characteristic in the Kilifi sample set.
Number Median log(10) 
lytA lytA quantity P-
Characteristic positive copies/mL IQR value*
Gender 0.419
Male 181 2.31 2.00 3.03
Female 155 2.39 2.07 3.20
Age in tertiles 0.588
0-7 months 84 2.29 2.07 2.90
7-31 months 121 2.32 1.99 3.02
31 months -13 .9  years 131 2.46 2.03 3.22
Invasive pneumococcal disease <0.001
Negative 262 2.25 2.00 2.80
Positive 39 4.23 2.73 5.48
Nasopharyngeal carriage by culture or PCR 0.645
Negative 7 2.52 2.09 3.10
Positive 104 2.51 2.12 3.29
Antibiotics prior to collection of blood sample 0.448
Absent 58 2.52 2.12 3.30
Present 13 2.74 2.37 3.10
HIV status 0.319
Negative 269 2.36 2.01 3.09
Positive 35 2.68 2.04 3.47
Case-control status
\ ; . V 
PERCH community control
\ -
0.194
29 ,;v 2.46 2.07 2.86 V
non-PERCH control 2 3.71 3.35 4.08
PERCH case 25 2.52 2.18 3.10
General admission 280 2.31 2.01 3.11
Extraction period 0.011
Jul-Dec 2010 32 2.38 1.92 2.80
Jan-Jun 2011 87 2.38 2.04 3.92
Jul-Dec 2011 61 2.19 1.96 2.56
Jan-Jun 2012 53 2.43 2.12 3.70
Jul-Dec 2012 36 2.21 1.89 2.78
Jan-Jun 2013 34 2.20 1.96 2.89
Jul-Dec 2013 33 2.52 2.18 4.29
Days from specimen collection to DNA
extraction 0.202
Within 3 days 278 2.32 2.01 3.09
More than 3 days 58 2.55 2.04 3.13
*Wilcoxon rank-sum for binary categorical data, Kruskal-Wallis for >2 categories
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Figure 11.3: Whole blood lytA concentration in logio copies/mL by participant group and 
nasopharyngeal carriage status in the Kilifi sample set. Cases include general paediatric 
admissions to Kilifi County Hospital. Carriage was defined as culture of S. pneumoniae 
from a nasopharyngeal swab or lytA PCR positivity from a nasopharyngeal/oropharyngeal 
swab.
11.3.1.4 Exploring lytA qPCR assay performance in K ilifi; categorising positive results
Having seen that specificity of the lytA assay was poor, and that there were many low 
positive results, we set out to investigate the assay performance to try and understand 
the problem. A receiver operating characteristic (ROC) curve was created using controls 
to set specificity and cases of IPD to set sensitivity, in order to explore a cut-off to 
categorise positives into strong and weak positive results. The initial ROC curve can be 
seen in figure 11.4. From this curve, a Ct value of 38 was selected as a cut-off, with a
sensitivity of 56% and a specificity of 96%. Samples with a Ct value of <38 were 
categorised as strong positives and samples with a Ct value of >38 were categorised as 
weak positives. Categories of positivity were then explored by sample collection date,
DNA extraction date, PCR run number, laboratory operator for DNA extraction, laboratory 
operator for PCR, to look for laboratory effects. Weak positive lytA qPCR results declined 
over time by DNA extraction period and by PCR period, strong positive lytA qPCR results 
did not decline as much over time by DNA extraction period and did not decline at all by 
PCR period, as can be seen in table 11.4. Positivity by laboratory operator can be seen in 
table 11.5 and table 11.6; differences in positivity by operator are confounded by 
differences over time. There was no evidence of an effect of seasonality when categories 
of positivity were examined by month of sample collection, as seen in figure 11.5.
o
LO1^o
~  o  ■55*! c  o
CDcn
At a cut-off of Ct=38, 
sensitivity = 56%, 
specificity = 96%
LO
CM
d
oo
d
0.00 0.25 0.50 0.75 1.00
1 - Specificity
A rea  un de r R O C  c u rve  =  0 .792 0
Figure 11.4: Receiver operating characteristic (ROC) curve using controls to set 
specificity and cases of invasive pneumococcal disease (IPD) to set sensitivity, in the
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Kilifi sample set. The ROC curve was used to select a Ct cut-off to categorise positives into 
strong and weak positive results.
Table 11.4: Whole blood lytA qPCR weak and strong positive samples by DNA extraction
period and by PCR period during the study in the Kilifi sample set.
Extraction period
lytA weak 
positive (%)
lytA strong 
positive (%) Total
Jul-Dec 2010 20 10.0 12 6.0 200
Jan-Jun 2011 30 1.9 57 3.6 1,574
Jul-Dec 2011 16 1.1 45 3.0 1,479
Jan-Jun 2012 6 0.4 47 3.3 1,432
Jul-Dec 2012 6 0.4 30 2.2 1,363
Jan-Jun 2013 1 0.1 33 3.1 1,065
Jul-Dec 2013 1 0.1 32 3.1 1,045
Total 80 
Chi-squared p-value compared to negatives
lytA weak
1.0
p<0.001
256
lytA strong
3.1
p=0.047
8,158
PCR period positive (%) positive (%) Total
Jan-Jun 2012 52 3.2 48 2.9 1,650
Jul-Dec 2012
v .
Jan-Jun 2013
3 1.8 8 4.9 164
.iv 3 0.2 50 2.9 1,746
Jul-Dec 2013 1 0.1 31 3.0 1,047
Jan-Jun 2014 21 0.6 119 3.4 3,551
Total 80 
Chi-squared p-value compared to negatives
1.0
p<0.001
256 3.1
p=0.566
8,158
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Table 11.5: Whole blood lytA PCR weak and strong positive samples by laboratory
operator and DNA extraction period during the study in the Kilifi sample set.
Laboratory operator 1 Laboratory operator 2
lytA category lytA category
Extraction weak strong Sub­ weak strong Sub­
period positive (%) positive (%) total positive (%) positive (%) total
Jul-Dec 2010 19 10.8 11 6.3 176 0 0.0 0 0.0 2
Jan-Jun 2011 6 4.0 13 8.6 152
Jul-Dec 2011 5 3.3 3 2.0 154
Jan-Jun 2012 0 0.0 0 0.0 26
Jul-Dec 2012 0 0.0 3 3.6 83 2 0.5 10 2.3 432
Jan-Jun 2013 0 0.0 16 5.1 314
Jul-Dec 2013 1 0.2 8 1.8 438
Sub-totals 30 5.1 30 5.1 591 3 0.3 34 2.9 1,186
Chi-squared p<0.001 p=0.154
Laboratory operator 3 Other laboratory operators
Extraction
lytA category 
weak strong Sub­
lytA category 
weak strong Sub­
period positive (%) positive (%) total positive (%) positive [%) total
Jul-Dec 2010
Jan-Jun 2011 0 0.0 1 7.1 14
Jul-Dec 2011
Jan-Jun 2012
Jul-Dec 2012 0 0.0 5 2.0 249
Jan-Jun 2013 0 0.0 8 2.1 379 0 0.0 2 7.7 26
Jul-Dec 2013 0 0.0 8 2.7 294
Sub-totals 0 0.0 21 2.3 922 0 0.0 3 7.4 40
p-value v v p=0.823 v NA
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Table 11.6: Whole blood lytA  PCR weak and strong positive samples by laboratory
operator and PCR period during the study in the Kilifi sample set
Laboratory operator 1 Laboratory operator 3
lytA category lytA category
PCR period
weak
positive
strong 
(%) positive (%)
Sub­
total
weak
positive (%)
strong
positive (%)
Sub­
total
Jan-Jun 2012 52 3.5 48 3.2 1,509
Jul-Dec 2012 3 1.8 8 4.9 164
Jan-Jun 2013 2 0.2 25 2.8 892 0 0.0 1 1.0 98
Jul-Dec 2013 0 0.0 9 2.7 334
Jan-Jun 2014 14 0.6 82 3.8 2,178 5 0.6 30 3.6 843
Sub-totals 71 1.4 172 3.4 5,077 5 0.5 31 3.3 941
Chi-squared p-value pcO.OOl p=0.303
Laboratory operator 4 
lytA category
PCR period
weak
positive
strong 
(%) positive (%)
Sub­
total
Jan-Jun 2012 0 0.0 0 0.0 140
Jul-Dec 2012
Jan-Jun 2013 1 0.1 24 3.2 755
Jul-Dec 2013 1 0.1 22 3.1 713
Jan-Jun 2014 2 0.4 7 1.3 532
Sub-totals 4 0.2 53 2.5 2,140
Chi-squared p-value p=0.101
Category
Percent
strong
positive
Category
Percent
weak
positive
Figure 11.5: Percent positivity of lytA PCR on whole blood specimens in the Kilifi sample
set by month of sample collection. Categories of positivity are defined as weak positives
with a Ct >38 and strong positives with a Ct<38.
20%
18%
Sample collection date
Univariable and multivariable logistic regression analyses can be seen in table 11.7 for 
strong positive lytA qPCR and table 11.8 for weak positive lytA qPCR as outcomes. 
Variables significant at a level of p<0.1 in either of the models, avoiding collinearity, and 
participant status (whether a control or a case/general admission), were carried through 
into the multivariable models.
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Nasopharyngeal carriage and HIV positivity were associated with strong positive lytA 
qPCR. Control status and extraction period were associated with a weak positive lytA 
qPCR and it was considered that weak positive results could be false positives. The 
analysis of the Kilifi data informed the analysis of the PERCH all-site data, seen next. The 
ROC plot for the Kilifi dataset was re-drawn, using raw quantity from the lytA qPCR 
(unadjusted for extraction:elution ratio), after limiting the dataset to children < 5 years of 
age (n=6,691) so that it would more closely approximate the PERCH age distribution. Two 
potential cut-offs were selected based on optimising sensitivity and specificity and were 
applied to the PERCH all-site data. These can be seen in figure 11.6.
oO -
o
~  o  to'-P- 
c  o
C ut o ff  at quantity 
>=519 copies/mL: 
sensitivity 47%, 
specificity 97%
LOcm - o C ut o ff  at quantity  
>=1080 copies/mL: 
sensitiv ity 41%, 
specificity 98%
o  o - 
d
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.7655
Figure 11.6: Receiver operating characteristic (ROC) curve using controls to set 
specificity and cases of invasive pneumococcal disease (IPD) to set sensitivity, in the 
Kilifi sample set iimited to children <5 years of age. The ROC curve was used to select a 
quantitative cut-off to categorise positives into strong and weak positive results to apply 
to the PERCH multi-site sample set.
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11.3.1.5 Comparison of Qiagen and EasyMag DNA extraction methods for lytA qPCR on 
blood, in Kilifi
There were 1,194 samples that underwent both Qiagen extraction and lytA qPCR for 
inclusion in the larger Kilifi dataset and EasyMag extraction and lytA qPCR for inclusion in 
the PERCH dataset. Of these samples, 1,101 were negative by both methods, 29 were 
positive by both methods, 39 were positive from the EasyMag extract but negative from 
the Qiagen extract and 25 were positive from the Qiagen extract but negative from the 
EasyMag extract. A z-test yielded a p-value of 0.271, indicating that there was not a 
significant bias towards one method or the other. Replacing negative results as a quantity 
of 1 before logi0-transformation revealed the scatterplot found in figure 11.7.
x = y  l in eCO
CD -
Q.
o
O)
3 -
CTO)
cn
CM -
O - • •
2 40 6 8
logquant3 
Q ia g e n  e x t r a c ts  lytA lo g 10 c o p ie s / m L
Figure 11.7: Pneumococcal concentration by lytA qPCR in logio copies/mL from paired 
whole blood samples that underwent DNA extraction by the Qiagen manual method 
and by the EasyMag automated method, from children in the Kilifi sample set.
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11.3.2 PERCH all-site results
11.3.2.1 lytA qPCR positivity among cases and controls in PERCH
The PERCH multi-site sample set consisted of 8,981 samples of which 4,986 came from 
community controls and 3,995 from cases of severe or very severe pneumonia. The 
breakdown of lytA positivity by site and case-control status can be found in table 11.9. 
Overall, 7.0% of cases and 5.4% of controls were lytA positive, chi-squared p=0.002.
Table 11.9: lytA PCR positivity from whole blood samples among cases and controls by 
site in the Pneumonia Etiology Research for Child Health (PERCH) study
Site
Controls 
lytA 
N positive (%)
Cases 
lytA 
N positive (%) Total
Kenya 751 48 6% 566 31 5% 1,317
The Gambia 608 47 8% 602 61 10% 1,210
Mali 715 38 5% 669 77 12% 1,384
Zambia 602 26 4% 524 32 6% 1,126
South Africa 963 98 10% 917 70 8% 1,880,
Thailand 622 5 1% 224 2 1% 846
Bangladesh 725 6 1% 493 5 1% 1,218
Total 4,986 268 5% 3,995 278 7% 8,981
11.3.2.2 Characteristics of cases and controls in PERCH
Characteristics of cases and controls in the multi-site PERCH sample set can be found in 
table 11.10.
261
Table 11.10 Characteristics of cases and controls in the Pneumonia Etiology Research
for Child Health (PERCH) multi-site sample set
Characteristic Controls (%) Cases (%) p-vaiue
Site:
Kenya 751 15.1 566 14.2
The Gambia 608 12.2 602 15.1
Mali 715 14.3 669 16.8
Zambia 602 12.1 524 13.1
South Africa 963 19.3 917 23.0
Thailand 622 12.5 224 5.6
Bangladesh 725 14.5 493 12.3 <0.001
Female gender 2,491 50.0 1,704 42.7 <0.001
Age:
2-5 months 1,534 30.8 1,625 40.7
6-15 months 1,625 32.6 1,314 32.9
16-59 months 1,827 36.6 1,056 26.4 <0.001
Nasopharyngeal carriage of pneumcoccus:
by PCR 3,617 76.7 2,675 72.0 <0.001
by culture 3,419 69.5 2,086 53.0 <0.001
PCV-10-type by culture* 930 30.8 565 30.1 0.595
by culture or PCR 4,025 82.3 2,963 77.1 <0.001
Blood culture:
positive for pneumococcus 
positive for another pathogen 
negative V \
-
45 
119 
V 3,831
1.1
3.0
95.9
Any virus in nasopharynx by multiplex PCR 2,716 57.5 2,932 79.1 <0.001
Pneumococcal conjugate vaccine status 2,469 50.8 2,068 53.4 0.014
Antibiotics prior to blood sample collection 111 2.4 1,571 41.4 <0.001
HIV infection 211 5.1 253 6.9 <0.001
Specimen extracted within a week of collection 1,488 29.8 1,072 26.8 0.002
*10-valent pneumococcal conjugate vaccine-type
11.3.2.3 lytA qPCR quantitative data in PERCH
The logio-transformed distribution of positive lytA qPCR results by case-control status and 
for cases with blood-culture confirmed IPD, can be seen in figure 11.8.
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Control whole blood loglytA quantity
•S'CO - coc _0} •
Q  cvi _
o  -L-J | | I I------------------------1------------------------1---------------------- 1-
0  1 2  3  4  5  6  7
lo g _ ly ta _ s q ty
Case whole blood loglytA quantity
4
lo g _ ly ta _ s q ty
CO -  C C\J -
Whole blood loglytA quantity in Invasive Pneumococcal Disease*
4
lo g _ ly ta _ s q ty
’ IPD defined by blood culture
30/45=67% IPD cases positive for lytA PCR on whole blood
Figure 11.8: Distribution of logi0-transformed lytA concentration in logio copies/mL, in 
whole blood samples in controls, in cases and in invasive pneumococcal disease (IPD) in 
the Pneumonia Etiology Research for Child Health (PERCH) multi-site sample set, IPD 
was defined by growth of S. pneumoniae from a blood culture. IPD cases are a subset of 
all cases.
The logio-transformed concentration of lytA in whole blood for positive samples is 
displayed by participant characteristic in table 11.11. In order to further explore the 
potential contribution of nasopharyngeal carriage to blood lytA positivity we looked at 
the lytA concentration in blood by case-control and nasopharyngeal carriage status; these 
can be seen in figure 11.9. Among controls, the median lytA concentration in blood for 
those without demonstrated nasopharyngeal carriage of pneumococcus by culture or PCR 
was 2.07 logio copies/mL (IQR 1.93-2.32 logio copies/mL) and for those with carriage was
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2.31 logio copies/mL (IQR 2.07-2.67 logio copies/mL), Wilcoxon rank-sum p=0.010. Among 
cases, the median lytA concentration in blood for those without nasopharyngeal carriage 
of pneumococcus was 2.31 logio copies/mL (IQR 2.07-2.78 logio copies/mL) and for those 
with carriage was 2.56 logio copies/mL (IQR 2.18-3.23 logio copies/mL), p=0.144.
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Table 11.11: Distribution of pneumococcal concentration in positive whole blood 
samples by lytA qPCR in logio copies/mL by participant characteristic in the Pneumonia 
Etiology Research for Child Health (PERCH) multi-site sample set.
Number Median loglO
lytA lytA quantity
Characteristic positive copies/mL IQR p-value*
Gender: 0.848
Male 265 2.39 2.10 2.95
Female 281 2.42 2.08 2.81
Age in tertiles: 0.196
2-5 months 188 2.37 2.10 2.71
6-15 months 200 2.44 2.07 2.94
16-59 months 158 2.45 2.09 3.14
PCV-10 vaccination status§: 0.690
Not vaccinated 158 2.46 2.10 2.91
Vaccinated 365 2.38 2.09 2.86
Blood culture: <0.001
No pneumococcus 248 2.47 2.14 3.01
Pneumococcus 30 3.64 2.86 4.99
Nasopharyngeal carriage by culture or PCR: 0.002
Negative 54 2.15 1.96 2.71
Positive 477 2.43 2.11 2.91
PCV-10 serotypes on nasopharyngeal culture§: 0.522
A Ur Ant nuoci it 232 2.41 2.10 2.83
Present 114 2.44 2.12 3.07
Any respiratory virus by multiplex PCR: V V; . 0.247
Absent 176 2.37 2.05 2.81
Present 338 2.43 2.11 2.86
Antibiotics prior to collection of blood sample: 0.004
Absent 406 2.38 2.07 2.84
Present 114 2.51 2.18 3.17
HIV status: 0.015
Negative 420 2.36 2.10 2.85
Positive 54 2.62 2.20 3.58
Case-control status: <0.001
Well community control 198 2.23 2.02 2.59
Community control with URTI symptoms 70 2.37 2.06 2.81
Hospitalised with severe pneumonia 165 2.46 2.13 2.99
Hospitalised with very severe pneumonia 113 2.70 2.24 3.33
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Characteristic
Number
lytA
positive
Median loglO 
lytA quantity 
copies/mL IQR
Site:
Kenya 79 2.34 2.10 2.71
The Gambia 108 2.38 2.10 2.80
Mali 115 2.77 2.31 3.47
Zambia 58 2.33 2.12 2.61
South Africa 168 2.28 2.07 2.72
Thailand 7 1.95 1.65 2.93
Bangladesh 11 1.97 1.75 2.10
Sample collection period:
Jul-Dec 2011 60 2.38 2.14 2.60
Jan-Jun 2012 152 2.48 2.15 3.00
Jul-Dec 2012 115 2.40 2.04 2.96
Jan-Jun 2013 144 2.36 2.11 2.76
Jul-Dec 2013 66 2.32 2.07 3.04
Jan-Jun 2014 9 2.07 1.83 2.52
Days from specimen collection to DNA extraction:
Within 7 days 165 2.41 2.10 2.91
More than 7 days 381 2.39 2.10 2.85
*Wilcoxon rank-sum for binary categorical data, Kruskal-Wallis for >2 categories 
§10-valent pneumococcal conjugate vaccine
p-value*
<0.001
0.211
0.569
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Figure 11.9: Whole blood lytA concentration in logio copies/mL by case-control status 
and nasopharyngeal (NP) carriage status in the Pneumonia Etiology Research for Child 
Health (PERCH) sample set. Carriage was defined as culture of S. pneumoniae from a 
nasopharyngeal swab or lytA PCR positivity from a nasopharyngeal/oropharyngeal swab.
11.3.2.4 Correlation between lytA concentration in blood and nasopharyngeal 
compartments in PERCH
The positive correlation between lytA concentration in whole blood and lytA 
concentration in the nasopharynx, for children who were positive in both compartments, 
can be seen in figure 11.10.
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Figure 11.10: Correlation between pneumococcal concentration in the nasopharynx and 
in whole blood, for positive samples by lytA qPCR, in logio lytA copies/mL, in the
11.3.2.5 Exploring lytA qPCR assay performance in PERCH; categorising positive results
Of the thresholds suggested by the ROC curve from the Kilifi dataset, the threshold at 
>1000 copies/mL in quantity prior to adjustment for extraction:elution ratio, was selected 
to apply to the PERCH all-site dataset to categorise positive samples into strong and weak 
positives. This threshold had better specificity than the lower threshold and was closer to 
the lim it of detection and linearity of the assay. Univariable and multivariable logistic 
regression was carried out to look for associations with strong positive and weak positive 
lytA PCR on whole blood. The results of the logistic regression for strong positive 
outcomes can be found in table 11.12 and for weak positive outcomes in table 11.13.
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Pneumonia Etiology Research for Child Health (PERCH) muiti-site sample set.
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11.3.2.6 Test parameters by site, in PERCH
The sensitivity and specificity of strong positive outcome at >1000 copies/mL was 
calculated for each PERCH site and tabulated in table 11.14. The sensitivities and 
specificities for African sites can also be seen in figure 11.11, with 95% confidence 
intervals. The positive and negative predictive values for the sensitivity and specificity at 
each site can be seen in table 11.15. A range of possible prevalence for IPD is displayed, 
including the prevalence of positive lytA results among cases at a cut-off of >1000 
copies/mL for each African site. Calculation of test parameters for Asian sites was limited 
to specificity as there were no cases of IPD as defined by blood culture in Thailand or 
Bangladesh.
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Figure 11.11: Sensitivity and specificity of a cut-off of 1000 copies/mL in lytA qPCR, by 
site. Sensitivity and specificity of a cut-off of 1000 copies/mL, before adjustment for DNA 
extraction:elution ratio, for a positive lytA qPCR on whole blood, with 95% confidence 
intervals, for African sites in the Pneumonia Etiology Research for Child Health (PERCH) 
sample set.
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Table 11.15: Test parameters of lytA qPCR on blood for African sites at a cut-off of 
>1000 copies/mL Positive and negative predictive values (PPV, NPV) for lytA qPCR on 
blood in the Pneumonia Etiology Research for Child Health (PERCH) sample set using a 
cut-off of >1000 copies/mL before adjustment for the DNA extraction:elution ratio, for a 
range of prevalence in invasive pneumococcal disease (IPD). Actual prevalence of lytA PCR 
positivity at this cut-off among cases for each site is shown in red. Sensitivity is set against 
IPD by blood culture and specificity is among controls.
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Test parameters: cut-off >1000 copies/mL
Kenya
Prevalence (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
0.1% 75% 98.4% 4.48% 99.97%
0.5% 75% 98.4% 19.06% 99.87%
1.0% 75% 98.4% 32.13% 99.74%
1.4% 75% 98.4% 39.96% 99.64%
5.0% 75% 98.4% 71.16% 98.68%
10.0% 75% 98.4% 83.89% 97.25%
The Gambia
Prevalence (%) Sensitivity (%) Specificity (%) PPV {%) NPV (%)
0.1% 40% 98.0% 1.96% 99.94%
0.5% 40% 98.0% 9.13% 99.69%
1.0% 40% 98.0% 16.81% 99.39%
3.7% 40% 98.0% 43.45% 97.70%
5.0% 40% 98.0% 51.28% 96.88%
10.0% 40% 98.0% 68.97% 93.63%
Mali
Prevalence (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
0.1% 74% 97.6% 2.99% 99.97%
0.5% 74% 97.6% 13.42% 99.87%
1.0% 74% 97.6% 23.75% 99.73%
5.0% 74% 97.6% 61.87% 98.62%
7.5% 74% 97.6% 71.43% 97.89%
10.0% 74% 97.6% 77.41% 97.13%
Zambia
Prevaience (%) Sensitivity (%) Specificity (%) PPV (%) NPV [%)
0.1% \; 57% 99.8%; 22.20% 99.96%
0.5% 57% 99.8% 58.88% 99.78%
1.0% 57% 99.8% 74.22% 99.57%
1.7% 57% 99.8% 83.13% 99.26%
5.0% 57% 99.8% 93.75% 97.78%
10.0% 57% 99.8% 96.94% 95.43%
South Africa
Prevalence (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
0.1% 0% 98.0% 0.00% 99.90%
0.5% 0% 98.0% 0.00% 99.49%
1.0% 0% 98.0% 0.00% 98.98%
2.7% 0% 98.0% 0.00% 97.25%
5.0% 0% 98.0% 0.00% 94.90%
10.0% 0% 98.0% 0.00% 89.82%
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11.3.2.7 Effect on PERCH study outcomes
Taking a cut-off of >1000 copies/mL in lytA qPCR on blood, would give an additional 87 
diagnoses of IPD on top of 28 diagnoses by blood culture and lytA PCR and 17 diagnoses 
by blood culture alone for the PERCH study, ie. the PERCH study would go from 45 cases 
of IPD to 132 cases, in this dataset.
11.4 Discussion
The lytA qPCR assay was positive among 1-10% of controls in seven different countries in 
Africa and Asia, from which we can conclude that the assay is not 100% specific for the 
diagnosis of IPD as has been previously reported.15,148 Why is this? Both the Italian group 
and the South African group used the same lytA primers and probe as those used in the 
Kilifi and PERCH datasets, published by the CDC and in widespread use globally.125 Even 
the extraction method used for the Kilifi dataset, the manual Qiagen method, was also 
used by both Rouphael et al and Azzari et al. The sample type used in Italy was whole 
blood but in South Africa it was serum. Given the similarity in the laboratory methods 
between Azzari et al and the data presented here, it is likely that differences lie in the 
populations tested.
The Italian group tested 147 healthy children aged 6 months to 16 years, with a median 
age of 4.9 years, who were attending hospital for allergies or celiac disease. The one­
sided 97.5% confidence interval around a point estimate of 100% among 147 samples is 
97.52%-100%. The South African group tested 100 HIV-negative children with a mean age 
of 5.8 years who were being followed up in a study of PCV-9. The one-sided 97.5% 
confidence interval around a point estimate of 100% among 100 samples is 96.37%-100%. 
In both the Kilifi dataset and in the multi-site PERCH study, the median age of controls
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was 1.1 years, with an IQR of 6 months to 2.1 years, so the population we studied was 
younger than the previously published data.
Half of the children studied in Italy and in South Africa previously were found to be 
carrying pneumococcus in the nasopharynx, by PCR in Italy and by culture in South Africa. 
In the PERCH study 82% of controls were found to be carrying pneumococcus by culture 
or PCR (70% by culture alone; 77% by PCR alone), in the Kilifi dataset 89% of controls 
were carrying pneumococcus by culture or PCR (78% by culture alone; 81% by PCR alone). 
So our data come from a younger population with a higher prevalence of nasopharyngeal 
carriage of pneumococcus.
Among PERCH controls who were PCR-positive for pneumococcus in the nasopharynx, the 
median nasopharyngeal concentration was 5.77 logio copies/mL (IQR 4.96-6.43 logio 
copies/mL) whereas in the Italian study the distribution was reported as a mean value of 
2.4 log copies/mL with an IQR of 2.2-B.7 iog copies/mL. Even allowing for differences in 
the standards used for qPCR, it is likely that the nasopharyngeal concentration of 
pneumococcus was higher in our population.
There are likely to be other differences between the Italian population and the PERCH 
study populations. The PERCH project was carried out in resource-poor countries among 
populations with low socio-economic opportunity. It is probable that the Italian children 
who were attending hospital for allergies or celiac disease came from a higher socio­
economic background.
The difference between the PERCH results and the previous South African study cannot 
only be a difference in populations, as South Africa was one of the sites in the PERCH 
project and had positive lytA qPCR results among 10% of controls in PERCH. Both
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populations came from Soweto, in Johannesburg, but the previously studied population 
were older and were selected on the basis of their caregivers responding to an invitation 
to come for a booster pneumococcal conjugate vaccine. The previously published South 
African study used serum for the lytA PCR, rather than whole blood, and this might also 
contribute to the difference in results. Serum does not contain white blood cells, which 
could be where pneumococcal DNA is concentrated.
The lytA qPCR method was published by the CDC in 2007125 and is in widespread use 
globally, so it is possible that other investigators have also used the assay in control 
groups and not published the results because they found positive results in controls. An 
assumption may have been made that there was lab error, which could have lead to 
publication bias. The Kilifi sample set and the PERCH project between them used seven 
different laboratories and found positives among every control population.
We set out to examine why the lytA qPCR assay is not specific. Only a strong positive 
outcome was associated With case status. Strong jaositives were also associated with HIV 
positivity in the presence of nasopharyngeal carriage of pneumococcus, which is 
biologically plausible because it is known that HIV is a strong risk factor for IPD.43,74 If we 
assume for a moment that strong positives are true positives, then what are the weak 
positives? Some of these could be true weak positives in cases of IPD, perhaps partly 
treated IPD. Some could be false positives in terms of the diagnosis of IPD, but what are 
they detecting? Does pneumococcal "DNAemia" occur among healthy children as has 
been suggested in the past?106 It has been thought that the false positives in the Dagan 
study may have been due to the non-specificity of the ply target gene for pneumococcus. 
However, non-pneumococcal streptococci would not be expected to be accessing the 
bloodstream sufficiently to cause positive PCR assays on blood samples either, and if they
do so then we should expect pneumococci to do the same. Analytical specificity aside, it is 
likely that Dagan et ol’s study was detecting pneumococcal DNA in the bloodstream of at 
least some of the healthy controls in whom ply PCR was positive.
Of course we must consider whether the technology of the methods could have 
introduced contamination resulting in false positives. This has been suggested 15 as a 
potential problem particularly of nested PCR,105,211 where amplicons are accessed during 
the assay unlike the real-time PCR assay used for PERCH, but remains a possibility with 
any amplification method. To investigate this we looked at sample positivity by sample 
collection date, DNA extraction date, PCR date and laboratory technologist in the Kilifi 
sample set, and included DNA extraction period in the univariable and multivariable 
analyses for both the Kilifi and PERCH datasets. In Kilifi there was an association with date 
and sample positivity, and given the expected collinearity between date data, extraction 
period was selected for inclusion in the logistic regression models because positivity 
varied most significantly by extraction period. There was variability in positivity between
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laboratory technologists but this was explained by differences over time.
It is possible that the association with extraction period represents the laboratory 
improving in molecular methods with time. Certainly in Kilifi we made improvements in 
laboratory quality assurance over the time period of the project, with implementation of 
a Standard Operating Procedure aimed at reducing the potential for intra-laboratory 
contamination (for example; unilateral workflow in the molecular laboratory, cleaning of 
laboratory workspace and equipment with commercially-available DNA-degrading 
solutions, frequent changing of gloves during molecular procedures, spinning down the 
contents of sample vials prior to opening them). However, weak positive samples and 
positive control samples were a feature of all seven laboratories testing samples in the
PERCH project and it seems very unlikely that false positives due to intra-laboratory 
contamination could explain all of these data.
Could there be another explanation for changes in positivity over the time course of the 
project? PCV-10 was introduced to the Kenyan National Immunisation schedule in 
January of 2011, shortly after data collection began for the larger Kilifi dataset (November 
2010) and shortly before the Kilifi arm of the PERCH project began (August 2011). 
Increasing use of PCV-10 in the community led to decreasing likelihood of IPD, which 
could account for decreasing numbers of positive samples with time, but it is hard to see 
how the vaccine might have decreased weak positive lytA qPCR results over time but not 
strong positives.
Nasopharyngeal carriage of pneumococcus is known to be a pre-requisite for IPD 66,67 and 
it has been the bane of IPD diagnostics for decades, especially among children where 
diagnosis is particuiariy difficult, it has therefore been assumed that nasopharyngeal 
carriage may cause false positive PCR assays when testing blood in the diagnosis of IPD 
and previous investigators15,148 were careful to include children with demonstrated 
nasopharyngeal carriage of pneumococcus when examining the specificity of lytA PCR for 
IPD. Our multivariable logistic regression model found significant interactions between 
carriage and HIV, and carriage and age, in strongly positive lytA qPCR. These are 
biologically plausible associations that are reassuring. When weak positive lytA qPCR was 
the outcome, we found significant associations between carriage and outcome for cases 
only, not among controls. This implies that carriage is associated with true positives but 
fails to make a case for either nasopharyngeal carriage or lab error causing false positives 
in the diagnosis of IPD. Biologically, nasopharyngeal pneumococcal carriage must be the 
source for pneumococcal "DNAemia" if this occurs.
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If we suppose that positive lytA PCR results among healthy controls are due to true 
pneumococcal "DNAemia", then we have another question to consider; what is invasion 
and what is invasive disease? Do pneumococci invade through the mucosa of the 
nasopharynx regularly enough to explain our findings among controls? Are we detecting 
organisms within white blood cells, already taken care of by the immune system? In that 
case, we further suppose that IPD occurs only when immune escape occurs after the 
relatively common invasion event is (rarely) unable to be contained and pneumococci are 
able to divide and grow in the bloodstream, allowing blood cultures to become positive.
A noteworthy finding from these data is the difference in lytA positivity by region. There 
is a clear difference in positivity between the African and the Asian sites within the PERCH 
project. There were no cases of IPD as defined by blood culture positivity in either of the 
two sites in Thailand or the two sites in Bangladesh that contributed to the PERCH 
project, and there were very few lytA positive samples from these sites, with just 1% of 
cases and 1% of controls testing positive from both Thailand and Bangladesh. We infer
v  , v  v
from this that there must be genetic differences in susceptibility to IPD between African 
and Asian populations. Nevertheless, nasopharyngeal carriage was common in Thailand 
(66% of controls and 57% of cases) and Bangladesh (87% of controls and 74% of cases), so 
the difference must be in either the likelihood of an invasion event or the handling of an 
invasion event, or both. lytA positivity was significantly lower among the Asian sites than 
African sites but the same among Asian controls as Asian cases, so if "DNAemia" is a real 
phenomenon then it must be occurring in Asia too, but at a lower frequency.
A clear limitation of this assay is the lower limit of reliable detection is approximately 
1000 copies/mL, or 100 copies/reaction, in raw concentration, equating to 500 copies/mL 
of whole blood after allowing for the extractionrelution ratio. Because the median lytA
concentration in blood was below this, at 178 copies/mL among controls and 338 
copies/mL among cases, we expect that there would have been more positives if the 
assay were more sensitive. It also means that the concentrations below 500 copies/mL 
are subject to lack of precision due to being below the lower limit of linearity of the 
quantitative PCR. The fact that we see biologically plausible associations using thresholds 
to categorise the data into strong and weak positives at 1000 copies/mL in raw 
concentration suggests that there is still useful information contained in the data despite 
these limitations. Given the low median concentrations of lytA in blood, it would not have 
been feasible to set the threshold higher.
The lytA qPCR assay in blood is not 100% specific in the diagnosis of IPD in all populations 
and should not be used as a diagnostic assay for clinical care without careful examination 
of test parameters population by population. For the PERCH project, setting a threshold 
of 1000 copies/mL and taking all positives above this threshold to be indicative of IPD 
would increase the number of cases of IPD from 45 by blood culture to 132 by blood
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culture or lytA qPCR. This could be a very helpful augmentation of endpoints for the 
PERCH project overall in assigning causality of pneumonia. It is possible that the lytA qPCR 
assay detects pneumococcal "DNAemia", or pneumococci that are no longer viable after 
being lysed or phagocytosed by the immune system. More work is needed to examine 
what happens when pneumococci breach the nasopharyngeal mucosa, how often this 
occurs, and the genetic differences in handling such invasion events between different 
human populations. Although it is important to understand the pathophysiology, the fact 
remains that pneumococcal PCR on blood specimens is non-specific in the diagnosis of 
IPD in children.
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Chapter Twelve
12 Discussion of contributions to the field
Nasopharyngeal carriage of pneumococcus appears to be a nearly ubiquitous part of 
being human.23 Carriage is a required antecedent to pneumococcal pneumonia and 
invasive pneumococcal disease (IPD), both of which are fortunately much less common 
occurrences.67,202 Young children are the main reservoir from which transmission occurs 
to others. Young children are also the group most at risk for IPD and pneumococcal 
pneumonia and yet they are the group among whom these diseases are the most difficult 
to diagnose.
Nasopharyngeal pneumococcal concentration does not hold promise as a diagnostic assay 
for pneumonia in children as it apparently does in adults,126 at least not in our population. 
Not only was there considerable overlap in nasopharyngeal pneumococcal concentration 
between well community controls, community controls with upper respiratory tract 
(URTI) symptoms and children admitted to hospital with severe or very severe 
pneumonia, but the community controls with URTI symptoms had statistically 
significantly greater pneumococcal concentration in the nasopharynx than did children 
with pneumonia. This was not just an antibiotic effect as it remained when the analysis 
was restricted to those in whom there was no evidence for prior antibiotic use, although 
there was probably still some confounding by antibiotic use remaining. These results 
differ from those previously published in Vietnam99 where all swabs were collected prior 
to antibiotic administration.
It is worth noting that the previously published work was carried out in South-East Asia,
where pneumococcus seems to be handled differently, presumably due to host genetic
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differences. In the multi-site PERCH study, children at Asian sites were less likely to carry 
pneumococcus than children at African sites, although carriage was still common. More 
remarkable though, was the fact that IPD, as diagnosed by blood cultures, was so rare 
that no cases were detected among children with severe or very severe pneumonia at the 
Asian sites, and lytA PCR on whole blood was dramatically less likely to be positive than in 
Africa.
Respiratory viruses are also a ubiquitous part of the human experience. As discussed in 
section 2.1.3 of the introduction, ecological studies,71'73 basic science experiments on 
human respiratory epithelial cell lines 77,83 and animal models 82,89'95 all tell us that 
bacteria in the nasopharynx are affected by the presence of respiratory viruses. Clinically, 
we note that severe bacterial pneumonia may follow respiratory virus infection.75 We can 
hypothesise that respiratory virus infection in humans increases the nasopharyngeal 
pneumococcal concentration and that the concentration of pneumococcus in the 
nasopharynx is associated with the likelihood of progression to pneumonia or IPD, as well
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as the likelihood of transmission of carriage.
Our study is the first longitudinal study of nasopharyngeal pneumococcal concentration 
by qPCR in children with episodes of respiratory virus infection. The concentration of 
pneumococcus in the nasopharynx of children <5 years of age increased 4-fold with the 
onset of a symptomatic respiratory virus infection with RSV or rhinovirus. The rise in 
pneumococcal concentration associated with respiratory viral infection was surprisingly 
modest but may be important for the risk of developing IPD or for transmission of 
pneumococcal carriage at a population level. The rise in pneumococcal concentration 
associated with respiratory viral infection may also be dependent on the pneumococcal 
serotype or strain; some pneumococci may be more likely to respond to respiratory viral
infection with an increase in concentration and in expression of pathogenicity than 
others. In our study there was a less marked decrease in pneumococcal concentration 
after the episode of viral infection that did not reach statistical significance. This may be 
an issue of timing; we took the mean pneumococcal concentration during the episode of 
viral infection relative to the mean pneumococcal concentration after the episode of viral 
infection. If the pneumococcal concentration remains elevated subsequent to viral 
clearance then it will be necessary to measure the time it takes for pneumococcal 
concentration to return to baseline in the future.
We don't know what the relationship between nasopharyngeal carriage density and 
IPD/pneumonia or between carriage density and transmission really is. If we assume that 
there is a sigmoid relationship, then we can postulate a threshold effect (as in figure 
12.1). For a 4-fold increase in pneumococcal concentration in response to respiratory viral 
infection, such as we found in our longitudinal study, to have an important population- 
level effect, this increase would need to meet a threshold for invasion or transmission.
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However, if the steep part of the sigmoid curve occurs in the centre of the population 
distribution of carriage density, then the relationship may be effectively linear -  or the 
relationship might not be sigmoid at all. If the threshold for transmission or for invasion 
occurs near the mean of the population normal curve for carriage density, then it would 
be possible to examine this. An animal model could be used to examine the relationship 
between carriage density and IPD, but the danger is that it might not hold true for 
humans. The relationship with transmission could be examined in a human longitudinal 
study but would need large enough numbers, especially if pneumococcal serotype was to 
be taken into consideration.
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Figure 12.1 Sketch of possible relationships between nasopharyngeal pneumococcal 
concentration and transmission or invasion
Quantitative PCR may help us to understand the relationship between carriage density 
and transmission or invasion. However, if the threshold for transmission or invasion lies 
close to the lower lim it of detection of the qPCR assay then quantitative results are 
difficult to use because the assay effectively becomes binary; detection or no detection. 
Complicating this is the fact that qPCR and culture appear to be complementary in 
detecting and quantifying nasopharyngeal carriage; qPCR is more sensitive, but we have 
found in this thesis, as have others,175 some samples may be culture positive and PCR 
negative as well as vice versa. Presumably this is due to the ability of PCR to detect non- 
viable organisms, and to sample handling and PCR inhibition. An additional complication 
is that qPCR assays are not well standardised across laboratories, so a threshold studied 
in one laboratory does not necessarily correspond to a threshold studied in another 
laboratory unless efforts are made to calibrate standards across laboratories, as for the 
PERCH project.
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The pattern of colonisation of the nasopharynx by pneumococcus after vaccination with 
PCV-10 is complex. The graphs of nasopharyngeal pneumococcal concentration by 
serotype among individual children over six months post PCV-10 demonstrate the striking 
changes in pneumococcal concentration that occur within individuals and the dominance 
of the prevailing serotype. Such changes in concentration could impact the risk of 
transmission or invasion.
The strength of the pneumococcal microarray is that it allows us to see these complex 
patterns of multiple serotype carriage, but there are two important weaknesses in the 
method. One is the artefact or step in the data that occurs with culture negative samples. 
Examination of culture-positive samples alone will introduce bias if culture-negative, lytA- 
positive samples are different in the quantity and pattern of pneumococcal serotypes 
present. The second is that the preliminary culture step introduces a bias for strains that 
multiply more effectively than other strains during the culture process. Quantitation of 
serotypes using a combination of lytA qPCR and pneumococcal microarray yields
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quantitative data that are complicated by the presence of many zero quantities, meaning 
data analysis is not straightforward.
Our microarray project found that VT pneumococcus did not substantially change post 
PCV-10, while NVT pneumococcus and total pneumococcal concentration increased, a 
somewhat weaker finding than we had expected to see. Perhaps a more important 
contribution to the field is the advance in understanding the complexity of the data 
generated by the approach. The pneumococcal microarray has been advocated by the 
PneuCarriage project1/1 as the method of choice for quantitative data that detects 
multiple serotype carriage and the next generation of vaccine studies with carriage 
outcomes are lining up to use it. Use of the pneumococcal microarray for cross-sectional
surveys rather than for longitudinal studies would be more straightforward but 
longitudinal studies are epidemiologically stronger for studying vaccine impact. We need 
to continue to innovate to find ways to study the nasopharyngeal environment more 
accurately.
The use of alu qPCR to adjust nasopharyngeal swab specimens for the amount of human 
specimen present in a vial of transport medium was a novel approach. Using this assay 
enabled us to detect two specimens that did not contain any human sample and exclude 
them from the analysis in the longitudinal study of pneumococcal concentration before, 
during and after respiratory virus infection. In this study, the analysis without alu 
adjustment yielded results with a similar order of magnitude to the adjusted analysis, but 
a slightly stronger effect; a 7-fold rather than a 4-fold rise in pneumococcal 
concentration. In the study of nasopharyngeal pneumococcal concentration among 
healthy community controls, community controls with URTI symptoms and cases of 
severe or very severe WHO-defined pneumonia, the analysis without adjustment for alu
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concentration again did not remarkably change the results or the conclusions drawn.
For examination of pneumococcal concentration before and after administration of the 
pneumococcal conjugate vaccine, use of alu qPCR to adjust the pneumococcal 
concentration for the concentration of human specimen present made only small 
changes to the results of the analysis of VT, NVT and total pneumococcal concentration 
over the six-month period post vaccination. VT pneumococcal concentration did not 
change over time whether or not alu adjustment was made; NVT pneumococcal 
concentration increased significantly whether or not alu adjustment was made. Total 
pneumococcal concentration did not change over time when unadjusted for alu 
concentration but did appear to increase over time post vaccination when alu adjustment
was made. In the study of changes in nasopharyngeal pneumococcal concentration in 
response to vaccine, rayon nasopharyngeal swabs had been used and in the other two 
studies nasopharyngeal flocked swabs were used, with which it may be easier to collect a 
standard sample volume.
Considering these three studies together, we can most probably conclude that if 
adequate training and monitoring of swab collectors is performed, a standard volume of 
transport medium used and ideally if nasopharyngeal flocked swabs are used, then 
adjustment for the concentration of human DNA in the swab transport medium is not 
necessary. An alternate conclusion is that alu qPCR was not an adequate method for 
adjusting the pneumococcal concentration for the quantity of human specimen present in 
swab transport medium. Considering that our validation study showed that human DNA 
concentration, as measured by alu qPCR, increased with improved swab collection and 
handling in volunteers; that human DNA concentration correlated with protein 
concentration; and that in the studies discussed above the direction of the effect was the
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same with and without adjustment for human DNA, we think that the method was 
reasonable.
It is noteworthy that using a threshold for positivity of 40 cycles, the lytA qPCR was 
positive on most nasopharyngeal swab samples in STGG studied, surpassing the 
proportion positive by culture or by PCR from swabs in viral transport medium. In chapter 
eight of this work, we have described data from the lytA qPCR performed on a subset of 
nasopharyngeal swabs in STGG collected in the PERCH project in Kilifi. The prevalence of 
carriage among these swabs in STGG was 98.6% but among nasopharyngeal swabs 
collected into Copan UTM and assayed using a 33-plex PCR from Fast-Track Diagnostics 
(which includes a lytA target) was 80.8% among the same individual study participants.
Even among swabs collected in viral transport medium, in the study of pneumococcal 
concentration before, during and after acquisition of respiratory viral infections, swab 
positivity was 93.4%. Detection of nasopharyngeal carriage by PCR rather than by the 
previous WHO standard culture is becoming more common and may lead to a paradigm 
shift in how we view nasopharyngeal carriage. Perhaps in some populations like ours, 
pneumococcal carriage is normally so common that with sensitive detection methods 
prevalence approaches 100%. Deciding at what amplification cycle threshold or 
quantitative value to set the cut-off for a positive PCR assay impacts upon the estimation 
of carriage prevalence by PCR.
If the CDC-lytA PCR primer and probe set that we used was not 100% specific for 
pneumococcus, this could explain high carriage prevalence detected by PCR compared to 
culture. As detailed in chapter two, various groups have found 100% analytical specificity 
for pneumococcus with a lytA PCR among 82 5. pseudopneumoniae or other closely
related non-pneumococcal streptococci.125,136,138,139 Testing the assay on a well-
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characterised collection of S. pseudopneumoniae, S. mitis and S. oralis known to contain 
the autolysin gene from around the world would be more reassuring but such a collection 
does not, to our knowledge, exist. Assuming pneumococcal carriage in our population of 
young children is nearly universal by PCR, we should consider whether associations with 
carriage hold true, or whether associations with carriage are only true for carriage at high 
enough levels to be culture-positive. Carriage appears to be more of a continuum than a 
binary phenomenon in our population.
An important contribution to the study of pneumococcal disease is the finding that lytA 
qPCR on whole blood samples is not specific for the diagnosis of invasive pneumococcal 
disease among children under 5 years of age. A cut-off can be set to improve specificity so
that the assay might be helpful in the PERCH study model, but in order to exclude positive 
results among all controls all useful sensitivity is lost. Disappointingly, the assay is 
therefore not of clinical utility in the diagnosis of IPD among children in low and lower- 
middle income countries, the group in whom we most need improved diagnostics.
In 1998, Dagan et al reported 17% of 202 healthy controls were positive for ply PCR from 
serum samples; children were significantly more likely to be positive than adults, and 
children in whom nasopharyngeal carriage was detected by culture were significantly 
more likely to be positive than those who were not carriers. The authors postulated that 
pneumococcal DNA was present from direct bloodstream invasion or by phagocytosis of 
organisms by lymphoid cells that then entered the bloodstream. They pointed out that 
the development of systemic immune responses to pneumococcal types after 
nasopharyngeal carriage lends weight to this hypothesis.105 Subsequently, ply has been 
found in non-pneumococcal streptococci, and the non-specificity of the assay for IPD has 
been largely overlooked because of the non-specificity for pneumococcus itself.
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However, in light of our findings of the non-specificity of the lytA assay for IPD across 
seven different populations and in seven different laboratories, it appears that healthy 
children in developing countries frequently have pneumococcal DNA circulating in their 
bloodstream, at levels not dissimilar to those seen in children with disease. Further work 
is needed to determine how this occurs, how often this occurs, and the relationship 
between pneumococcal invasion resulting in harmless "DNAemia" and that resulting in 
IPD with serious morbidity and mortality. Although these questions are of considerable 
biological interest, answering them is unlikely to change the fact that among children,
PCR on blood specimens is non-specific in the diagnosis of IPD.
293
Chapter Thirteen
13 References
1. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child 
mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 
2012;379:2151-61.
2. Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulholland EK. Pneumonia research to 
reduce childhood mortality in the developing world. J Clin Invest 2008;118:1291-300.
3. Scott JAG, Hammitt LL, Bwanaali T, et al. Impact of introducing 10-valent 
pneumococcal conjugate vaccine in Kenya on invasive pneumococcal disease among 
children aged <5 years. 8th International Symposium on Pneumococci and Pneumococcal 
Diseases; 2012 March 11-15, 2012; Iguafu Falls, Brazil.
4. Levine OS, O'Brien KL, Deloria-Knoll M, et al. The Pneumonia Etiology Research for 
Child Health Project: a 21st century childhood pneumonia etiology study. Clin Infect Dis 
2012;54 Suppl 2:S93-101.
5. Hammitt LL, Kazungu S, Morpeth SC, et al. A preliminary study of pneumonia v 
etiology among hospitalized children in Kenya. Clin Infect Dis 2012;54 Suppl 2:S190-9.
6. Webb C, Ngama M, Ngatia A, et al. Treatment failure among Kenyan children with 
severe pneumonia-a cohort study. Pediatr Infect Dis J 2012;31:el52-7.
7. Berkley JA, Munywoki P, Ngama M, et al. Viral etiology of severe pneumonia 
among Kenyan infants and children. JAMA 2010;303:2051-7.
8. Munywoki P. Transmission of Respiratory Syncitial Virus in households: who 
acquires infection from whom? : Open University; 2013.
9. Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus 
infection in infants: a household cohort study in rural Kenya. J Infect Dis 2014;209:1685- 
92.
10. Hammitt LL, Ojal J, Bashraheil M, et al. Immunogenicity, impact on carriage and
reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein
294
D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
PLoS One 2014;9:e85459.
11. Challenges in global immunization and the Global Immunization Vision and 
Strategy 2006-2015. Wkly Epidemiol Rec 2006;81:189.
12. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal 
conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-46.
13. Scott JA, Mlacha Z, Nyiro J, et al. Diagnosis of invasive pneumococcal disease 
among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G 
antibodies to pneumococcal surface adhesin A. Clin Diagn Lab Immunol 2005;12:1195- 
201.
14. Vernet G, Saha S, Satzke C, et al. Laboratory-based diagnosis of pneumococcal 
pneumonia: state of the art and unmet needs. Clin Microbiol Infect 2011;17 Suppl 3:1-13.
15. Azzari C, Cortimiglia M, Moriondo M, et al. Pneumococcal DNA is not detectable in 
the blood of healthy carrier children. J Med Microbiol 2011.
16. Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular 
biosynthetic locus from all 9b pneumococcal serotypes. PLoS genetics 2006;2:e31.
17. Calix JJ, Nahm MH. A new pneumococcal serotype, HE, has a variably inactivated 
wcjE gene. J Infect Dis 2010;202:29-38.
18. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive 
pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
19. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after 
pneumococcal vaccination. Lancet 2011.
20. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and 
serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in 
England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8.
21. Johnson DR, D'Onise K, Holland RA, Raupach JC, Koehler AP. Pneumococcal 
disease in South Australia: vaccine success but no time for complacency. Vaccine 
2012;30:2206-11.
295
22. Mate C, Omolo L, Karani A, et al. NetSPEAR: Six years of surveillance for 
pneumococcal disease in the East African Region. 7th International Symposium for 
Pneumococcus and Pneumococcal Diseases; 2010; Tel Aviv, Israel.
23. Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob 
Chemother 1986;18 Suppl A:35-45.
24. Austrian R, Gold J. Pneumococcal Bacteremia with Especial Reference to 
Bacteremic Pneumococcal Pneumonia. Ann Intern Med 1964;60:759-76.
25. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal 
relationships between invasive and carriage Streptococcus pneumoniae and serotype- and 
clone-specific differences in invasive disease potential. J Infect Dis 2003;187:1424-32.
26. Brueggemann AB, Muroki BM, Kulohoma BW, et al. Population genetic structure 
of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal 
conjugate vaccine. PLoS One 2013;8:e81539.
27. Almeida ST, de Lencastre H, Sa-Leao R. Epidemiology and population structure of 
serotypes 1, 5 and 7f carried by children in Portugal from 1996-2010 before introduction 
of the 10-valent and 13-valent pneumococcal conjugate vaccines. PLoS One 
2013;8:e75442.
V V ■ ■ \;
28. Tettelin H, Nelson KE, Paulsen IT, et al. Complete genome sequence of a virulent 
isolate of Streptococcus pneumoniae. Science 2001;293:498-506.
29. Obert C, Sublett J, Kaushal D, et al. Identification of a Candidate Streptococcus 
pneumoniae core genome and regions of diversity correlated with invasive pneumococcal 
disease. Infect Immun 2006;74:4766-77.
30. Embry A, Hinojosa E, Orihuela G. Regions of Diversity 8, 9 and 13 contribute to 
Streptococcus pneumoniae virulence. BMC Microbiol 2007;7:80.
31. Wei H, Havarstein LS. Fratricide is essential for efficient gene transfer between 
pneumococci in biofilms. Applied and environmental microbiology 2012;78:5897-905.
32. Shak JR, Vidal JE, Klugman KP. Influence of bacterial interactions on pneumococcal 
colonization of the nasopharynx. Trends in microbiology 2013;21:129-35.
296
33. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of 
capsular polysaccharide and teichoic acid with the virulence of Streptococcus 
pneumoniae. J Infect Dis 1998;177:368-77.
34. Sanchez G, Hinojosa CA, Shivshankar P, et al. Changes in capsular serotype alter 
the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 
2011;6:e26587.
35. van Rossum AM, Lysenko ES, Weiser JN. Host and bacterial factors contributing to 
the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect 
Immun 2005;73:7718-26.
36. Kimaro Mlacha SZ, Romero-Steiner S, Hotopp JC, et al. Phenotypic, genomic, and 
transcriptional characterization of Streptococcus pneumoniae interacting with human 
pharyngeal cells. BMC Genomics 2013;14:383.
37. Price KE, Greene NG, Camilli A. Export requirements of pneumolysin in 
Streptococcus pneumoniae. J Bacteriol 2012;194:3651-60.
38. Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. Are anticapsular 
antibodies the primary mechanism of protection against invasive pneumococcal disease? 
PLoS Med 2005;2:el5.
V V V V ■
39. Vernatter J, Pirofski LA. Current concepts in host-microbe interaction leading to 
pneumococcal pneumonia. Current opinion in infectious diseases 2013;26:277-83.
40. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients 
with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010;89:403-25.
41. Bogaert D, Thompson CM, Trzcinski K, Malley R, Lipsitch M. The role of 
complement in innate and adaptive immunity to pneumococcal colonization and sepsis in 
a murine model. Vaccine 2010;28:681-5.
42. Picard C, Puel A, Bustamante J, Ku CL, Casanova JL. Primary immunodeficiencies 
associated with pneumococcal disease. Current opinion in allergy and clinical immunology 
2003;3:451-9.
297
43. von Gottberg A, Cohen C, de Gouveia L, et al. Epidemiology of invasive 
pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine 
2013;31:4200-8.
44. Neill DR, Coward WR, Gritzfeld JF, et al. Density and duration of pneumococcal 
carriage is maintained by transforming growth factor betal and T regulatory cells. 
American journal of respiratory and critical care medicine 2014;189:1250-9.
45. Verschoor CP, Dorrington MG, Novakowski KE, et al. MicroRNA-155 is required for 
the clearance of Streptococcus pneumoniae from the nasopharynx. Infect Immun 2014.
46. Wright AK, Bangert M, Gritzfeld JF, et al. Experimental human pneumococcal 
carriage augments IL-17A-dependentT-cell defence of the lung. PLoS Pathog 
2013;9:el003274.
47. Das R, LaRose Ml, Hergott CB, Leng L, Bucala R, Weiser JN. Macrophage migration 
inhibitory factor promotes clearance of pneumococcal colonization. Journal of 
immunology 2014;193:764-72.
48. Joyce EA, Popper SJ, Falkow S. Streptococcus pneumoniae nasopharyngeal 
colonization induces type I interferons and interferon-induced gene expression. BMC 
Genomics 2009;10:404.v /  v, v
49. Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R. Impaired innate and 
adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an 
infant mouse model. Infect Immun 2009;77:1613-22.
50. Krone CL, Trzcinski K, Zborowski T, Sanders EA, Bogaert D. Impaired innate 
mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae 
colonization. Infect Immun 2013;81:4615-25.
51. Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and 
rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in 
healthy adults. American journal of respiratory and critical care medicine 2013;187:855-
64.
52. Cohen JM, Khandavilli S, Camberlein E, Flyams C, Baxendale HE, Brown JS. 
Protective contributions against invasive Streptococcus pneumoniae pneumonia of
298
antibody and Thl7-cell responses to nasopharyngeal colonisation. PLoS One 
2011;6:e25558.
53. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4+ 
T cells mediate antibody-independent acquired immunity to pneumococcal colonization. 
Proc Natl Acad Sci USA 2005;102:4848-53.
54. Lu L, Ma Z, Jokiranta TS, Whitney AR, DeLeo FR, Zhang JR. Species-specific 
interaction of Streptococcus pneumoniae with human complement factor H. Journal of 
immunology 2008;181:7138-46.
55. Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly 
invasive does not mean highly lethal. The European respiratory journal 2010;36:712-3.
56. Stroeher UH, Kidd SP, Stafford SL, Jennings MP, Paton JC, McEwan AG. A 
pneumococcal MerR-like regulator and S-nitrosoglutathione reductase are required for 
systemic virulence. J Infect Dis 2007;196:1820-6.
57. Yamaguchi M, Terao Y, Mori-Yamaguchi Y, et al. Streptococcus pneumoniae 
invades erythrocytes and utilizes them to evade human innate immunity. PLoS One 
2013;8:e77282.
58. Agafwal V, Asmat TM, Dierdorf Nl, Hauck CR, Hamnherschmidt S. Polymeric- 
immunoglobulin receptor-mediated invasion of Streptococcus pneumoniae into host cells 
requires a coordinate signaling of SRC family of protein-tyrosine kinases, ERK, and c-Jun 
N-terminal kinase. The Journal of biological chemistry 2010;285:35615-23.
59. lovino F, Brouwer MC, van de Beek D, Molema G, Bijlsma JJ. Signalling or binding: 
the role of the platelet-activating factor receptor in invasive pneumococcal disease. 
Cellular microbiology 2013;15:870-81.
60. Gradstedt H, lovino F, Bijlsma JJ. Streptococcus pneumoniae invades endothelial 
host cells via multiple pathways and is killed in a lysosome dependent manner. PLoS One 
2013;8:e65626.
61. Marks LR, Davidson BA, Knight PR, Hakansson AP. Interkingdom signaling induces 
Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic 
colonization to disease. mBio 2013;4.
299
62. Pettigrew MM, Marks LR, Kong Y, Gent JF, Roche-Hakansson H, Hakansson AP. 
Streptococcus pneumoniae and influenza: dynamic changes in the pneumococcal 
transcriptome during transition from biofilm formation to invasive disease. Infect Immun 
2014.
63. Harvey RM, Hughes CE, Paton AW, Trappetti C, Tweten RK, Paton JC. The impact 
of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain- 
dependent. PLoS One 2014;9:el03625.
64. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental 
link between pneumococcal carriage and disease. Expert review of vaccines 2012;11:841-
55.
65. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of 
pneumococcal pneumonia. Lancet 2009;374:1543-56.
66. Gray BM, Converse GM, 3rd, Dillon HC, Jr. Epidemiologic studies of Streptococcus 
pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of 
life. J Infect Dis 1980;142:923-33.
67. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the 
key to pneumococcal disease. Lancet Infect Dis 2004;4:144-54. v
68. van den Bergh MR, Biesbroek G, Rossen JW, et al. Associations between 
pathogens in the upper respiratory tract of young children: interplay between viruses and 
bacteria. PLoS One 2012;7:e47711.
69. Fairchok MP, Martin ET, Chambers S, et al. Epidemiology of viral respiratory tract 
infections in a prospective cohort of infants and toddlers attending daycare. J Clin Virol 
2010;49:16-20.
70. Pappas DE, Hendley JO, Hayden FG, Winther B. Symptom profile of common colds 
in school-aged children. Pediatr Infect Dis J 2008;27:8-11.
71. Peltola V, Heikkinen T, Ruuskanen O, et al. Temporal association between 
rhinovirus circulation in the community and invasive pneumococcal disease in children. 
Pediatr Infect Dis J 2011;30:456-61.
300
72. Jansen AG, Sanders EA, A VDE, AM VANL, Hoes AW, Hak E. Invasive pneumococcal 
and meningococcal disease: association with influenza virus and respiratory syncytial 
virus activity? Epidemiol Infect 2008;136:1448-54.
73. Murdoch DR, Jennings LC. Association of respiratory virus activity and 
environmental factors with the incidence of invasive pneumococcal disease. J Infect 
2009;58:37-46.
74. Wolter N, Cohen C, Tempia S, et al. HIV and influenza virus infections are 
associated with increased blood pneumococcal load: a prospective, hospital-based 
observational study in South Africa, 2009-2011. J Infect Dis 2014;209:56-65.
75. O'Brien KL, Walters Ml, Sellman J, et al. Severe pneumococcal pneumonia in 
previously healthy children: the role of preceding influenza infection. Clin Infect Dis 
2000;30:784-9.
76. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. 
JAMA 2013;309:275-82.
77. Avadhanula V, Rodriguez CA, Devincenzo JP, et al. Respiratory viruses augment 
the adhesion of bacterial pathogens to respiratory epithelium in a vira! species- and cel! 
type-dependent manner. J Virol 2006;80:1629-36. v v
78. Golda A, Malek N, Dudek B, et al. Infection with human coronavirus NL63 
enhances streptococcal adherence to epithelial cells. J Gen Virol;92:1358-68.
79. Kimaro Mlacha SZ, Peret TC, Kumar N, et al. Transcriptional adaptation of 
pneumococci and human pharyngeal cells in the presence of a virus infection. BMC 
Genomics 2013;14:378.
80. Yokota S, Okabayashi T, Hirakawa S, Tsutsumi H, Himi T, Fujii N. Clarithromycin 
suppresses human respiratory syncytial virus infection-induced Streptococcus 
pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line. 
Mediators of inflammation 2012:2012:528568.
81. Avadhanula V, Wang Y, Portner A, Adderson E. Nontypeable Haemophilus 
influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein. J 
Med Microbiol 2007;56:1133-7.
301
82. Hament JM, Aerts PC, Fleer A, et al. Direct binding of respiratory syncytial virus to 
pneumococci: a phenomenon that enhances both pneumococcal adherence to human 
epithelial cells and pneumococcal invasiveness in a murine model. Pediatric research 
2005;58:1198-203.
83. Hament JM, Aerts PC, Fleer A, et al. Enhanced adherence of Streptococcus 
pneumoniae to human epithelial cells infected with respiratory syncytial virus. Pediatric 
research 2004;55:972-8.
84. Ishizuka S, Yamaya M, Suzuki T, et al. Effects of rhinovirus infection on the 
adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J 
Infect Dis 2003;188:1928-39.
85. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to 
nasal epithelial cells simultaneously. The Laryngoscope 2009;119:1406-11.
86. Trappetti C, Kadioglu A, Carter M, et al. Sialic acid: a preventable signal for 
pneumococcal biofilm formation, colonization, and invasion of the host. J Infect Dis 
2009;199:1497-505.
87. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during 
coinfection by providing host sialylated substrates as a nutrient source. Cell host & 
microbe 2014;16:55-67.
88. Raza MW, Blackwell CC, Elton RA, Weir DM. Bactericidal activity of a monocytic 
cell line (THP-1) against common respiratory tract bacterial pathogens is depressed after 
infection with respiratory syncytial virus. J Med Microbiol 2000;49:227-33.
89. Diavatopoulos DA, Short KR, Price JT, et al. Influenza A virus facilitates 
Streptococcus pneumoniae transmission and disease. FASEB J 2010;24:1789-98.
90. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus 
and Streptococcus pneumoniae. PLoS Pathog 2013;9:el003238.
91. Mina MJ, Klugman KP, McCullers JA. Live Attenuated Influenza Vaccine, But Not 
Pneumococcal Conjugate Vaccine, Protects Against Increased Density and Duration of 
Pneumococcal Carriage After Influenza Infection in Pneumococcal Colonized Mice. J Infect 
Dis 2013.
302
92. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. 
Influenza enhances susceptibility to natural acquisition of and disease due to 
Streptococcus pneumoniae in ferrets. J Infect Dis 2010;202:1287-95.
93. Short KR, Reading PC, Wang N, Diavatopoulos DA, Wijburg OL. Increased 
nasopharyngeal bacterial titers and local inflammation facilitate transmission of 
Streptococcus pneumoniae. mBio 2012;3.
94. Wren JT, Blevins LA, Pang B, et al. Influenza A Virus Alters Pneumococcal Nasal 
Colonization and Middle Ear Infection Independently of Phase Variation. Infect Immun 
2014.
95. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from 
the lungs of mice following primary respiratory syncytial virus infection. Journal of 
medical virology 2006;78:829-38.
96. Kukavica-lbrulj I, Hamelin ME, Prince GA, et al. Infection with human 
metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol 
2009;83:1341-9.
97. Verkaik NJ, Nguyen DT, de Vogel CP, et al. Streptococcus pneumoniae exposure is 
associated with human metapneumovirus seroconversion and increased susceptibility to 
in vitro HMPV infection. Clin Microbiol Infect 2011;17:1840-4.
98. Rodrigues F, Foster D, Nicoli E, et al. Relationships between rhinitis symptoms, 
respiratory viral infections and nasopharyngeal colonization with Streptococcus 
pneumoniae, Haemophiius influenzae and Staphylococcus aureus in children attending 
daycare. Pediatr Infect Dis J 2013;32:227-32.
99. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of 
Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in 
Vietnamese children. Pediatr Infect Dis J 2011;30:11-8.
100. Launes C, de-Sevi!!a MF, Selva L, Garcia-Garcia JJ, Pallares R, Munoz-Almagro C. 
Viral coinfection in children less than five years old with invasive pneumococcal disease. 
Pediatr Infect Dis J 2012;31:650-3.
303
101. Korppi M. Are all pneumococcal infections mixed infections with viruses? Pediatr 
Infect Dis J 2012;31:1000-1; author reply 1.
102. Adegbola RA, DeAntonio R, Hill PC, et al. Carriage of Streptococcus pneumoniae 
and other respiratory bacterial pathogens in low and lower-middle income countries: a 
systematic review and meta-analysis. PLoS One 2014;9:el03293.
103. Roca A, Bottomley C, Hill PC, et al. Effect of age and vaccination with a 
pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal 
carriage. Clin Infect Dis 2012;55:816-24.
104. Gray BM, Turner ME, Dillon HC, Jr. Epidemiologic studies of Streptococcus 
pneumoniae in infants. The effects of season and age on pneumococcal acquisition and 
carriage in the first 24 months of life. Am J Epidemiol 1982;116:692-703.
105. Lipsitch M, Abdullahi O, D'Amour A, et al. Estimating rates of carriage acquisition 
and clearance and competitive ability for pneumococcal serotypes in Kenya with a 
Markov transition model. Epidemiology 2012;23:510-9.
106. Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical 
relevance or Detection oi pneumococcal DNA m sera of children by PCR. J Clin Microbiol 
1998;36:669-73.
V V V; V
107. Verhelst R, Kaijalainen T, De Baere T, et al. Comparison of five genotypic 
techniques for identification of optochin-resistant pneumococcus-like isolates. J Clin 
Microbiol 2003;41:3521-5.
108. Whatmore AM, Efstratiou A, Pickerill AP, et al. Genetic relationships between 
clinical isolates of Streptococcus pneumoniae, Streptococcus oralis, and Streptococcus 
mitis: characterization of "Atypical" pneumococci and organisms allied to S. mitis 
harboring S. pneumoniae virulence factor-encoding genes. Infect Immun 2000;68:1374-
82.
109. Harris KA, Turner P, Green EA, Hartley JC Duplex real-time PCR assay for detection 
of Streptococcus pneumoniae in clinical samples and determination of penicillin 
susceptibility. J Clin Microbiol 2008;46:2751-8.
304
110. Seki M, Yamashita Y, Torigoe H, Tsuda H, Sato S, Maeno M. Loop-mediated 
isothermal amplification method targeting the lytA gene for detection of Streptococcus 
pneumoniae. J Clin Microbiol 2005;43:1581-6.
111. Hassan-King M, Baldeh I, Secka O, Falade A, Greenwood B. Detection of 
Streptococcus pneumoniae DNA in blood cultures by PCR. J Clin Microbiol 1994;32:1721- 
4.
112. Kumar S, Wang L, Fan J, et al. Detection of 11 common viral and bacterial 
pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients 
by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) 
or automated (electronic microarray) detection. J Clin Microbiol 2008;46:3063-72.
113. Zhang Y, Isaacman DJ, Wadowsky RM, Rydquist-White J, Post JC, Ehrlich GD. 
Detection of Streptococcus pneumoniae in whole blood by PCR. J Clin Microbiol 
1995;33:596-601.
114. Stralin K, Tornqvist E, Kaltoft MS, Olcen P, Flolmberg FI. Etiologic diagnosis of adult 
bacterial pneumonia by culture and PCR applied to respiratory tract samples. J Clin 
Microbiol 2006;44:643-5.
115. Morozumi M, Nakayama E, Iwata S{ et al. Simultaneous detection of pathogens in 
clinical samples from patients with community-acquired pneumonia by real-time PCR 
with pathogen-specific molecular beacon probes. J Clin Microbiol 2006;44:1440-6.
116. Sheppard CL, Harrison TG, Morris R, Hogan A, George RC. Autolysin-targeted 
LightCycler assay including internal process control for detection of Streptococcus 
pneumoniae DNA in clinical samples. J Med Microbiol 2004;53:189-95.
117. Isaacman DJ, Zhang Y, Reynolds EA, Ehrlich GD. Accuracy of a polymerase chain 
reaction-based assay for detection of pneumococcal bacteremia in children. Pediatrics 
1998;101:813-6.
118. Stralin K, Bac km an A, Holmberg H, Fredlund H, Olcen P. Design of a multiplex PCR 
for Streptococcus pneumoniae; Haemophilus influenzae, Mycoplasma pneumoniae and 
Chlamydophila pneumoniae to be used on sputum samples. APMIS 2005;113:99-111.
305
119. Butler JC, Bosshardt SC, Phelan M, et al. Classical and latent class analysis 
evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of 
pneumococcal pneumonia in adults. J Infect Dis 2003;187:1416-23.
120. Messmer TO, Whitney CG, Fields BS. Use of polymerase chain reaction to identify 
pneumococcal infection associated with hemorrhage and shock in two previously healthy 
young children. Clin Chem 1997;43:930-5.
121. Resti M, Micheli A, Moriondo M, et al. Comparison of the effect of antibiotic 
treatment on the possibility of diagnosing invasive pneumococcal disease by culture or 
molecular methods: a prospective, observational study of children and adolescents with 
proven pneumococcal infection. Clin Ther 2009;31:1266-73.
122. Abdeldaim G, Herrmann B, Moiling P, et al. Usefulness of real-time PCR for lytA, 
ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia. Clin 
Microbiol Infect 2009.
123. Abdeldaim G, Herrmann B, Korsgaard J, Olcen P, Blomberg J, Stralin K. Is 
quantitative PCR for the pneumolysin {ply) gene useful for detection of pneumococcal 
lower respiratory tract infection? Clin Microbiol Infect 2009;15:565-70.
124. Avni T, Mansur N, Leibovici L, Paul M. PCR using blood for diagnosis of invasive 
pneumococcal disease: systematic review and meta-analysis. J Clin Microbiol 
2010;48:489-96.
125. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement 
of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal 
DNA. J Clin Microbiol 2007;45:2460-6.
126. Albrich WC, Madhi SA, Adrian PV, et al. Use of a rapid test of pneumococcal 
colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis 2012;54:601-9.
127. Rudolph KM, Parkinson AJ, Black CM, Mayer LW. Evaluation of polymerase chain 
reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol 1993;31:2661-6.
128. Hull D, Lopez R, Garcia E. Characteristic signatures of the lytA gene provide a basis 
for rapid and reliable diagnosis of Streptococcus pneumoniae infections. J Clin Microbiol 
2006;44:1250-6.
306
129. Marks LR, Reddinger RM, Hakansson AP. High levels of genetic recombination 
during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. 
mBio 2012;3.
130. Muzzi A, Donati C. Population genetics and evolution of the pan-genome of 
Streptococcus pneumoniae. International journal of medical microbiology : IJMM 
2011;301:619-22.
131. Greiner O, Day PJ, Bosshard PP, Imeri F, Altwegg M, Nadal D. Quantitative 
detection of Streptococcus pneumoniae in nasopharyngeal secretions by real-time PCR. J 
Clin Microbiol 2001;39:3129-34.
132. van Haeften R, Palladino S, Kay I, Keil T, Heath C, Waterer GW. A quantitative 
LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF. Diagn Microbiol 
Infect Dis 2003;47:407-14.
133. Abdeldaim GM, Stralin K, Olcen P, Blomberg J, Herrmann B. Toward a quantitative 
DNA-based definition of pneumococcal pneumonia: a comparison of Streptococcus 
pneumoniae target genes, with special reference to the Spn9802 fragment. Diagn 
Microbiol Infect Dis 2008;60:143-50.
134. McAvin JC, Reilly PA, Roudabush RM, et al. Sensitive and specific method for rapid 
identification of Streptococcus pneumoniae using real-time fluorescence PCR. J Clin 
Microbiol 2001;39:3446-51.
135. Kee C, Palladino S, Kay I, et al. Feasibility of real-time polymerase chain reaction in 
whole blood to identify Streptococcus pneumoniae in patients with community-acquired 
pneumonia. Diagn Microbiol Infect Dis 2008;61:72-5.
136. Park HK, Lee SJ, Yoon JW, et al. Identification of the cpsA gene as a specific marker 
for the discrimination of Streptococcus pneumoniae from viridans group streptococci. J 
Med Microbiol 2010;59:1146-52.
137. Zbinden A, Kohler N, Bloemberg GV. recA-based PCR assay for accurate 
differentiation of Streptococcus pneumoniae from other viridans streptococci. J Clin 
Microbiol 2011;49:523-7.
307
138. Greve T, Moller JK. Accuracy of using the lytA gene to distinguish Streptococcus 
pneumoniae from related species. J Med Microbiol 2012;61:478-82.
139. Messmer TO, Sampson JS, Stinson A, Wong B, Carlone GM, Facklam RR. 
Comparison of four polymerase chain reaction assays for specificity in the identification of 
Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2004;49:249-54.
140. Nagai K, Shibasaki Y, Hasegawa K, et al. Evaluation of PCR primers to screen for 
Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common 
macrolide resistance determinants. J Antimicrob Chemother 2001;48:915-8.
141. Kee C, Fatovich DM, Palladino S, et al. Specificity of a quantitative real-time 
polymerase chain reaction assay for the detection of invasive pneumococcal disease: 
identifying Streptococcus pneumoniae using quantitative polymerase chain reaction.
Chest 2010;137:243-4.
142. Azzari C, Moriondo M, Indolfi G, et al. Realtime PCR is more sensitive than 
multiplex PCR for diagnosis and serotyping in children with culture negative 
pneumococcal invasive disease. PLoS One 2010;5:e9282.
143. Resti M, Moriondo M, Cortimigiia M, et ai. Community-Acquired Bacteremic
v Pneumococcal Pneumonia in Children: Diagnosis and Serotyping by Real-Time Polymerase 
Chain Reaction Using Blood Samples. Clin Infect Dis 2010;51:1042-9.
144. Azzari C, Moriondo M, Indolfi G, et al. Molecular detection methods and 
serotyping performed directly on clinical samples improve diagnostic sensitivity and 
reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian 
children. J Med Microbiol 2008;57:1205-12.
145. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated 
with genomic bacterial load. Chest 2009;136:832-40.
146. Cvitkovic Spik V, Beovic B, Pokorn M, et al. Improvement of pneumococcal 
pneumonia diagnostics by the use of rt=PCR on plasma and respiratory samples. 
Scandinavian journal of infectious diseases 2013;45:731-7.
147. Werno AM, Anderson TP, Murdoch DR. Association between pneumococcal load 
and disease severity in adults with pneumonia. J Med Microbiol 2012;61:1129-35.
308
148. Rouphael N, Steyn S, Bangert M, et al. Use of 2 pneumococcal common protein 
real-time polymerase chain reaction assays in healthy children colonized with 
Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2011.
149. Carrol ED, Guiver M, Nkhoma S, et al. High pneumococcal DNA loads are 
associated with mortality in Malawian children with invasive pneumococcal disease. 
Pediatr Infect Dis J 2007;26:416-22.
150. Esposito S, Zampiero A, Terranova L, et al. Pneumococcal bacterial load 
colonization as a marker of mixed infection in children with alveolar community-acquired 
pneumonia and respiratory syncytial virus or rhinovirus infection. Pediatr Infect Dis J 
2013;32:1199-204.
151. Albrich WC, Madhi SA, Adrian PV, et al. Pneumococcal colonisation density: a new 
marker for disease severity in HIV-infected adults with pneumonia. BMJ open 
2014;4:e005953.
152. Wolter N, Tempia S, Cohen C, et al. High nasopharyngeal pneumococcal density, 
increased by viral coinfection, is associated with invasive pneumococcal pneumonia. J 
Infect Dis 2014;210:1649-57.
153. Hamano-Hasegawa K, Morozumi M, Nakayama E, et al. Comprehensive detection 
of causative pathogens using real-time PCR to diagnose pediatric community-acquired 
pneumonia. J Infect Chemother 2008;14:424-32.
154. Lahti E, Peltola V, Waris M, et al. Induced sputum in the diagnosis of childhood 
community-acquired pneumonia. Thorax 2009;64:252-7.
155. Stralin K, Herrmann B, Abdeldaim G, Olcen P, Holmberg H, Moiling P. Comparison 
of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lytA and 
Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. J Clin 
Microbiol 2014;52:83-9.
156. Mbelle N. Huebner RE. Wasas AD KimnraA Phana I klnaman KP lmmiinnpr«=»niritvIflMWIIW I ’ / I IMW.MIIWI • 1 * »"’/ V< • •/ '"••’-•■O */ ’*• '“’O*    '-O-*- -/
and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. 
J Infect Dis 1999;180:1171-6.
309
157. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of 
Streptococcus pneumoniae in Gambian children who participated in a 9-valent 
pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 
2009;28:990-5.
158. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on 
nasopharyngeal colonization among immunized and unimmunized children in a 
community-randomized trial. J Infect Dis 2007;196:1211-20.
159. Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent 
pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus 
pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from 
cross-sectional carriage studies. The Lancet Global Health 2014;2:e397-405.
160. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal 
conjugate vaccine on pneumococcal colonization among unvaccinated household 
members. Clin Infect Dis 2008;47:989-96.
161. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on 
adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive 
pneumococcal disease. J Infect Dis 2006;193:1487-94.
V ■ ' V: V: v
162. McCool TL, Weiser JN. Limited role of antibody in clearance of Streptococcus 
pneumoniae in a murine model of colonization. Infect Immun 2004;72:5807-13.
163. Pasinato A, Indolfi G, Marchisio P, et al. Pneumococcal serotype distribution in 
1315 nasopharyngeal swabs from a highly vaccinated cohort of Italian children as 
detected by RT-PCR. Vaccine 2014;32:1375-81.
164. Auranen K, Rinta-Kokko H, Goldblatt D, et al. Colonisation endpoints in 
Streptococcus pneumoniae vaccine trials. Vaccine 2013;32:153-8.
165. da Gloria Carvalho M, Pimenta FC, Jackson D, et al. Revisiting pneumococcal 
carriage by use of broth enrichment and PCR techniques for enhanced detection of 
carriage and serotypes. J Clin Microbiol 2010;48:1611-8.
310
166. Turner P, Hinds J, Turner C, et al. Improved detection of nasopharyngeal 
cocolonization by multiple pneumococcal serotypes by use of latex agglutination or 
molecular serotyping by microarray. J Clin Microbiol 2011;49:1784-9.
167. Wyllie AL, Chu ML, Schellens MH, et al. Streptococcus pneumoniae in Saliva of 
Dutch Primary School Children. PLoS One 2014;9:el02045.
168. O'Brien KL, Nohynek H. Report from a WHO Working Group: standard method for 
detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 
2003;22:el-ll.
169. Hendley JO, Sande MA, Stewart PM, Gwaltney JM, Jr. Spread of Streptococcus 
pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis 
1975;132:55-61.
170. Huebner RE, Dagan R, Porath N, Wasas AD, Klugman KP. Lack of utility of 
serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of 
different pneumococcal serotypes. Pediatr Infect Dis J 2000;19:1017-20.
171. Satzke C, Dunne EM, Porter BD, et al. PneuCarriage project: identifying the 
optimum pneumococcal serotyping method(s), including detection of multiple serotype 
carriage. International Symposium on Pneumococcus and Pneumococcal Diseases; 2014; 
Hyderabad, India.
172. Brugger SD, Hathaway LJ, Muhlemann K. Detection of Streptococcus pneumoniae 
strain cocolonization in the nasopharynx. J Clin Microbiol 2009;47:1750-6.
173. Ota MO, Roca A, Bottomley C, et al. Pneumococcal antibody concentrations of 
subjects in communities fully or partially vaccinated with a seven-valent pneumococcal 
conjugate vaccine. PLoS One 2012;7:e42997.
174. Gritzfeld JF, Gordon SB, Cremers A. Detection limits in pneumococcal carriage. 
Pediatr Infect Dis J 2013;32:425-6.
175. Gritzfeld JF, Cremers AJ, Ferwerda G, et al. Density and duration of experimental 
human pneumococcal carriage. Clin Microbiol Infect 2014.
311
176. Chien YW, Vidal JE, Grijalva CG, et al. Density interactions among Streptococcus 
pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of 
young Peruvian children. Pediatr Infect Dis J 2013;32:72-7.
177. Carvalho Mda G, Bigogo GM, Junghae M, et al. Potential nonpneumococcal 
confounding of PCR-based determination of serotype in carriage. J Clin Microbiol 
2012;50:3146-7.
178. Carvalho Mda G, Pimenta FC, Moura I, et al. Non-pneumococcal mitis-group 
streptococci confound detection of pneumococcal capsular serotype-specific loci in upper 
respiratory tract. PeerJ 2013;l:e97.
179. Wanjiru E, Foster D, Kosi V, Karani A, Morpeth SC, Scott JA. Molecular serotyping 
in a quality assurance scheme for the Quellung reaction, pending introduction of the 
pneumococcal conjugate vaccine to Kenya. 7th International Symposium on 
Pneumococci and Pneumococcal Diseases; 2010 March 14-18, 2010; Tel Aviv, Israel.
180. Hirama T, Yamaguchi T, Miyazawa H, et al. Prediction of the pathogens that are 
the cause of pneumonia by the battlefield hypothesis. PLoS One 2011;6:e24474.
181. Aianio A, Desoubeaux G, Sarfati C, et ai. Real-time PCR assay-based strategy for 
differentiation between active Pneumocystis jirovecii pneumonia and colonization in 
immunocompromised patients. Clin Microbiol Infect 2011;17:1531-7.
182. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information 
for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
183. Huggett J, Laver T, Tamisak S, et al. Considerations for the development and 
application of control materials to improve metagenomic microbial community profiling. 
Accred Qual Assur 2013;18:77-83.
184. Smith MD, Sheppard CL, Hogan A, et al. Diagnosis of Streptococcus pneumoniae 
infections in adults with bacteremia and community-acquired pneumonia: clinical 
comparison of pneumococcal PCR and urinary antigen detection. J Clin Microbiol 
2009;47:1046-9.
312
185. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of 
Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in 
Vietnamese children. Pediatr Infect Dis J 2010;30:11-8.
186. Smieja M, Castriciano S, Carruthers S, et al. Development and evaluation of a 
flocked nasal midturbinate swab for self-collection in respiratory virus infection diagnostic 
testing. J Clin Microbiol 2010;48:3340-2.
187. Bandt D, Monecke S. Development and evaluation of a real-time PCR assay for 
detection of Pneumocystis jiroveci. Transpl Infect Dis 2007;9:196-202.
188. Boddicker JD, Rota PA, Kreman T, et al. Real-time reverse transcription-PCR assay 
for detection of mumps virus RNA in clinical specimens. J Clin Microbiol 2007;45:2902-8.
189. Ohrmalm L, Wong M, Rotzen-Ostlund M, Norbeck O, Broliden K, Tolfvenstam T. 
Flocked nasal swab versus nasopharyngeal aspirate for detection of respiratory tract 
viruses in immunocompromised adults: a matched comparative study. BMC Infect Dis 
2010;10:340.
190. Cannas A, Kalunga G, Green C, et al. Implications of storing urinary DNA from 
different populations for molecular analyses. PLoS One 2009;4:e6985.
191. the mfold Web Server. Rensselaer Polytechnic Institute, at  ^
http://mfold.rna. albany.edu/?q=mfold/dna-folding-form.
192. BuG@S. at http://bugs.sgul.ac.uk/.
193. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal 
pneumonia among adults: a systematic review and meta-analysis of diagnostic 
techniques. PLoS One 2013;8:e60273.
194. Charkaluk ML, Kalach N, Mvogo H, et al. Assessment of a rapid urinary antigen 
detection by an immunochromatographic test for diagnosis of pneumococcal infection in 
children. Diagn Microbiol Infect Dis 2006;55:89-94.
195. Abdullahi O, Karani A, Tigoi CC, et al. The prevalence and risk factors for 
pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. 
PLoS One 2012;7:e30787.
313
196. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic 
Surveillance System (KHDSS). Int J Epidemiol 2012;41:650-7.
197. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd ed. 
New York: Marcel Dekker; 2008.
198. Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in 
the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 
1959;38:213-65.
199. Grijalva CG, Griffin MR, Edwards KM, et al. The role of influenza and parainfluenza 
infections in nasopharyngeal pneumococcal acquisition among young children. Clin Infect 
Dis 2014;58:1369-76.
200. Wisdom A, Leitch EC, Gaunt E, Harvala H, Simmonds P. Screening respiratory 
samples for detection of human rhinoviruses (HRVs) and enteroviruses: comprehensive 
VP4-VP2 typing reveals high incidence and genetic diversity of HRV species C. J Clin 
Microbiol 2009;47:3958-67.
201. Hammitt LL, Kazungu S, Welch S, et al. Added value of an oropharyngeal swab in 
detection of viruses in children hospitalized with lower respiratory tract infection. J Clin 
Microbiol 2011;49:2318-20.V. v v. v
202. Gwaltney JM, Jr., Sande MA, Austrian R, Hendley JO. Spread of Streptococcus 
pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and 
serum antibody. J Infect Dis 1975;132:62-8.
203. von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive 
pneumococcal disease in South Africa. N Engl J Med 2014;371:1889-99.
204. Tigoi CC, Gatakaa H, Karani A, et al. Rates of acquisition of pneumococcal 
colonization and transmission probabilities, by serotype, among newborn infants in Kilifi 
District, Kenya. Clin Infect Dis 2012;55:180-8.
205. El Aila NA, Emler S, Kaijalainen T, et al. The development of a 16S rRNA gene 
based PCR for the identification of Streptococcus pneumoniae and comparison with four 
other species specific PCR assays. BMC Infect Dis 2010;10:104.
314
206. Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, Satzke C. 
Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus 
pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus 
in Fijian children. J Clin Microbiol 2012;50:1034-8.
207. Adetifa IM, Antonio M, Okoromah CA, et al. Pre-vaccination nasopharyngeal 
pneumococcal carriage in a Nigerian population: epidemiology and population biology. 
PLoS One 2012;7:e30548.
208. Hill PC, Cheung YB, Akisanya A, et al. Nasopharyngeal carriage of Streptococcus 
pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 2008;46:807-14.
209. Abdullahi O, Wanjiru E, Musyimi R, Glass N, Scott JA. Validation of nasopharyngeal 
sampling and culture techniques for detection of Streptococcus pneumoniae in children in 
Kenya. J Clin Microbiol 2007;45:3408-10.
210. Weddle G, Jackson MA, Selvarangan R. Reducing blood culture contamination in a 
pediatric emergency department. Pediatr Emerg Care 2011;27:179-81.
211. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for 
detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from 
adults with community-acquired pneumonia. J Clin Microbiol 2003^41:63-6.
315
Chapter Fourteen
14 Appendices
14.1 Appendix A: STATA code for selection of viral episodes
14.1.1 Cleaning the data and generating extra variables needed
The STATA code began with removal of unnecessary variables and specimens other than 
nasopharyngeal swabs, and checking for duplicates in terms of study ID and sample date, 
which together made up the unique identifier for a nasopharyngeal swab in this dataset. 
The study ID was unique to the participant. Variables such as number of children per 
household, number of smokers per household, poverty level, cooking fuel type, cooking 
inside the house, type of toilet available, water source; that could potentially be 
associated with P.asooharvnsea! n n p n m n r n r r a l  r a r r ia p p  wprp ppnprptprl All <;\A/ah<; from  
participants overvthe age of five years at enrolment were then dropped from the data. v 
Five households had rhinovirus subtyping data available, but with different variable 
names, these were harmonised under one variable name. Any Ct values that were 
improbably low were checked with the laboratory team and changed to 0, as these were 
due to wandering baseline, and not true amplification.
The nasopharyngeal swab PCR data was made binary for each viral target, with a Ct value 
of <35 counted as positive, and a Ct>35, an undetected Ct or a missing Ct counted as 
negative. Each rhinovirus subtype was considered as an individual viral target.
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An upper respiratory tract infection (URTI) was defined as the presence of cough, coryza, 
sore throat, nasal flaring or wheeze, in practice, all URTI were made up of a cough or 
coryza or both.
clear matrix 
clear
set mem 500m 
set more off 
capture log close
log using "WAIFW selections", text replace V
cd "/Users/smorpeth/Documents/Susan's stuff/Kilifi/PhD Kilifi/WAIFWin PhD" 
use "Entire WAIFW
dataset/waifw_Jield_mpx_clean_300412_susan_confounders_rhino5_51_34_19_40.dta"
br
drop location slname village student occupation reasonnfs awaynfs comments
awaycomment away anyothercomplains othercomplaints unablefeed headnodding
consciousievel unabletalk cyanosis referralby clinician temp resprate oxygensats heartrate
317
diag2 diagfw extractiondate extractionby pcrdote pcrby nfss sampledatel oge_code 
lad_id r_extractiondate r_extractionby serial month dash sampleid extractiondate2 lab_id 
r_pcrdate r_pcrby sampledate2 sampledateyear sampledatemonth sampledateday 
sampledatedayl sampledateyearl
drop v9 hhname hhheadname
duplicates report visitid 
duplicates report studyid sampledate
***check whether can use this compound unique id without dropping missing or duplicate 
visitids***
codebook sampletype
V: V V;
drop if  sampletype == 2 
***2  is oral flu id ** * 
drop if  nfs == 0 
duplicates report visitid
***Generating variables needed as potential confounders iate r* * * * * **
***Number o f children in the household***
318
sort hhid studyid sampledate
egen tag_studyid=tag(studyid)
*this tags the first of each studyid as 1 and all the rest as 0
tab tag_studyid/
codebook studyid
by hhid: gen nkids=sum(tag_studyid) if  age_start<16
by hhid: replace nkids=nkids[_n-l] i f  age_start>=16
by hhid: gen Nkids=nkids[_N]
drop nkids
V V ■ V
tab Nkids
* * *Number o f adults in the household who are smokers***
bysort hhid: gen nsmoke=sum(tag_studyid) ifsmoker==l
by hhid: replace nsmoke=nsmoke[_n-l] ifsmoker==0 / smoker==.
by hhid: gen Nsmoke=nsmoke[_N]
replace Nsmoke=0 if  Nsmoke==.
drop nsmoke
tab Nsmoke 
***Poverty level by assets***
codebook bicycle tvvideo motorcycle radio mobilephone electricity cowsbin goatsbin 
chickenbin turkeybin ducksbin housetype mudwall houseowner
gen assets = bicycle + tvvideo + motorcycle + radio + mobilephone + electricity + cowsbin 
/ / /
+ goatsbin + chickenbin + turkeybin + ducksbin 
tab assets
V V: V V
* * * Cooking fuel * * *
code book toilet toilettype burn waste fuelcook placecook watersource watersite
***to ile t is any toilet, placecook gives more info than fuelcook, watersource more useful 
than * watersite
gen hygiene=l ifto ile t==l & (watersource==l / water source==4)
*watersource 1 is a closed well, 4 is piped. Other watersources are open well, open and 
closed well, *piped and open well or missing
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replace hygiene=2 if  toilet==l & watersource!=1 & watersource 1=4 
replace hygiene=3 if  toilet==0 & (watersource==l / watersource==4) 
replace hygiene=4 if  toilet==0 & watersource!=l & watersource 1=4 
replace hygiene=. iftoilet==. / watersource==. 
tab hygiene
***1 is the best hygiene score (has a toilet and a safe water source), 4 is the worst (has 
neither), toilet *scores as more important than the water source
tab placecook
gen cookinside = 3 if  placecook==3 
replace cookinside = 2 i f  piacecook==l
\: V V; V ■
replace cookinside = 1 i f  placecook==2 
replace cookinside =. i f  placecook==. 
tab cookinside
***1 is the best cookinside score (cooks outside), 2 is moderate (cooks in different house), 
3 is worst (cooks in house where sleeps)
drop if  age_start > 5 
duplicates report visitid
duplicates list visitid
duplicates report studyid sampledate
replace rhinospp = hrv_species i f  rhinospp == "" & hrv_species != ""
***lmprobably low Ct values*** 
list studyid sampledate visitid e229 i f  e229>0 & e229<14 
list studyid sampledate visitid nl63 i f  nl63>0 & nl63<14 
list studyid sampledate visitid oc43 if  oc43>0 & oc43<14 
list studyid sampledate visitid adeno ifadeno>0 & adeno<14
■ \ :  ■ V ■ v  .
list studyid sampledate visitid piv4 i f  piv4>0 & piv4<14 
list studyid sampledate visitid rhino i f  rhino>0 & rhino<14
list studyid sampledate visitid flua flub flue i f  (flua>0 &flua<14) / (flub>0 & flub<14) / / /
I (fluc>0&fluc<14)
*none of the other targets had any Ct<14 
replace e229=0 if  e229>0 & e229<10 
replace n163=0 if  nl63>0 & nl63<10
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replace oc43=0 i f  oc43>0 & oc43<10
replace adeno=0 if  adeno>0 & adeno<10
replace piv4=0 if  piv4>0 & piv4<14
replace rhino=0 i f  rhino>0 & rhino<14
replace flua=0 ifflua>0&flua<14
replace flub=0 ifflub>0&flub<14
replace fluc=0 iffluc>0 &fluc<14
***RSV-A***
V V ■ V;
gen rsvabin = 1 i f  rsva > 0 &  rsva < 36
replace rsvabin = 0 i f  rsva == 0
replace rsvabin = 0 i f  rsva >35 & rsva <.
replace rsvabin = 0 i f  rsva ==.
***making the Ct values binary ie pos or neg***
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* * * RSV-B* * *
gen rsvbbin = 1 i f  rsvb > 0 &  rsvb < 36
replace rsvbbin = 0 i f  rsvb == 0
replace rsvbbin = 0 i f  rsvb >35 & rsvb <.
replace rsvbbin = 0 i f  rsvb ==.
***making the Ct values binary ie pos or neg***
* * *OC-43 * * *Coronavirus * * *
v ■ v
gen oc43bin = 1 i f  oc43>0& oc43 <36
replace oc43bin = 0 i f  oc43 == 0
replace oc43bin = 0 i f  oc43 >35 & oc43 <.
replace oc43bin = 0 i f  oc43 ==.
***making the Ct values binary ie pos or neg***
* * *NL-63 * * *Coronavirus * * *
324
gen nl63bin = 1 if  nl63 > 0 &  nl63 < 36 
replace nl63bin = 0 i f  n 163 == 0 
replace n!63bin = 0 i f  nl63 >35 & nl63 <. 
replace nl63bin = 0 i f  nl63 ==.
***making the Ct values binary ie pos or neg***
* * *e~229***Coronavirus * * *
gen e229bin = 1 i f  e229>0& e229 <36
V  \ ;
replace e229bin = 0 i f  e229 == 0 
replace e229bln = 0 if  e229 > 35 & e229 <. 
replace e229bin = 0 i f  e229 ==.
***making the Ct values binary ie pos or neg***
***Rhinovirus A l* * *
gen rhinospp_olbin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "A1"
replace rhinospp_albin = 0 i f  rhino == 0
replace rhinospp_albin = 0 if  rhino >35 & rhino <.
replace rhinospp_albin = 0 i f  rhinospp 1= "A l"
***making the Ct values binary ie pos or neg***
***Rhinovirus A2***
gen rhinospp_a2bin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "A2"
replace rhinospp_a2bin = 0 i f  rhino == 0
V  V; ■ V;
replace rhinospp_a2bin = 0 i f  rhino >35 & rhino <.
replace rhinospp_a2bin = 0 i f  rhinospp != "A2"
***making the Ct values binary ie pos or neg***
***Rhinovirus A3***
gen rhinospp_a3bin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "A3"
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replace rhinospp_a3bin = 0 i f  rhino == 0 
replace rhinospp_a3bin = 0 i f  rhino >35 & rhino <. 
replace rhinospp_a3bin = 0 if  rhinospp != "A3"
***making the Ct values binary ie pos or neg***
***Rhinovirus
***check in main dataset whether rhinospp or hrv_species contains all o f this data fo r the 
4 rhino typed households
gen rhinospp_a4bin = 1 i f  rhino >0 & rhino <36 & rhinospp == "A4"
V V: V V
replace rhinospp_a4bin = 0 i f  rhino == 0 
replace rhinospp_a4bin = 0 i f  rhino >35 & rhino <. 
replace rhinospp_a4bin = 0 i f  rhinospp != "A4"
***making the Ct values binary ie pos or neg***
)fc i f c ^  ^
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***check in main dataset whether rhinospp or hrv_species contains all of this data fo r the 
4 rhino typed households
gen rhinospp_a5bin = 1 i f  rhino >0 & rhino < 36 & rhinospp == "A5" 
replace rhinospp_a5bin = 0 i f  rhino == 0 
replace rhinospp_a5bin = 0 i f  rhino >35 & rhino <. 
replace rhinospp_a5bin = 0 i f  rhinospp != "A5"
***making the Ct values binary ie pos or neg***
***Rhinovirus B l* * *
\  v . v v  • Vi ­
gen rhinospp_blbin = 1 i f  rhino >0 & rhino < 36 & rhinospp == "B l"
replace rhinospp_blbin = 0 if  rhino == 0
replace rhinospp_blbin = 0 i f  rhino >35 & rhino <.
replace rhinospp_blbin = 0 i f  rhinospp != "B l"
***making the Ct values binary ie pos or neg***
***Rhinovirus Cl ** *
328
gen rhinospp_clbin = 1 i f  rhino >0 & rhino < 36 & rhinospp == "C l" 
replace rhinospp_clbin = 0 i f  rhino == 0 
replace rhinospp_clbin = 0 i f  rhino >35 & rhino <. 
replace rhinospp_clbin = 0 i f  rhinospp != "C l"
***making the Ct values binary ie pos or neg***
***Rhinovirus C2***
gen rhinospp_c2bin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "C2"
\: \:
replace rhinospp_c2bin = 0 i f  rhino == 0 
replace rhinospp_c2bin = 0 i f  rhino >35 & rhino <, 
replace rhinospp_c2bin = 0 i f  rhinospp != "C2" 
***making the Ct values binary ie pos or neg***
***Rhinovirus C3***
329
gen rhinospp_c3bin = 1 i f  rhino >0 & rhino < 36 & rhinospp == "C3"
replace rhinospp_c3bin = 0 i f  rhino == 0
replace rhinospp_c3bin = 0 i f  rhino >35 & rhino <.
replace rhinospp_c3bin = 0 i f  rhinospp != "C3"
***making the Ct values binary ie pos or neg***
***Rhinovirus C4***
gen rhinospp_c4bin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "C4"
replace rhinospp_c4bin = 0 i f  rhino == 0
V V V
replace rhinospp_c4bin = 0 i f  rhino >35 & rhino <.
replace rhinospp_c4bin = 0 If rhinospp != "C4"
***making the Ct values binary ie pos or neg***
***Rhinovirus C5***
gen rhinospp_c5bin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "C5"
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replace rhinospp_c5bin = 0 if  rhino == 0
replace rhinospp_c5bin = 0 i f  rhino >35 & rhino <.
replace rhinospp_c5bin = 0 i f  rhinospp != "C5"
***making the Ct values binary ie pos or neg***
***Rhinovirus D l* * *
gen rhinospp_dlbin = 1 i f  rhino > 0 &  rhino < 36 & rhinospp == "D l"
replace rhinospp_dlbin = 0 i f  rhino == 0
replace rhinospp_dlbin = 0 i f  rhino >35 & rhino <.
V V: V: ■
replace rhinospp_dlbin = 0 i f  rhinospp != "D l"
***making the Ct values binary ie pos or neg***
***Rhinovirus E l* * *
gen rhinospp_elbin = 1 if  rhino > 0 &  rhino < 36 & rhinospp == "E l"
replace rhinospp_elbin = 0 i f  rhino == 0
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replace rhinospp_elbin = 0 if  rhino >35 & rhino <. 
replace rhinospp_elbin = 0 i f  rhinospp != "E l"
***making the Ct values binary ie pos or neg***
***GENERAL RHINOVIRUS*** 
gen rhino_bin = 1 i f  rhino > 0 &  rhino < 36 
replace rhino_bin = 0 i f  rhino == 0 
replace rhino_bin = 0 i f  rhino >35 & rhino <. 
replace rhino_bin = 0 i f  rhino ==.
***making the Ct values binary ie pos or neg fo r general rhino because needed fo r
V ■ V V V
coinfection assessment***
***UNKNOWN RHINOVIRUS***
gen rhino_Ubin = 1 i f  rhino > 0 &  rhino <36&  rhinospp =="U" 
replace rhino_Ubin = 0 i f  rhino == 0 
replace rhino_Ubin = 0 i f  rhino >35 & rhino <. 
replace rhino_Ubin = 0 i f  rhinospp != "U"
***m aking  the Ct values binary ie pos or neg fo r  unknown rhinos because needed fo r
coinfection assessm ent***
* * * Influenza A ***
gen fluabin = 1 if f lu a > 0 &  flua <36 
replace fluabin = 0 ifflua  == 0 
replace fluabin = 0 ifflua  > 35 & flua <. 
replace fluabin = 0 ifflua  ==.
***making the Ct values binary ie pos or neg***
V V; V
***lnfluenza B***
gen flubbin = 1 i f  flub >0  & flub < 36 
replace flubbin = 0 i f  flub == 0 
replace flubbin = 0 i f  flub > 35 &flub <. 
replace flubbin = 0 i f  flub ==.
333
***m aking  the Ct values binary ie pos or n e g ** *
***lnfluenza C***
gen flucbin = 1 i f  flue > 0 &  flue < 36 
replace flucbin = 0 i f  flue == 0 
replace flucbin = 0 i f  flue >35 & flue <. 
replace flucbin = 0 i f  flue ==.
***making the Ct values binary ie pos or neg***
V; '
gen hmpvbin = 1 i f  hmpv > 0 & hmpv < 36 
replace hmpvbin = 0 i f  hmpv == 0 
replace hmpvbin = 0 i f  hmpv >35 & hmpv <. 
replace hmpvbin = 0 i f  hmpv ==.
***making the Ct values binary ie pos or neg***
* * *Adenovirus * * *
gen adenobin = 1 i f  adeno > 0 &  adeno < 36 
replace adenobin = 0 i f  adeno ==0 
replace adenobin = 0 i f  adeno >35 & adeno <. 
replace adenobin = 0 i f  adeno ==.
***making adeno Ct values binary ie pos or neg; because will need these later to assess 
co-infections
V: V V: \ ;
***Mycoplasma pneumoniae***
gen mycopbin = 1 i f  my cop > 0 &  mycop < 36 
replace mycopbin = 0 i f  mycop == 0 
replace mycopbin = 0 i f  mycop >35 & mycop <. 
replace mycopbin = 0 i f  mycop ==.
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***m ak in g  mycop Ct values binary ie pos or neg, because will need these later to assess
co-infections
***pj^y_2 * * *
gen pivlbin = 1 i f  p iv l > 0 &  p iv l < 36 
replace pivlbin = 0 i f  p iv l == 0 
replace pivlbin = 0 i f  p iv l >35 & p iv l <. 
replace pivlbin = 0 i f  p iv l ==.
***making p iv l Ct values binary ie pos or neg, because will need these later to assess co- 
infections }, },
gen piv2bin = 1 i f  piv2 > 0 &  piv2 < 36
 1----- . - < u _ n  __ n
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replace piv2bin = 0 i f  piv2 >35 & piv2 <. 
replace piv2bin = 0 i f  piv2 ==.
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***m aking  piv2 Ct values binary ie pos or neg, because will need these later to assess co-
infections
gen piv3bin = 1 i f  piv3 > 0 &  piv3 < 36 
replace piv3bin = 0 i f  piv3 == 0 
replace piv3bin = 0 i f  piv3 >35 & piv3 <. 
replace piv3bin = 0 i f  piv3 ==.
***making piv3 Ct values binary ie pos or neg, because will need these later to assess co- 
infections v '
gen piv4bin = 1 i f  piv4 > 0 &  piv4 < 36 
replace piv4bin = 0 i f  piv4 == 0 
replace piv4bin = 0 i f  piv4 >35 & piv4 <. 
replace piv4bin = 0 i f  piv4 ==.
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***m aking  piv4 Ct values binary ie pos or neg, because will need these later to assess co-
infections
save "WAIFW_selections_30Aprill2.dta", replace 
drop urti
***existing definition of urti is as below but also seems to include "sick" which adds some 
subjects sick *with other illnesses
gen urti=cough== 1 / runnynose ==11 sorethroat == 1
tab urti
tgb urti cough }, },
tab urti runnynose 
tab cough runnynose 
tab urti sorethroat
gen any_virus=0
replace any_virus=l ifrsvabin==l / rsvbbin==l / oc43bin==l / nl63bin==l / e229bin==l 
/ / /
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I fluabin==l / flubbin==l / flucbin==l / hmpvbin==l / rhino_bin==l
14.1.2 Defining episodes of infection with each viral target
The data was sorted by study ID and sample date, and received an ordered number, 
within each study ID. The data were then made panel data using the xtset command. A 
variable for the episode of infection with the first viral target, RSV A, was generated using 
the binary variable for RSV as defined by the Ct for RSV as above. The episode of 
infection was then expanded to include all negative swabs that lay between positive 
swabs as long as those positive swabs were within 14 days of each other, using lag and 
lead commands in the panel data. Finally if there were not at least 2 positive swabs within 
a 14-day period, then the episode variable became negative. This ensured that the 
definition of an episode must include at least 2 swabs positive for RSV-A with a Ct<35, 
within a 14-day period.
V ■ V: V ■
///define rsvainfection episodes 
sort studyid sampledate 
by studyid: gen order=_n
xtset studyid order
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*rsva episode
****note f  means forward and I means lag. see help xtset fo r a description o f these 
commands***
gen rsvainf=l i f  rsvabin==l
replace rsvainf=l i f  l.rsvabin==l &frsvabin==l & rsvainf==. &fsampledate- 
l.sampledate<15
replace rsvainf=l i f  l.rsvabin==l &f2.rsvabin==l & rsvainf==. &f2.sampledate- 
l.sampledate<15
replace rsvainf=l i f  I2.rsvabin==l &frsvabin==l & rsvainf==. &fsampledate- 
I2.sampledate<15
replace rsvainf=l i f  l.rsvabin==l &f3.rsvabin==l & rsvainf==. &f3.sampledate- 
l.sampledate<15
replace rsvainf=l i f  I2.rsvabin==l &f2.rsvabin==l & rsvainf==. &f2.sampledate-
12.sampledate<15
replace rsvainf=l i f  I3.rsvabin==l &fl.rsvabin==l & rsvainf==. &fl.sampledate-
13.sampledate<15
replace rsvainf=0 if  rsvainf==.
replace rsvainf=0 ifrsvabin==l & l.rsvainf==0 & frsva in f ==0 //m ust have >1 swab positive
label var rsvainf "rsva episode"
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***this codes a swab as part of an rsva episode if  the child had at least 2 positive swabs 
within 2 *weeks
Next the URTI variable was used to generate a variable for "ever URTI" ie. had the 
participant had URTI symptoms at any point during that viral infection episode? This was 
because URTI symptoms can come and go, or be variably reported, so an episode was 
now defined as; at least 2 swabs positive for RSV-A with a Ct<35, within a 14-day period, 
during which the participant suffered from URTI symptoms on at least one occasion. 
These episodes are marked with a variable indicating the start of an RSV infection 
episode.
by studyid: gen nrsvainf=sum (rsvainf)
■ V \; \; .
by studyid: gen nurti=sum(urti) i f  rsvainf==l
by studyid: replace nurti=nurti[_n-l] i f  nurti==. 
by studyid: gen everurti=nurti[_N]>0
//s ta rt o f rsva episodes of interest
gen srsvainf=rsvainf==l & nrsvainf==l & everurti==l
tab srsvainf
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***this means that only episodes during which the child was symptomatic at any time 
are marked
***srsvainf is start of rsva infection episode
The start of each RSV infection episode was then numbered, because we wanted to be 
able to select only the first episode in each household. Variables for the number of RSV-A 
infections per household and the start of the RSV-A infections in that household were 
generated. If more than one participant per household started an RSV-A infection 
episode on the same date, then all of those participants were marked as the start of RSV- 
A infection episodes for that household. All swabs in those first RSV-A episodes per 
household were marked using the 'nrsvaselect' variable.
V ■ V V .
by studyid: gen nsrsvainf=sum(srsvainf) 
tab nsrsvainf
replace srsvainf=0 if  nsrsvainf>1 
* * *nsrsvainf is numbering the start of the rsva infection episodes so that we end up with
—  / . .  x L *  £ :_ x  * __uiuy m tr jiisi c/l//ouuc
drop nurti everurti
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***so that it can be used again fo r the next virus***
//identify the first child infected with symptomatic rsva per hh 
gsort hhid sampled ate -srsvainf studyid
//starts with the rsvainf infections sample were collected the same date 
by hhid: gen nrsva_hh=sum(srsvainf)
***nrsva_hh is number o f rsva infections in the household 
***srsvainf_hh is start o f rsva infections in the household 
by hhid: gen srsvainf_hh=nrsva_hh==l & srsvainf ==1
\; v v v: ■
by hhid: replace srsvainf_hh=l i f  nrsva_hh==2 & nrsva_hh[_n-l]==1 / / /
& sampledate==sampledate[_n-l]
by hhid: replace srsvainf_hh=l i f  nrsva_hh==3 & nrsva_hh[_n-l]==2 / / /
& nrsva_hh==l & sampledate==sampledate[_n-l]
***ensures that i f  2 or 3 children all started with rsva infections on the same date, 
are aii *inciuded
sort studyid sampledate
by studyid: gen nrsvaselect=sum(srsvainf_hh==l) if  rsva in f ==1 & nsrsvainf==l 
by studyid: gen srsvaselect=l i f  nrsvaselect==l & nrsvaselect[_n-l]!=l 
drop nrsvaselect
by studyid: gen nrsvaseiect=sum(srsvaselect==l)
replace nrsvaselect=0 i f  rsva in f ==0
***selects the rsva episode samples during the infection episode, i f  the firs t fo r that 
household
\: ■ \: V V .
The data being in order of study ID and sample date, the xtset command was used again 
to create panel data, again by order within study ID. All swabs within 2 weeks prior to the 
RSV-A infection episode were marked as "Before" swabs, all swabs during the episode 
were marked as "During" swabs, and all swabs within 4 weeks after the episode were 
marked as "After" swabs, using the 'rsvaselect' variable. The number of selected RSV-A 
episodes and the number of swabs in the "Before", "During" and "After" categories for 
RSVA were checked using the 'tab' commands.
drop order
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by studyid: gen order=_n 
xtset studyid order
//select samples 
gen rsvaselect=0
//selects samples 2 weeks BEFORE the rsva episode
replace rsvaselect=l if  f.nrsvaselect==l & f.sampledate-sampledate<15 & 
nrsvaselect==0
replace rsvaselect=l i f  f2.nrsvaselect==l &f2.sampledate-sampledate<15 & 
nrsvaselect==0 N, }, J
replace rsvaselect=l i f  f3.nrsvaselect==l & f3.sampledate-sampledate<15 & 
nrsvaselect==0
replace rsvaselect=l iff4.nrsvaselect==l & f4.sampledate-sampledate<15 & 
nrsvaselect==0
replace rsvaselect=l i f  f5.nrsvaselect==l & f5.sampledate-sampledate<15 & 
nrsvaseiect==G
replace rsvaselect=l i f  f6.nrsvaselect==l & f6.sampledate-sampledate<15 & 
nrsvaselect==0
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//selects samples DURING the rsva episode
replace rsvaselect=2 i f  nrsvaselect==l
//selects 4 weeks AFTER
replace rsvaselect=3 i f  l.nrsvaselect==l & sampledate-l.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I2.nrsvaselect==l & sampledate-l2.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I3.nrsvaselect==l & sampledate-l3.sampledate<29 & 
nrsvaselect==0
V • V:. V
replace rsvaselect=3 i f  14.nrsvaselect==l & sampledate-l4.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I5.nrsvaselect==l & sampledate-l5.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I6.nrsvaselect==l & sampledate-l6.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I7.nrsvaselect==l & sampledate-l7.sampledate<29 & 
nrsvaselect==0
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replace rsvaselect=3 if  I8.nrsvaselect==l & sampledate-l8.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 if  I9.nrsvaselect==l & sampledate-l9.sampledate<29 & 
nrsvaselect==0
replace rsvaselect=3 i f  I10.nrsvaselect==l & sampledate-H0.sampledate<29 & 
nrsvaselect==0
tab srsvainf_hh 
tab rsvaselect
A co-infection variable was created so that if a swab selected as being before, during or
V V V: ■ v
after an RSV-A episode, was also positive for another virus (or Mycoplasma pneumoniae), 
it was tagged. All of this code was subsequently repeated for each other viral target.
*Make a coinfection variable which is positive i f  before, during or after any selected viral 
episode
*a swab is positive fo r any other virus 
gen coinfect=0
replace coinfect=l i f  (rsvaselect==l / rsvaselect==2 / rsvaselect==3) & / / /
(adenobin==l / rsvbbin==l / oc43bin==l / nl63bin==l / e229bin==l / fluabin==l / 
flubbin==l I flucbin==l / hmpvbin==l / / /
I rhino_bin==l / pivlbin==l / piv2bin==l / piv3bin==l / piv4bin==l / mycopbin==l)
14.1.3 Overall swab selections for all viral targets
Finally, the overall selections for all viruses were marked so that all "Before" swabs were 
marked, all "During" swabs were marked and all "After" swabs were marked. These 
selected swabs were exported using the 'outsheet' command, located in the freezer 
archive, and lytA qPCR was run on the DNA previously extracted from the selected swabs.
***Overall Selections***
\: ■ \ ; . V V
gen overallselect = 1 i f  rsvaselect == 1 / rsvbselect == 1 / oc43select ==11 nl63select == 1
I / / /
e229select ==11 rhinospp_alselect ==11 rhinospp_a2select == 1 / rhinospp_a3select == 
1 / / /
I rhinospp_a4select == 1 / rhinospp_a5select == 1 / rhinospp_blselect == 1 / / /
I rhinospp_clselect == 1 / rhinospp_c2select == 1 / rhinospp_c3select == 1 / / /
I rhinospp_c4select == 1 / rhinospp_c5select == 1 / rhinospp_dlselect == 1 / / /
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I rhinospp_elselect == 1 / fluaselect ==11 flubselect == 1 / flucselect == 1 / hmpvselect 
==1
replace overallselect = 2 i f  overaIIselect ==. & (rsvaselect ==2 1 rsvbselect == 2 / / /
I oc43select ==2 1 nl63select ==2 / e229select ==2 1 rhinospp_alselect == 2 / / /
I rhinospp_a2select ==2 1 rhinospp_a3select ==2 j rhinospp_a4select == 2 / / /
I rhinospp_a5select ==2 1 rhinospp_blselect ==2 1 rhinospp_clselect == 2 / / /
I rhinospp_c2select ==2 j rhinospp_c3select ==2 / rhinospp_c4select == 2 / / /
I rhinospp_c5select ==2 1 rhinospp_dlselect ==2 j rhinospp_elselect ==2 1 fluaselect == 
2 / / /
I flubs/elect ==2 / flucselect ==2 / hmpvselect == 2)
replace overallselect = 3 if  overallselect ==. & (rsvaselect ==31 rsvbselect ==3 j  
oc43select == 3 / / /
I nl63select ==3 j  e229select ==3 I rhinospp_alselect ==3 I rhinospp_a2select == 3 / / /
I rhinospp_a3select == 3 / rhinospp_a4select == 3 / rhinospp_a5select == 3 / / /
I rhinospp_blselect ==3 1 rhinospp_clselect ==3 1 rhinospp_c2select ==3 / / /
I rhinospp_c3select == 3 / rhinospp_c4select ==3 1 rhinospp_c5select == 3 / / /
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I rhinospp_dlselect == 3 / rhinospp_elselect == 3 / fluaselect == 3 / flubselect == 3 / / /
I flucselect == 3 / hmpvselect == 3)
replace overallselect = 0 if  overallselect ==.
preserve
keep hhid study id visitid sampledate overallselect rsvaselect rsvbselect oc43select/ / /  
nl63select e229select rhinospp_alselect rhinospp_a2select rhinospp_a3select / / /
rhinospp_a4select rhinospp_a5select rhinospp_blselect rhinospp_clselect / / /
rhinospp_c2select rhinospp_c3select rhinospp_c4select rhinospp_c5select / / /
\ . . V . V  V  V
rhinospp_dlselect rhinospp_elselect fluaselect flubselect flucselect hmpvselect
keep if  overallselect != 0
outsheet using "overall_selections_revised300412_susan3_confounders"/ replace
restore
save ,,WAIFW_selections_30Aprill2.dta,,/ replace
log close
350
14.2 Appendix B: Nasopharyngeal pneumococcal concentration before, 
during and after episodes of symptomatic viral upper respiratory tract 
infection with RSV or rhinovirus
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Appendix B: Nasopharyngeal pneumococcal concentration in lytA copies/pg of human 
DNA, before, during and after each studied episode of symptomatic upper respiratory
tract infection (URTI) with RSV or rhinovirus in children <5 years old. The y-axis of each
358
graph is in logio scale. The swab numbers on the x-axes are consecutive twice-weekly 
swabs. Where a swab was not collected or the sample was unavailable, the bar is missing. 
Where a swab was not missing but did not have detectable pneumococcus by lytA qPCR, 
it is marked zero. For RSV episodes, swabs collected during the episode are marked in 
red, for rhinovirus these are blue. Swabs two weeks before and four weeks after each 
viral episode are black. Bars marked with an asterisk indicate swabs that were co-infected 
with another respiratory virus by multiplex PCR.
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